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ABSTRACT 
 
Seeking the optimal pharmaceutical formulation is considered one of the most 
critical research components during the drug development stage. It is also an R&D effort 
incorporating design of experiments and optimization techniques, prior to scaling up a 
manufacturing process, to determine the optimal settings of ingredients so that the 
desirable performance of related pharmaceutical quality characteristics (QCs) specified 
by the Food and Drug Administration (FDA) can be achieved. It is widely believed that 
process scale-up potentially results in changes in ingredients and other pharmaceutical 
manufacturing aspects, including site, equipment, batch size and process, with the 
purpose of satisfying the clinical and market demand. Nevertheless, there has not been 
any single comprehensive research work on how to model and optimize the 
pharmaceutical formulation when scale-up changes occur. Based upon the FDA 
guidance, the documentation tests for scale-up changes generally include dissolution 
comparisons and bioequivalence studies. Hence, this research proposes optimization 
models to ensure the equivalent performance in terms of dissolution and bioequivalence 
for the pre-change and post-change formulations by extending the existing knowledge of 
formulation optimization. First, drug professionals traditionally consider the mean of a 
QC only; however, the variability of the QC of interest is essential because large 
variability may result in unpredictable safety and efficacy issues. In order to 
simultaneously take into account the mean and variability of the QC, the Taguchi quality 
loss concept is applied to the optimization procedure. Second, the standard 2×2 crossover 
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design, which is extensively conducted to evaluate bioequivalence, is incorporated into 
the ordinary experimental scheme so as to investigate the functional relationships 
between the characteristics relevant to bioequivalence and ingredient amounts. Third, as 
many associated FDA and United States Pharmacopeia regulations as possible, regarding 
formulation characteristics, such as disintegration, uniformity, friability, hardness, and 
stability, are included as constraints in the proposed optimization models to enable the 
QCs to satisfy all the related requirements in an efficient manner. Fourth, when dealing 
with multiple characteristics to be optimized, the desirability function (DF) approach is 
frequently incorporated into the optimization. Although the weight-based overall DF is 
usually treated as an objective function to be maximized, this approach has a potential 
shortcoming: the optimal solutions are extremely sensitive to the weights assigned and 
these weights are subjective in nature. Moreover, since the existing DF methods consider 
mean responses only, variability is not captured despite the fact that individuals may 
differ widely in their responses to a drug. Therefore, in order to overcome these 
limitations when applying the DF method to a formulation optimization problem, a 
priority-based goal programming scheme is proposed that incorporates modified DF 
approaches to account for variability. 
The successful completion of this research will establish a theoretically sound 
foundation and statistically rigorous base for the optimal pharmaceutical formulation 
without loss of generality. It is believed that the results from this research will have the 
potential to impact a wide range of tasks in the pharmaceutical manufacturing industry. 
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CHAPTER 1 
INTRODUCTION 
 
Pharmaceutical optimization has been defined as the implementation of 
systematic approach to establish the best possible settings of material and process 
variables under a given set of conditions that will result in the production of a 
pharmaceutical product with predetermined and specified characteristics each time it is 
manufactured (Singh et al., 2005). First, formulation development, which is the process 
to produce a final drug product by combining active pharmaceutical ingredients (APIs) 
and inactive ingredients, makes a significant contribution to the delivery of a drug to the 
body. Formulation designers seek optimal formulations in order to maximize the clinical 
benefit of drug ingredients by means of delivering the right amount, at the right rate, to 
the right site, at the right time (Gibson, 2001). Second, sponsors are dedicated to 
optimizing the manufacturing process by taking into account both ingredients and process 
parameters, so that the manufacturability and scale-up ability of drugs can be ensured. 
This dissertation focuses on the formulation optimization and aims at developing 
comprehensive optimization models incorporating design of experiments (DOE) and 
response surface methodology (RSM) for new tablets while all related regulatory 
requirements are satisfied. Hence, an overview of the development process of new drugs 
is presented in Section 1.1. Research motivations and significance are provided in Section 
1.2. Along with these motivations, research tasks to be conducted in this work are 
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introduced in Section 1.3. Finally, the organization of this dissertation is described in the 
last section.  
 
1.1 An Overview of Development Process of New Drugs 
The drug can be categorized into the new and generic drugs. Developing a new 
drug is an extremely expensive, time-consuming, and risky proposition. Based on a U.S. 
government publication titled ―Focus on: Intellectual Property Rights‖ (Field et al., 
2006), it is estimated that the annual cost of developing a new drug varies widely from a 
low of $800 million to nearly $2 billion. Moreover, drug companies usually spend 12 to 
15 years to discover and develop a new drug and have to take the risk of a low probability 
of getting a payoff. It is known that only about 30 percent of new drugs actually earn 
enough revenue during their product lifecycle to recover the cost of development. The 
good news is that the new drug approval rate is relatively high in the United States. 
According to Tsuji and Tsutani (2010), 325 out of the 398 (81.7%) new drugs were 
approved from 1999 to 2007. Once a new drug is developed, the drug company receives a 
drug patent which provides protection related to rights and benefits for selling the new 
drug lasting around 20 years. When the patent expires, other drug companies are allowed 
to start developing, manufacturing, and selling a generic version of the novel drug. Since 
generic drug makers do not develop a drug from scratch but copy the content of APIs of 
the new drug, the costs to bring the generic drug to market are less; therefore, generic 
drugs are less expensive.  
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Unfortunately, the relatively higher price of new drugs alone cannot ensure their 
desirable quality. Based on the report about drug recalls published weekly by the Food 
and Drug Administration (FDA) (2009-2010), 58 new drugs out of 190 were recalled 
because of their various quality issues from January 2009 to February 2010. Furthermore, 
drug recalls usually lead to substantial economy loss. For example, the J&J‘s recalling its 
new children's medicines in 2010 would ―shave J&J's sales by $300 million this year‖, a 
JP Morgan analyst Weinstein said in 2010. Therefore, in order to decrease these negative 
effects on developing new drugs, the reduction of development time and costs 
specifically, and continual improvement of quality in general, have recently gained more 
interest in pharmaceutical industry. Formulation development significantly impacts these 
costs, time and related pharmaceutical quality characteristics (QCs) throughout the 
development of new drugs (Hwang & Noack, 2011).  
The entire development process of new drugs can be broken into several key 
stages: drug discovery, preclinical phase, investigational new drug application, clinical 
phase (I, II, III), new drug application (NDA), FDA review, NDA approval, 
manufacturing, and post-marketing surveillance. Each stage must meet the regulatory 
standards regarding safety, efficacy and quality. Figure 1.1 shows the framework of 
developing a new drug from Phase I to manufacture. Phase I trials are designed to learn 
more about the safety of a new drug, and they may also collect some information 
concerning efficacy. The purposes of these studies are the rapid elimination of potential 
failures from the pipeline, definition of biological markers for efficacy or toxicity, and 
demonstration of early evidence of efficacy. Phase II studies are designed to determine 
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whether the new drug is effective in treating, disease or condition for which it is intended, 
short-term side effects, and risks in patients. Phase III trials, which are conducted on 
larger patient populations under conditions that more closely approximate medical 
practices, provide the scientific evidence required for the approval of a new drug. With 
the completion of Phase III trials, sponsors submit NDA to the FDA for marketing 
approval. Once FDA accepts NDA, FDA starts the review program. The NDA review 
generally involves medical, biopharmaceutical, pharmacology, statistical, chemistry, 
microbiology, labeling, and inspection of sites reviews. Drugs must be manufactured in 
accordance with standards called good manufacturing practices, and the FDA inspects 
manufacturing facilities before a drug can be approved. Marketing approval, when 
received, the drug company is able to manufacture and market the new drug. 
 
Figure 1.1 Framework for New Drug Development 
During the period of discovery and preclinical phase, it is important to consider 
the biopharmaceutical properties of the drug substance including in vivo and in vitro 
F
o
rm
u
latio
n
 D
ev
elo
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en
t
Phase I Phase II Phase III FDA Review Launch
Time
Biopharmaceutics
◆Candidate Drug Substance
Process Feasibility 
Study
Formulation 
Optimization
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Process Scale-Up
Preformulation
Process Validation Manufacture
◆NDA Submission 
and Review
Preliminary 
Screening Study
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dissolution performance and bioavailability profiles (Gibson, 2001). Note that dissolution 
testing is a key analytical study used for characterizing how an API is extracted out of a 
dosage form, while the bioavailability is associated with the rate and extent to which the 
API is absorbed from a drug product and becomes available at the site of action (FDA, 
2003). For the development of robust formulation and process, critical formulation issues 
must be first identified from the preformulation work, such as dissolution rate, stability, 
stabilization, and processing difficulties due to poor powder properties of the API (Smith 
& O'Donnell, 2006). Once the critical formulation issues are identified, the target product 
profile of the new drug, including the route of administration, maximum and minimum 
dose, delivery requirement and appearance, is needed to be established. The target profile 
serves as a guide for formulation designers to set up formulation strategies and keep 
formulation effort focused and efficient (Hwang & Kowalski, 2005). The formulation 
strategy is associated with a systematic approach to identifying the optimal composition 
and process during the period of formulation development which includes four studies: 
process feasibility, preliminary screening, formulation optimization, and process 
optimization. Based on the results of preliminary screening studies, formulation scientists 
seek optimal levels of selected excipients, also known as inactive ingredients, in order to 
achieve the target profile of the formulation, while meeting various requirements related 
to time, costs, ingredient amounts, and manufacturing feasibility. Note that excipients are 
added to a formulation to enhance certain performance of a drug. After the final 
formulation is determined during the stage of formulation optimization, the 
manufacturing process, such as granulation, milling, drying and blending, will be 
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optimized by evaluating critical process parameters. Commonly, with the completion of 
formulation development, the manufacturing process is scaled up from the laboratory, 
through the pilot, and to the commercial production scale. 
 
1.2 Research Motivation and Significance 
In the real world, process scale-up during the development of new drugs often 
results in modifications concerning ingredients, site, batch size, and manufacturing. The 
FDA guidance (1995) for immediate-release (IR) solid oral dosage forms requires that 
drug developers provide documentation tests so as to exclude the need for reestablishing 
the drug safety and efficacy by means of submitting duplicate data to the FDA. It should 
be mentioned that the pre-change formulation is chosen as a reference standard against 
the test post-change one for the related tests. Documentation tests usually include in vitro 
dissolution comparisons and in vivo bioequivalence studies. The former is an analytical 
study that investigates the similarity of the dissolution performance between the reference 
and test formulations, while the latter is conducted to compare the bioavailability 
between the two formulations of a drug product with respect to the rate and extent of 
absorption. It should be mentioned that the crossover design is widely utilized to 
determine bioequivalence. An example template of a single-dose, two-treatment, two-
period, two-sequence (2×2) crossover design is shown in Figure 1.2. An equal number of 
subjects is randomly assigned to each of the two sequences (FDA, 1995). Within the first 
sequence, the reference formulation is administered to subjects first, while the test 
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formulation is administered first within the second one. The 2×2 crossover design is 
discussed in greater detail in Chapter 4.  
 
Figure 1.2 2×2 Crossover Design Scheme 
The basic motivation of this work is twofold. First, the formulation optimization 
issue arises when scale-up changes occur, which has not been adequately addressed in the 
previous investigations. Second, when dealing with multiple QCs to be optimized, the 
desirability function (DF) approach can be incorporated into formulation optimization. 
However, this approach has several weaknesses that affect the accuracy of optimal 
solutions. The following subsections provide the research significance derived from this 
motivation. Note that the oral administration route is the one most often used, and tablets 
are the most popular oral dosage forms. Hence, this dissertation focuses on the tablet 
formulation optimization problem.  
 
1.2.1 Significance I: Formulation Optimization for Scale-Up Changes 
As discussed earlier, formulation optimization is conducted to determine the 
optimal excipient amounts of the formulation so that the target profile can be achieved. It 
is also believed that formulation optimization plays a critical role during the formulation 
developing process (Hwang & Kowalski, 2005; Hwang & Noack, 2011). Therefore, it is 
necessary to propose a methodology that extends the application of current formulation 
Subject Randomization
Sequence 1
Sequence 2
Reference Test
ReferenceTest
Period 1 Period 2
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optimization when the excipient amounts need to be modified. That is, after the period of 
formulation development, formulation optimization can be conducted so as to ensure the 
equivalent performance in documentation tests between the reference and test 
formulations when scale-up changes in excipients occur. Figure 1.3 describes the 
extension of formulation development. 
 
Figure 1.3 A Simplified Extended Pharmaceutical Formulation Development 
Similar to the current formulation optimization study, many formulation factors 
and responses need to be evaluated in the extended study. The factors are the excipient 
amounts, while the responses are relevant to the critical pharmaceutical QCs generally 
selected based on the target product profile and documentation tests, such as uniformity, 
hardness, disintegration, stability, dissolution, and bioavailability performance. The DOE 
technique is one of the most efficient and effective approaches to evaluate the 
relationship between the response and factors. Once the relationship is identified, the 
formulation can be mathematically optimized by choosing the best combination of 
excipient amounts to achieve the specific goals. It is critical to mention that  
1) the input factors of DOE remain the same as the decision variables of the 
optimization procedure; 
   Formulation Development
Process 
Feasibility 
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Formulation 
Optimization 
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2) the optimization constraints are developed according to the regulatory 
requirements on the responses of DOE; 
3) the objective function of the current formulation optimization is to 
minimize or maximize specific characteristic associated with the target 
profile, while the extended optimization is to ensure the equivalent 
performance in documentation tests required by the FDA. 
Moreover, the extended formulation optimization procedure is able to provide 
continuous improvement of product quality from the period of formulation development 
to the scale-up stage. During the formulation development, formulation optimization is 
performed to obtain the desirable ingredient amounts of a formulation so as to achieve the 
target profile. Within the scale-up phase, scale-up changes in the ingredient amounts 
potentially challenge the safety and efficacy of the changed formulation. In this case, 
formulation optimization is useful to determine the optimal amounts of ingredients for 
guaranteeing the equivalence with respect to safety and efficacy between the original and 
new formulations.  
 
1.2.2 Significance II: Assessment of Similarity in Dissolution and Bioequivalence 
It is necessary to integrate the regular assessment methods for the two 
documentation tests into the proposed formulation optimization models. Several 
approaches are available for evaluating the similarity in dissolution and bioequivalence 
between formulations; however, different numerical results can be obtained depending on 
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the methods used. Despite the recommendations of FDA on some of these methods, there 
remains no agreement over which is the best method. 
 
 Dissolution comparisons 
According to the FDA guideline (2000), the two factors f1 and f2 are useful to 
determine if the dissolution profiles of two formulations are similar (see section titled 
―Assessment of In Vitro Dissolution‖ of the Chapter 2). The main drawback of the 
recommended evaluation methods is that they are applicable to the dissolution data with 
low variability only. The variance is generally considered essential to the safety and 
efficacy issues because individual subjects may differ widely in their responses to a drug. 
If the variance of the test formulation is comparatively large, the safety and efficacy of 
the test formulation may be questionable. In order to overcome this shortcoming, a 
rigorous technique should be developed for simultaneously comparing both the mean and 
variance related to the dissolution data for the reference and test formulations (see 
Chapter 3). 
 
 Bioequivalence Assessment 
First, as stated earlier, the crossover design is widely conducted during the 
bioequivalence study, since its main advantage is that it excludes the inter-subject 
variability from the comparison between formulations. Under the proposed optimization 
scheme, it is essential to incorporate this special type of experimental design into the 
ordinary DOE technique so as to evaluate the relationships between the factors and 
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responses associated with the characteristics of bioequivalence studies. In order words, a 
crossover design is performed at each experimental run within the DOE format. Second, 
a discretization method, specifically the linear trapezoidal technique, is most frequently 
used to approximate the bioequivalence characteristics (FDA, 2006a) because of its 
simplicity. However, the continuous methods, which involve curve fitting and more 
mathematical calculations, are also applicable to the bioequivalence evaluation. Both 
methods are discussed and compared in greater detail in Chapter 4. 
 
1.2.3 Significance III: Taguchi Quality Loss Concept and Regulatory Constraints 
When optimizing a formulation, the drug designer is typically dedicated to 
optimizing the performance regarding the mean of a QC. However, the variance of a QC 
is considered essential because large variance may result in safety and efficacy issues. 
Based on the Taguchi quality loss concept, any deviation from target values will result in 
costs and consequently quality loss. This concept appears to be appealing to drug 
developers because it evaluates the deviations from target profiles of both the mean and 
variance. On the other hand, although multiple regulatory constraints in the formulation 
optimization problem are acknowledged, there is little formal research on integrating the 
quality loss concept as well as all the related FDA requirements with scientific 
formulation optimization techniques. Therefore, comprehensive optimization models 
taking into consideration the Taguchi quality loss concept and as many associated 
constraints as possible need to be developed in order (1) to optimize both the mean and 
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variance of the QC of interest and (2) to ensure that the related QCs of the tablet 
formulation satisfy all the requirements in an efficient manner.  
 
1.2.4 Significance IV: Modified Desirability Approach and Goal Programming 
When applying RSM to the optimization of a new drug formulation, drug 
designers are usually faced with multiple QCs of interest, namely, multi-response surface 
(MRS) optimization problems. In this case, the DF approach can be incorporated into the 
optimization where the weight-based overall DF is usually considered an objective 
function to be maximized. However, this approach has a potential shortcoming: the 
optimal solutions are extremely sensitive to the weights assigned and assigning these 
weights is a very subjective process. Since the goal programming technique is one of the 
most popular approaches to finding good solutions in a multi-objective problem (Rardin, 
1998), a priority-based optimization scheme can be a more effective alternative that is 
performed based upon the priority instead of the numerical weight for each individual 
characteristic. Moreover, since the existing DF methods only consider the mean of a QC, 
variability is not captured despite the fact that individuals may differ widely in their 
responses to a drug. Finally, the commonly used RSM, which calls for the development 
of linear or quadratic response surface designs in estimating the QC of interest, may be 
less effective for the estimation than a higher-order model (Shaibu & Cho, 2009). 
Considering that the estimation accuracy heavily impacts the effectiveness in seeking 
optimal solutions, the traditional low-order response surface functions may not always be 
suitable. Therefore, in order to improve the effectiveness of the traditional approach to 
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formulation optimization for multiple characteristics, (1) the conventional DF method is 
modified to take into consideration both the mean and variability of a QC by proposing 
two separate DFs- empirical and mechanistic (see Chapter 5), (2) a priority-based goal 
programming model is proposed to optimize individual desirability of the multiple 
characteristics with the purpose of determining the best compromise among the 
characteristics, and (3) as one of the few research attempts integrating higher-order 
response surface functions into the formulation optimization procedure, the use of higher-
order (up to fourth-order) regression functions is proposed in Chapter 5 in order to 
improve the estimation accuracy of response surfaces and thereby the effectiveness of the 
optimization. 
 
1.3 Research Tasks 
In order to achieve the research goal, which is to develop optimization models for 
the extended tablet formulation development, some of the fundamental questions should 
be answered. The fundamental research questions of this work include: 
Question 1: What types of DOE and assessment methods for documentation tests 
should be applied to the evalution of the response mean and varability 
related to dissolution comparisons and bioequivalence studies? 
Question 2: How can we develop an optimization scheme that allows a drug designer 
to minimize both deviations from the target values and variability of the 
related QCs? 
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Question 3: What regulatory requirements are involved in an extended tablet 
formulation optimization problem? 
Question 4: How can we validate the optimization results? 
Based on the research questions above, the major research tasks to be 
accomplished are presented as follows: 
Task 1: The investigations of the existing assessment methods for dissolution 
comparisons and bioequivalence studies, various DOE techniques used in 
formulation optimization procedure, and enhanced optimization methods 
which take into consideration multiple QCs concerning the mean and 
variability of the related QCs. 
Task 2: The study of all the possible related regulatory constraints for the tablet 
optimization problem; the development of extended formulation optimization 
models.  
Task 3: The comparisons of the existing and proposed approaches. 
Task 4: The validation of the results of the proposed optimization methodologies.  
The first task is implemented in Chapter 2. The second and third tasks are 
accomplished by integrating appropriate DOE, RSM, and associated assessment methods 
for the documentation tests into the optimization procedure while taking into account 
necessary constraints. Finally, validation studies are conducted by means of sensitivity 
analysis in this work.  
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1.4 Outline of Dissertation 
The overall structure of the research is shown in Table 1.1. Chapter 1 mainly 
introduces research significance and tasks. In Chapter 2, a review of the relevant research 
in the literature and pertinent technological basis for the formulation optimization are 
provided, including mathematical models of dissolution and bioequivalence studies, 
fundamental definitions of scale-up changes, various DOE techniques, and several widely 
used optimization methodologies. Chapters 3, 4 and 5 present the proposed formulation 
optimization models for dissolution comparisons, bioequivalence studies, and MRS 
problems, respectively. Finally, Chapter 6 includes a description of the research 
achievements and scope for future study.  
Table 1.1 Dissertation Structure 
Chapter Feature 
1 
Overview of the development process of new drugs, research 
motivations, significance and tasks 
2 
Literature reivew of assessment methods for dissolution and 
bioequivalence testing, DOE techniques, and optimization 
methodologies 
3 
A formulation optimization model for dissolution comparisons with 
several proposed objective functions 
4 
A formulation optimization model for bioequivalence studies with 
two assessment methods 
5 
An MRS formulation optimization model incorporating modified DF 
and priority-based goal programming methods  
6 Summary of research findings, contributions, and further work 
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CHAPTER 2 
LITERATURE REVIEW AND KNOWLEDGE BACKGROUND 
 
In this chapter, an overview of the literature and knowledge basis for the 
formulation modeling and optimization is presented and divided into separate sections, 
namely, biopharmaceutical tests, scale-up changes for IR solid orally administered drugs, 
DOE approaches, and common optimization methodologies. Section 2.1 provides a brief 
review of the existing mathematical models employed to implement biopharmaceutical 
supports for the formulation development. Sections 2.1.1, 2.1.2, and 2.1.3 introduce the 
assessment of in vitro dissolution tests, the evaluation of in vivo bioavailability studies, 
and the establishment of in vitro/in vivo correlation (IVIVC), respectively. Scale-up 
changes and requirements on related documentation tests for IR oral formulations are 
outlined in Section 2.2. In Section 2.3, diverse types of DOE techniques applied to the 
formulation optimization problem are discussed. Several popular optimization 
methodologies are presented in detail in Section 2.4. Finally, Section 2.5 is the summary 
of this chapter. 
 
2.1 Typical Biopharmaceutical Tests for Formulation Development 
To investigate the clinical benefits of drug ingredients, biopharmaceutical tests 
are rigorously performed from the stage of preformulation, through formulation 
development, to filling FDA applications. The biopharmaceutical tests for the 
formulation development, which typically include in vitro dissolution testing, in vivo 
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bioavailability evaluation, and IVIC studies, are conducted to assess the in vitro impact of 
physicochemical properties of drugs on the bioavailability of drugs (Shargel et al., 2004). 
Following sections introduce the assessment of these studies for oral drug profiles. 
 
2.1.1 Assessment of In Vitro Dissolution 
In vitro dissolution testing of solid dosage forms is the most frequently used 
biopharmaceutical test in the drug development. It is conducted from the start of dosage 
form development and in all subsequent processes. Standard in vitro dissolution tests 
measure the rate and extent of dissolution or release of the drug substance from a drug 
product. Drug release is often determined by formulation factors such as excipients. 
Excipients are inactive pharmaceutical ingredients that enhance certain performance of 
the drug. According to Shargel et al. (2004), Hwang et al. (2011), and the United States 
Pharmacopeia (USP) document (2009a), common excipients used in solid drugs are 
summarized in Table 2.1. 
Moreover, one of the most common responses measured to analyze the 
dissolution performance of a formulation is the ingredient amount dissolved at a certain 
point in time. Both linear and nonlinear regression models (Yuksel et al., 2000; Berry & 
Likar, 2007) that evaluate the response over time can be applied to in vitro dissolution 
tests, as shown in Table 2.2. 
In Table 2.2, A(t) is the percent dissolved after time t, kd is the dissolution rate constant, 
and τr is a rate parameter which is a scale factor of the time axis, α is scale factor, and β is 
a parameter that characterizes the shape of the curve. Dave et al. (2004) indicated that the 
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method developed by Bamba et al. (1979) could be adopted for selecting the most 
appropriate model based on the results of F-statistics. 
Table 2.1 Common Excipients Used in Solid Drug Products 
Ingredient Functional Properties Examples 
Binder 
To provide the adhesion for holding the 
ingredients in a tablet together. 
Carboxymethylcellulose (CMC) Sodium, 
Hydroxypropyl Methylcellulose 
(HPMC) 
Diluent 
To provide the bonding strength and to fill 
out the additional volume/weight.  
Lactose, Dicalcium Phosphate, 
Microcrystalline Cellulose (MMC) 
Disintegrant To help break apart the tablet. 
Sodium Starch Glycolate, Crospovidone, 
Starch 
Lubricant To increase the lubricity for manufacturing. Magnesium Stearate, Stearic Acid, Talc 
Gildant To enhance the flowability. Silicon Dioxide, Talc 
Coating Agent 
To stabilize the drug against degradation 
and to make tablets easier to swallow.  
HPMC 
 
Table 2.2 Regression Models for In Vitro Dissolution Tests 
Function Equation 
First-order (Gibaldi & Feldman, 1967)   
Hixson-Crowell (Hixson & Crowell, 1931)   
Higuchi (Higuchi, 1963)   
Weibull (Langenbucher, 1976)   
Logistic (Romero et al., 1991)   
Gompertz (Dawoodbhai et al., 1991) 
 
 
Another approach to obtain the parameter that describes the dissolution rate is to 
use the statistical moment technique to determine the mean dissolution time (MDT) (Von 
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Hattingberg, 1984). This method has the advantage of being applicable to all types of 
dissolution profiles, and it does not require fitting to any regression model. However, lack 
of data points close to the final plateau level will potentially affect the evaluation 
accuracy of MDT (Gibson, 2001). The MDT can be computed by (Brockmeier, 1986) 
, 
where  is the midpoint of the i
th
 time period during which the fraction, ΔMi, has been 
released from the drug. Note that the length of each time period is given by the sampling 
intervals. 
Issues arise when two dissolution performances are compared. According to the 
FDA guidance (1997b), for major changes concerning scale-up and post-approval 
changes, a dissolution profile comparison performed under identical conditions for the 
product before and after the change(s) is recommended. Dissolution profiles may be 
considered similar by virtue of overall profile similarity (Moore & Flanner, 1996) 
, 
and similarity at each point in time  
 , (2.1) 
where n is the number of points in time, and Rt and Tt are the cumulative amounts 
dissolved at time t for the reference and test formulations, respectively. Curves can be 
considered similar when f1 and f2 values are respectively on the intervals (0, 15) and (50, 
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100). Once the similarity of dissolution curves is established, the equivalent performance 
with respect to safety and efficacy of the test and reference products is ensured (FDA, 
1997b). The main advantages of this method are that the f1 and f2 are easy to compute and 
they both provide a single value to describe the extent of difference/similarity of two 
dissolution profiles. Since f1 and f2 are mentioned for use in a number of FDA guidance, 
they are considered the most popular method to compare dissolution profiles. In practice, 
formulation researchers are more interested in evaluating the dissolution similarity at 
each point in time with the f2.  
However, Chow et al. (1997) and Polli et al. (1997) pointed out that the values of 
f1 and f2 were sensitive to the number of points in time used. O'Hara et al. (1998) also 
summarized the disadvantages of this method that the f1 and f2 equations did not take into 
account the variability or correlation structure in the data, and the basis of criteria used to 
decided on difference or similarity was unclear. Shah et al. (1998) discussed the 
statistical properities of the estimate of f2, , based on sample means and concluded that 
the commonly used  was a biased and conservative estimate of f2. 
Chow et al. (1997), Polli et al. (1997), and Yuksel et al. (2000) made significant 
efforts to summarize and examine the general approaches for describing and comparing 
dissolution profiles: ANOVA-based, model-dependent, and model-independent methods. 
(1) The ANOVA-based method uses repeated measures designs to detect differences 
between dissolution profiles. The percents dissolved are dependent variables and time is 
the repeated factor. (2) For the model-dependent method, the linear or nonlinear 
dissolution models presented in Table 2.2 are fitted to the test and reference dissolution 
2fˆ
2fˆ
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profiles. The estimated parameters for both profiles are then employed for the pairwise 
comparison using t-test (Bolton & Bon, 2009). (3) In addtion to the f1 and f2 method, 
Rescigno (1992) introduced the Rescigno index as an alternative model-independent 
method. The indices are originally used to compare blood plasma concentration profiles; 
however, they do not take into account the variability or correlation related to the 
dissolution data, and there are no criteria for judging difference or similarity between 
dissolution profiles (O'Hara et al., 1998). The indices are denoted by ξi (i = 1, 2) and can 
be calculated by  
, 
where Rt and Tt are the mean values of percent dissolved for the reference and test 
formulations at time t, and tn is the last point in time. When the value of ξi (i = 1, 2) 
approaches zero, the similarity between dissolution profiles can be ensured. According to 
O'Hara et al. (1998), the denominator of ξi can be considered a scaling factor, and the 
indices ξi (i = 1, 2) can then be reviewed as a function of the weigthed average of the 
veritical distances between the test and reference mean profiles at each point in time. 
Moreover, Chow et al. (1997) proposed a method for the comparison of dissolution 
profiles that can be regarded as being similar to that used in the assessment of the average 
bioequivalence (ABE) for two formualtions. This method uses the concept of ‗local‘ and 
‗global‘ similarity to assess the closeness between the test and reference dissolution 
profiles. The assessment of global similiarity assumes that the true relative dissolution 
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rate at each location is the same for all the time, while local similarity presuppose that 
each location has the same relative dissolution rate. O'Hara et al. (1998), however, 
revealed that the main drawbacks of this method were that its power and Type I error 
were unknown. Finally, Anderson et al. (1998) indicated that Dissolution Efficiency (DE) 
(Khan, 1975) could also be used to evaluate the similarity of dissolution profiles. In 
Equation (2.2), DE, defined as the area under the dissolution curve between time t1 and t2, 
is expressed as a percentage of the curve at maximum dissolution, y100, over the same 
time period.  
 , (2.2) 
where y is the percentage of dissolved.  
 
2.1.2 Evaluation of Bioavailability Studies 
Bioavailability studies are widely performed during the formulation development 
to evaluate the absorption properties of a drug, establish bioequivalence between 
formulations, and develop IVIVCs. In a bioavailability study, the drug plasma 
concentrations after administration are followed over an appropriate time interval. The 
standard bioavailability characteristics after a single-dose administration are the 
maximum plasma concentration (Cmax), the time to reach Cmax (tmax), and the area under 
the plasma concentration-time curve (AUC). Figure 2.1 illustrates a typical plasma 
concentration profile. It should be noted that sampling is generally more frequent at time 
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intervals in the ascent to the peak concentration and around the peak in order to detect the 
Cmax and tmax as accurately as possible under the experimental condition. 
 
Figure 2.1 A Typical Plasma Concentration-Time Curve 
Cmax and tmax are influenced by several pharmacokinetic properties such as the 
absorption rate (Ka) and the elimination rate (Ke). If a drug exhibits first-order absorption, 
the drug concentration (C) in the plasma at any time t can be calculated based on the 
following equation (Shargel et al., 2004): 
 . (2.3) 
Correspondingly, Cmax and tmax 
can be obtained by (Shargel et al., 2004): 
  (2.4)  
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where F is the extent of oral drug bioavailability expressed as a fraction, D is the 
administered dose, Ke is the first-order elimination rate constant, and Vd is the apparent 
volume in the body in which the drug is dissolved. However, Cmax and tmax are single-
point characteristics, which do not take into account all data sampled during the 
absorption process. According to Gibson (2001), Cmax and tmax are not useful as pure 
measures of the absorption rate but can be utilized in comparisons of the test and 
reference plasma concentration profiles. In addition, they cannot accurately identify the 
maximum in the case of rapid dissolution processes.  
AUC, on the hand, is used to evaluate the extent of absorption. Similar to Cmax and 
tmax, it is only of interest as a relative characteristic for comparisons of between different 
profiles. Several methods exist for evaluating the AUC from time 0 to t which is denote 
by AUC0-t. These methods include the interpolation using the trapezoidal rule, the 
Lagrange and spline methods, the use of a planimeter, the use of digital computers, and 
the physical method that compares the weight of a paper corresponding to the area under 
the experimental curve to the weight of a paper of known area (Chow & Liu, 2009). The 
calculation of AUC is commonly determined by the linear trapezoidal rule. Yeh et al. 
(1978) discussed the strengths and weaknesses of using the Lagrange and spline methods 
against the trapezoidal rule in the aspect of interpolation. According to the linear 
trapezoidal rule, the summation of the areas of a series of trapezoids, which are formed 
between the data for two contiguous points in time, is computed. This approximate 
method requires that blood sampling be frequent enough so that the curvature of the 
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plasma concentrations between two data points is negligible. The area under each 
segment between two data points for the linear trapezoidal is determined by 
 , (2.6) 
where Ci is the plasma concentration for the sample obtained at time ti. The AUC, 
however, should be calculated from zero to infinity, not just to the time of the last blood 
sample, as is so often done. The AUC0-∞ can be estimated by (Tozer & Rowland, 1980): 
 , (2.7) 
where Cn is the concentration at the last measured sample after drug administration, and 
Ke is the elimination rate constant, which can be estimated as the slope of the terminal 
portion of the log concentration-time (Shargel et al., 2004), as shown in Figure 2.2. 
As stated in the FDA guidance (2003), it is recommended to perform a natural 
log-transformation of Cmax and AUC before analysis, since the transformed data are 
believed to be normally distributed. No assumption checking or verification of the log-
transformation data is encouraged. On the basis of log-transformed data, the FDA (2003) 
requires that both AUC and Cmax of the test formulation be within 80% to 125% of those 
of the reference formulation at the 90% significance level for the establishment of ABE. 
However, Liu et al. (1992) studied the distribution of log-transformed pharmacokinetic 
data assuming that the hourly concentrations were normally distributed. The results 
indicated that the log-transformed data over time were not normally distributed under 
certain conditions.  
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Figure 2.2 Logarithmic Drug Plasma Concentration-Time Curve for an Oral 
Administration 
 
Moreover, it is not uncommon to pass AUC but fail Cmax. In this case, ABE 
cannot be claimed according to the FDA guidance on bioequivalence. According to 
Hauck et al. (2001), some regulatory agencies consider a wider bioequivalence limit for 
Cmax, because of the typically higher variability of Cmax compared to AUC. The European 
Medicines Agency (EMEA) and World Health Organization (WHO) guidelines use a 
wider equivalence standard of (70%, 133%) for Cmax. Endrenyi et al. (1991) indicated 
that could be used as another bioequivalence measure between formulations. 
It was also revealed that the variability of  was substantially decreased 
compared with Cmax under most conditions (Endrenyi & Yan, 1993). However, 
 is not currently selected as the required pharmacokinetic responses for 
approval of drug products by any of the regulatory authorities in the world. On the other 
hand, it is very likely that we may pass Cmax but fail AUC. In this case, it is suggested that 
we may look at partial AUC as an alternative measure of bioequivalence (Chen et al., 
maxC AUC
maxC AUC
maxC AUC
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2001). One of the possible reasons is that the incremental area under the plasma 
concentration-time curve representing 10-30% of the total AUC may be more sensitive 
than either Cmax or tmax in detecting the difference of absorption rates between 
formulations (Rosenbaum et al., 1990).  
 
2.1.3 Establishment of IVIVC 
Increasing clinical or market demand for tablet drugs necessitates the expansion 
of the production scale. Scale-up may encompass modifications concerning ingredients, 
site, batch size and manufacturing. When any of these changes occurs, in vivo 
bioequivalence studies need to be performed to prove the equivalent efficacy and safety 
of the new formulation. Bioequivalence studies are generally time-consuming and costly 
procedures. However, the establishment of IVIVC may minimize the need for conducting 
the expensive in vivo studies. According to the FDA guidance (FDA, 1997a), IVIVC is a 
predictive mathematical model describing the relationship between an in vitro property of 
a formulation and a relevant in vivo characteristic. Four different types of correlation are 
defined in FDA guidance (FDA, 1997a), namely, Level A, B, C, and Multiple-Level C. It 
should be mentioned that the Level A correlation is the most commonly developed type 
of correlation in NDAs submitted to the FDA, and Gibson (2001) pointed out that only 
the Level A correlation was accepted by FDA as an evidence for eliminating in vivo 
bioequivalence studies. Therefore, the focus of the following review is primarily centered 
on the Level A correlation.  
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A Level A correlation can be developed by a two-stage approach: (1) the in vivo 
dissolution profile is estimated from the plasma concentration profiles for the test 
formulation and an oral solution that is considered a reference formulation in the IVIVC 
bioavailability study, and (2) the estimated in vivo data is correlated with the in vitro 
dissolution profile. This type of correlation is generally linear in which the in vitro and in 
vivo dissolution-time curves may be directly superimposable or may be made to be 
superimposable by the use of a scaling factor (e.g., time scaling and a scaling of the 
amount dissolved). Figure 2.3 illustrates a general Level A correlation. Once a Level A 
correlation is established, the in vivo plasma concentration profile of the test formulation 
can be predicted from the in vitro dissolution data and the bioavailability performance of 
the oral solution and thereby the in vivo bioequivalence study for the test and reference 
formulations can be substituted by the comparison of their in vitro dissolution profiles. 
 
Figure 2.3 A Level A Correlation of Drug Dissolution 
A Level B correlation is developed according to the principle of statistical 
moment analysis. It can be utilized when a Level A correlation is not possible. A Level C 
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correlation establishes a single-point relationship between a characteristic of the in vitro 
dissolution profile (e.g., amount dissolved at 1h) and a bioavailability characteristic (e.g., 
Cmax, tmax and AUC). A multiple Level C correlation takes into account multiple measures 
related to the dissolution and bioavailability profiles. Since a Level B or C correlation 
does not establish a point-to-point relationship, its likelihood of predicting the entire in 
vivo plasma concentration profile from the in vitro dissolution data is relatively lower, 
compared to a Level A correlation (Gibson, 2001; Emami, 2006). Level B or Level C 
correlations, therefore, have a limited use for regulatory purpose. 
 
2.2 Scale-Up Changes and Related Documentation Tests for IR Oral Drugs 
When an oral drug undergoes scale-up changes, the documentation tests, 
including the dissolution comparison and bioequivalence study, are conducted to exclude 
the need for reestablishing the drug safety and efficacy by retesting the patients 
administrating each formulation. Based on the FDA guidance (1995) for IR orally 
administered drugs, levels of change and involved documentation tests are summarized in 
Table 2.3. Under some circumstances, in vivo bioequivalence studies can be substituted 
by comparing in vitro dissolution profiles of the test and reference formulations. In 
addition to the establishment of IVIVC, depending on the Biopharmaceutics 
Classification System (BCS), bioequivalence studies can be eliminated if the following 
requirements are met: (1) APIs are classified as Class 1, (2) the test and reference 
formulations have rapid dissolution profiles, and (3) the coefficient of variation (CV) of 
dissolution data for the test and reference formulations should not be more than 20% at 
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Table 2.3 Scale-Up Changes and Related Tests for IR Orally Administered Drugs 
 Level Classification Dissolution Documentation 
Bioequivalence 
Documentation 
C
h
an
g
es in
 th
e A
m
o
u
n
t o
f 
In
activ
e In
g
red
ien
ts 
I 
The total additive effect of 
all excipient changes 
should not change by more 
than 5%. 
None beyond application 
requirements. 
None. 
II 
The total additive effect of 
all excipient changes 
should not be more than 
10%. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
None: if the 
similarity of two 
dissolution profiles 
cannot be ensured, 
refer to Level III. 
III 
Level III changes are those 
that are likely to have a 
significant impact on 
formulation quality. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
In vivo 
bioequivalence 
study or acceptable 
IVIVC. 
S
ite C
h
an
g
es 
I 
Changes within a single 
facility. 
None beyond application 
requirements. 
None. 
II 
Changes within a 
contiguous campus or 
between facilities in 
adjacent city blocks. 
None beyond application 
requirements. 
None. 
III 
Changes in manufacturing 
site to a different campus. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
None. 
B
atch
 S
ize 
C
h
an
g
es 
I 
Changes up to and 
including a factor of 10 
times the size of the pilot 
batch. 
None beyond application 
requirements. 
None. 
II 
Changes beyond a factor 
of 10 times the size of the 
pilot batch. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
None. 
E
q
u
ip
m
en
t 
C
h
an
g
es 
I 
A change to alternative 
equipment of the same 
design and operating 
principles. 
None beyond application 
requirements. 
None. 
II 
A change in equipment to 
a different design and 
operating principles. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
None. 
P
ro
cess C
h
an
g
es 
I 
Such changes as mixing 
times and operating speeds 
within application limits. 
None beyond application 
requirements. 
None. 
II 
Such changes as mixing 
times and operating speeds 
beyond application limits. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
None. 
III 
Changes in the type of 
process used in the 
manufacture of the 
product. 
The dissolution profiles of the 
reference and test formulations 
should be similar. 
In vivo 
bioequivalence 
study or acceptable 
IVIVC. 
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the earlier points in time (e.g., 10 min) and should not be more than 10% at other points 
in time. Note that the BCS classifies APIs into four types: high solubility and high 
permeability (Class 1), low solubility and high permeability (Class 2), high solubility and 
low permeability (Class 3), and low solubility and low permeability (Class 4) (FDA, 
2000).  
 
2.3 DOE Supports in Formulation Optimization 
DOE was first applied to the agricultural industry. With the spread of DOE, the 
first publication for the pharmaceutical industry appeared in 1952 (Hwang, 1998). Over 
the years, it has been widely acknowledged that DOE is one of the most efficient methods 
for identifying the effects of ingredient amounts on critical QCs related to a 
pharmaceutical formulation, such as dissolution, friability, disintegration, and hardness. 
Estimated response functions can then be obtained by performing a regression analysis 
based on the DOE results. In order to determine the optimal formulation, the estimated 
functions are finally employed to implement the optimization procedure where they are 
minimized, maximized, or ensured to be within the criteria specified by the FDA. 
Additionally, suitable user-friendly software packages, such as Minitab, SAS, JMP, 
NEMROD, and Design-Expert, also contribute to a quick uptake of DOE, since the 
computing environments help drug designers reduce the time and materials as well as 
mitigate the risk of failure (Gupta & Kaisheva, 2003).  
In practice, various DOE methods, such as full or fractional factorial experimental 
designs, response surface designs including central composite designs (CCDs) and Box-
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Behnken designs (Box & Behnken, 1960), mixture designs, and Taguchi designs, are 
extensively applied to the formulation optimization: 
 Factorial designs. Ragonese et al. (2002) and Hwang et al. (2011) indicated that 
factorial designs were frequently used during the phase of preliminary screening 
studies which were designed to select the excipients for the initial formulation. 
Factorial designs can be divided into full factorial designs and fractional factorial 
designs. In a full factorial design, each possible combination of factors is 
evaluated. Hwang et al. (2001b) and Hwang et al. (2001a) used full factorial 
experimental designs to evaluate the effects of diluents-related and lubricant-
related factors on the tablet characteristics, such as compression. Gohel et al. 
(2004) and Patel et al. (2007) also conducted a two-factor, three-level full 
factorial design to prepare and evaluate a drug formulation. The fractional 
factorial design allows a large number of factors to be evaluated using a relatively 
small number of experimental runs. Kincl et al. (2004) conducted a tablet 
formulation optimization study in which a fractional factorial design was used to 
investigate the effects of the physicochemical factors on the release performance 
of a tablet drug.  
 Response surface designs. Response surface designs mainly include CCDs and 
Box–Behnken designs, which usually use quadratic polynomial regression 
functions instead of linear equations to investigate the response surface. CCDs 
combined with the RSM have been widely used in response surface modeling and 
optimization, since they are systematic and efficient methods to study the effects 
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of multiple factors on formulation characteristics (Abu-Izza et al., 1996). Gupta et 
al. (2001) performed a CCD to study the effects of three factors of a colonic drug 
delivery system on two formulation responses. Ibri et al. (2002) and Singh et al. 
(2006) conducted a CCD with two factors and several responses to optimize the 
release performace of a tablet formulation. On the other hand, the main advantage 
of Box–Behnken designs over CCDs is that they ensure that all factors are never 
simultanenously set at their high levels and therefore all design points are more 
likely to remain within their safe operation zones (Kincl et al., 2005). In the 
literature, Sastry et al. (1997), Nazzal et al. (2002), and Kincl et al. (2005) 
conducted three-factor, three-level Box-Behnken designs based on the RSM to 
investigate, characterize, and optimize critical characteristics associated with 
pharmaceutical formulations.  
 Mixture designs. Mixture designs are useful in situations where the amounts of 
individual components in a formulation require optimization, but where each 
individual amount is constrained by a maximum value for the overall formulation 
(Gorman & Hinman, 1962). The weight percentages of ingredients are considered 
input factors. In the literature, RSM-based mixture designs like simplex lattice 
designs were conducted to prepare systematic formulations (Huang, Tsai, Yang, 
Chang, Wu, et al., 2004; Patel et al., 2007). Campisi et al. (1998) utilized a D-
optimal mixture design to analyze the theophylline solubility in a four-component 
formulation optimization problem; meanwhile, El-Malah et al. (2006) 
demonstrated that a D-optimal mixture design was effective to evaluate the effects 
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of three pharmaceutical ingredients on the release profile of a formulation. 
Hariharan et al. (1997) applied a four-component mixture design to optimize a 
tablet formulation with the most desirable properties; however, Piepel (1999) 
pointed out that they ignored the fixed components by working in terms of the 
relative proportions. In order to overcome this weakness, Piepel (1999) proposed 
an enhanced mixture-of-mixture design. In reality, input factors are not 
constrained to the contents of a drug, because extra manufacturing processing 
parameters, such as stirring speed (Bhavsar et al., 2006), may be involved. In this 
case, it is difficult to apply mixture designs to the formulation optimization. 
 Taguchi designs. As one of the popular DOE methods, Taguchi methods can help 
formulators extract much critical information from only a few experimental trials. 
Wang et al.(1996) utilized a seven-factor, three-level orthogonal Taguchi 
experimental design (L27) to find the optimal formation of chitosan. The L and the 
subscript, 27, represent the Latin square and the number of experimental runs, 
respectively. Varshosaz et al. (2009) applied an L8 orthogonal array design to 
obtaining the optimal release system of an oral tablet with chitosan beads. 
Moreover, Taguchi designs together with the overall desriability funtion (DF) can 
be conducted to deal with a multi-objective formulation optimization problem 
(Wang et al., 1996).  
The wide application of DOE to the formulation optimization is summarized in Table 2.4, 
where DCP, RSD, and TPP stand for Dibasic Calcium Phosphate, relative standard 
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deviation (the ratio of the standard deviation to the mean, expressed as a percentage), and 
Tripolyphosphate, respectively. 
 
2.4 Opitmization Methodologies for Selecting Pharmaceutical Formulations 
Using prospectively planned and appropriately designed DOE techniques, the 
formulation comprising of several input factors and output responses can be effectively 
evaluated. Generally, since the relationship between the factors and response is unknown, 
enhanced estimation techniques are applied to predicting the response quantitatively from 
the combination of the factors. In the literature, a twofold tendency for investigating the 
relationship can be found, which includes artificial neural network (ANN) techniques and 
ordinary regression approaches employing either first- or higher-order polynomial 
equations. On the basis of the prediction results, optimization techniques are then applied 
to determining the optimal input factor settings under a set of specified constraints. 
Several optimization algorithms, including modified computer optimization methodology 
(Takayama & Nagai, 1989; Takayama et al., 1999), Taguchi quadratic loss function 
(Taguchi, 1985), and DF (Derringer & Suich, 1980) approaches, are typically applied in 
the literature. Following subsections discuss the ANN prediction methods and three 
common optimization methodologies in greater detail. 
 
2.4.1 ANN Prediction Techniques 
An ANN, as a learning system based on a computational technique, is 
increasingly applied to describing the nonlinear relationship between pharmaceutical 
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Table 2.4 Summary of the DOE Application in Formulation Development and Optimization 
Year Author 
Optimization 
Target 
DOE 
Method 
Inactive Ingredients Factors Responses 
1996 Aub-Izza et 
al. 
Optimizing the 
overall properties of 
a sustained-release 
formulation 
CCDs N/A Emulsifier concentration, 
drug to polymer ratio, 
composition of the internal 
phase of emulsion 
The time for 85% release, 
loading efficiency, yield, 
percentage of loose surface 
crystals, overall 
desirability 
1996 Wang et al. Optimizing the 
formulation of 
Cisplatin-loaded 
Chitosan 
microspheres 
Taguchi 
designs 
Disintegrant: Chitosan Concentration of Chitosan, 
volume ratio of water and 
oil phase, stirring rate, 
percentage of Cisplatin, oil 
phase type, Chitosan type, 
stabilization time 
Percentage of particle 
numbers, drug content, 
drug trapping efficiency, 
overall desirability 
1997  Hariharan et 
al. 
Optimizing a 
sustained-release 
tablet formulation 
with the most 
desirable properties 
Mixture 
designs 
Suspending agent: γ-
carrageenan, CMC Sodium 
Diluent: DCP, Lactose 
 
The amounts of γ-
carrageenan, CMC 
Sodium, Lactose, and DCP 
The time taken to release 
80% drug, the release 
exponent, the crushing 
strength 
1997 Sastry et al. Optimizing an 
osmotically 
controlled 
formulation 
Box-
Behnken 
designs 
Suspending agent: 
Carbopol 934P 
Orifice size, coating level, 
the amount of Carbopol 
934P 
The cumulative percent of 
the drug release on time for 
10%, 25%, 50% and 75% 
release 
1998 Campisi et 
al. 
Evaluating the 
evolution of 
theophylline 
solubility 
Mixture 
designs 
Humectant: Propylene 
Glycol  
Lubricant: Polyethylene 
Glycol 
Solvent: Ethanol 
The amounts of 
Polyethylene Glycol, 
water, Propylene Glycol, 
and Ethanol 
The evolution of 
theophylline solubility 
1998 Hwang et 
al.  
Optimizing a tablet 
formulation 
Fractional 
factorial 
designs 
Diluents: Lactose Binder: 
Avicel 
Disintegrant: Starch 1500, 
Na Starch Glycolate 
Lubricant: Magnesium 
Stearate 
Glidant: Talc 
Active ingredients particle 
size, percentage of active 
ingredients, 
Lactose/Avicel ratio, 
Avicel particle size, Avicel 
density, disintegrant type, 
percentage of disintegrant, 
Percentage of blend 
uniformity, compression 
force RSD, ejection force, 
tablet weight RSD, tablet 
hardness, disintegration 
time, percent of dissolved 
at 5min 
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 percentage of Talc, 
percentage of Magnesium 
Stearate 
1999 Piepel Optimizing a 
sustained-release 
tablet formulation 
with the most 
desirable properties 
Mixture-of-
mixture 
designs 
Suspending agent: γ-
carrageenan, CMC Sodium 
Diluent: DCP, Lactose 
 
The amounts of γ-
carrageenan, CMC 
Sodium, Lactose, and DCP 
The time taken to release 
80% drug, the release 
exponent, the crushing 
strength 
2001a Hwang et 
al.  
Evaluating the 
compression 
characteristics of a 
tablet 
Full 
factorial  
designs 
Diluent: MCC 
Lubricant: Magnesium 
Stearate  
  
Lubricant level, lubrication 
time, compression speed, 
particle size, particle 
density 
Compression force RSD, 
ejection force,  tablet 
weight RSD, hardness, 
friability 
2001b Hwang et 
al.  
Evaluating the 
compression 
characteristics of a 
tablet 
Full 
factorial 
designs 
Diluent: DCP, Lactose 
Lubricant: Magnesium 
Stearate  
Lubricant level, lubrication 
time, compression speed, 
Compression force RSD, 
ejection force,  tablet 
weight RSD, hardness, 
friability 
2002 Nazzal et 
al. 
Characterizing and 
optimizing a tablet 
dosage 
Box-
Behnken 
designs 
Diluent: Maltodextrin, 
MMC 
Coating agent: 
Copolyvidone 
The amounts of 
Copolyvidone, 
Maltodextrin, and MMC 
Tablet weight, flowability 
index, tensile strength, 
percentage of friability, 
disintegration time, the 
cumulative percent of the 
drug release after 45min 
2002 Ibri et al. Optimizing aspirin 
extended release 
tablets 
CCDs Coating agent: Eudragit
®
 
RS PO 
The amount of Eudragit
®
 
RS PO, tablet hardness 
In vitro dissolution profiles 
at 1h, 2h, 4h, and 8h, 
release order, release 
constant 
2003 Gupta et al.  Identifying optimal 
preservatives for a 
formulation 
I-optimal 
designs 
Persevative: Benzyl 
Alcohol, Chlorobutanol, 
Methylparaben, 
Propylparaben, Phenol, M-
Cresol 
Amounts of Benzyl 
Alcohol, Chlorobutanol, 
Methylparaben, 
Propylparaben 
Formulation stability and 
antimicrobial efficacy (i.e., 
the bacterial and fungal 
count) 
2004 Gohel et al.  Evaluating the 
effect of the 
amounts of camphor 
and Crospovidone 
on the 
disintegration time, 
Full 
factorial 
designs 
Disintegrant: Crospovidone 
 
Amounts 
of Camphor and 
Crospovidone 
Disintegration time, 
percentage friability 
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and percentage 
friability 
2004 Huang et al. Developing and 
optimizing a 
extended-release 
formulation 
Mixture 
designs 
Diluent: MCC, and Lactose 
Binder: HPMC 
The amounts of HPMC, 
MCC, and Lactose 
The drug release percent at 
1.5, 4, 8, 14, and 24h 
2004 Kincl et al.  Evaluating and 
characterizing 
critical parameters 
which have a 
significant effect on 
the drug release 
Fractional 
factorial 
designs 
N/A Apparatus, rotation speeds, 
pH, relative ionic strength, 
salt, producer of the on-
line dissolution system 
The percentage of the 
released drug product in 
2h, 4h, 6h, 8h, 10h, 12h, 
and 24h 
2005 Kincl et al. Characterizing and 
optimizing the drug 
release performance 
Box-
Behnken 
designs 
N/A Rotation speeds, pH, and 
ionic strengths of the 
dissolution medium 
The Cumulative 
percentage of the dissolved 
drug in 2, 6,12,and 24h 
2006 El-Malah et 
al. 
Evaluating the 
effect of three 
matrix ingredients 
on thephylline 
release rates for a 
tablet formulation 
D-optimal 
mixture 
designs 
Suspending agent: 
Polyethylene Oxide, 
Carbopol 
Diluent: Lactose 
 
The amounts of 
Polyethylene Oxide, 
Carbopol, and Lactose 
Percent thephylline 
released in 2h, and 4h, 
percent amount release in 
6h, 8h, and 12h, similarity 
factor (f2) 
2006 Singh et al. Optimizing the drug 
release profile and 
bioadhesion for 
controlled release 
tablets 
CCDs Suspending agent: CMC 
Sodium, Carbopol 934P 
The amounts of Carbopol 
934P and CMC Sodium 
Release exponent, 
bioadhesive strength, the 
percentage of the released 
drug product at 18h, 24h, 
time taken to lease 50% of 
the drug 
2007a Patel et al. Developing an 
optimum drug 
delivery system 
containing 
Carbamazepine 
Simplex 
lattice 
designs 
Alkalizing agent: Sodium 
Bicarbonate 
Binder: Ethylcellulose, 
HPMC K4 M 
 
The amounts of HPMC K4 
M, Sodium Bicarbonate, 
and Ethylcellulose 
The floating lag time, the 
time required for 50% and 
80% drug dissolution 
2007b Patel et al.  Developing and 
optimizing a 
controlled-release 
multiunit floating 
system with 
Full 
factorial 
designs 
Binder: Ethylcellulose 
 
The 
amounts of Gelucire 43/01  
and Ethylcellulose  
The percentage drug 
released in 
1, 5, and 10 hours 
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desirable release 
performance 
2009 Varshosaz 
et al. 
Optimizing a 
sustained-release 
formulation  
Taguchi 
designs 
Disintegrant: Chitosan Chitosan weight, 
concentration of Chitosan 
and Sodium TPP, pH of 
TPP, cross-linking time 
after addition of Chitosan 
The rate of drug release, 
mean release time, release 
efficiency, particle size of 
the beads 
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factors and response by means of iterative training of data obtained from a designed 
experiment (Takayama et al., 2000). Figure 2.4 shows a typical structure of hierarchical 
ANN which is composed of three input units (I1, I2, I3), three hidden units (H1, H2, H3), 
and two output units (O1, O2). The units in neighboring layers are fully interconnected 
with links corresponding to synapses. Processing takes place in each hidden layer and 
output layer, and the processing unit sums its input from the previous layer and then 
utilities the sigmoidal function to compute its output to the following layer according to 
the equations (Takayama et al., 1999): 
 
and , 
where wpq is the weight of the connection from unit p to unit q, and xp is the output value 
from the previous layer. Once yq is computed, f(yq) is conducted to the following layer as 
an output value varying continuously between 0 and 1. Finally, αs is a parameter related 
to the shape of the sigmoidal function.  
Based on Armstrong (2006), iterative training should be applied to the network in 
order to identify a set of weight values that minimizes the differences between the outputs 
of the network and the measured response values. The weight of each transmission is 
initially set as a low randomly chosen value, and then it is changed after comparing the 
computed output values with the measured ones. This process will be repeated until the 
differences fall in the predetermined interval.  
 
q pq py w x  
1
1 s q
q y
f y
e



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Figure 2.4 A Typical Structure of ANN 
ANN has successful been applied to solving various problems in pharmaceutical 
research such as drug product development (Hussain et al., 1991; Takahara et al., 1997a; 
Takahara et al., 1997b), estimating diffusion coefficients (Jha et al., 1995), characterizing 
crushing and disintegration effects (Rocksloh et al., 1999), forecasting the mechanism of 
drug action (Weinstein et al., 1992), and predicting certain pharmacokinetic parameters 
(Hussain et al., 1993; Smith & Brier, 1996). Fan et al. (2004) conducted a formulation 
optimization procedure incorporating the RSM and compared the solutions resulting from 
the ANN and second-order regression techniques. In their study, ANN was found to be 
more suitable for formulating paclitaxel emulsions. Moreover, it was concluded that the 
second-order polynomial equation could be less effective in expressing a nonlinear 
relationship between the factors and response than ANN (Takahara et al., 1997a; 
Takayama et al., 1999; Takayama et al., 2000). However, it is of importance to mention 
that the RSM incorporating regression approaches may show superiority in the estimation 
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of responses compared to the ANN approach, considering the robustness of the prediction 
model against outliers (Bourquin et al., 1998). 
 
2.4.2 Common Optimization Methodologies 
The pharmaceutical formulation optimization can be considered a mathematical 
process of minimization (or maximization) of an objective function while satisfying 
various constraints. Generally, the ingredient amounts of a formulation compose the input 
factor vector, which is denoted by x, and the constraints are associated with the 
regulatory requirements on certain drug performance, for instance, dissolution, friability, 
and stability. In the review of recent literature, the objective function is generally set up 
using three methodologies including modified computer optimization techniques, 
Taguchi quality loss concept, and DF approaches.  
 
 Modified computer optimization methodology 
The modified computer-based optimization approach can be divided into single-
objective and multiple-objective. Based on Takayama and Nagai (1989), the single-
objective optimization for pharmaceutical formulations can be viewed in terms of 
minimization (or maximization) of the objective function, F(x), under the following 
inequality and equality constraints: 
 .
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As it is difficult to solve the constrained optimization problem described above 
without any mathematical modifications, the constrained optimization problem can be 
transformed to one that is unconstrained by adding a penalty function as follows: 
, 
when Gi(x) < 0, Φi = 1; when Gi(x) ≥ 0, Φi = 0, 
where T(x,r) is the transformed unconstrained objective function, r is a perturbation 
parameter (r > 0), and Φi is a step function by which the objective function is penalized.  
On the other hand, when the optimization problem includes several objectives, 
related multiple responses should be incorporated into a single function. Based on 
Takayma et al. (1999), the generilized distance between the predicted value of each 
repsonse and the optimum one that was individually calcualted using Khuri and Conlon 
methods (1981) is given by 
 , 
where S(x) is the distance function generalized by the standard deviation (SD), SDk, of 
the observed values for each response, FDk(x) is the optimum value of each response, and 
FOk(x) is the estimated value of each response. Similarly, the transformed function, 
T(x,r), is expressed as 
,
 
when Gi(x) < 0, Φi = 1; when Gi(x) ≥ 0, Φi = 0. 
         
2 21 1, Φi i iT r F r G r H
    x x x x
     
1
2
2
x x
x k k
k k
FD FO
S
SD
   
  
 

 



 
   
     
1 2
2
2 21 1, Φk k i i i
k
FD FO
T r r G r H
SD
 
   
    
   
  
x x
x x x
 44 
 
The optimum solution is estimated as the point, x
*
(r), which results in a minimum 
value of T(x,r). Based on the modified computer methodology, Takayama and Nagai 
(1989) and Takayama et al. (1999) conducted formulation optimization procedures using 
the regression and ANN approaches, respectively. 
 
 Taguchi quadratic loss function 
Taguchi quality philosophy emphasizes the need for concurrently investigating 
the mean and variability of QCs of interest, and three categories of characteristics were 
set up, namely, nominal-the-best (NTB), smaller-the-better (STB), and larger-the-better 
(LTB). Any deviation from target values of the mean and variance will result in costs and 
consequently quality loss. Hence, a number of quality loss functions have been developed 
to relate a key characteristic of a product to its performance in terms of quality. Kailash 
and Cho (1994) proposed the Laurent series expansion of the quality loss function for 
LTB characteristics. Cho and Leonard (1997) presented a class of quasi-convex quality 
loss functions for use in target problem research. Shaibu and Cho (2006) provided 
exponential-type quality loss functions for proper applications to real-world issues.  
In particular, the quadratic quality loss function for a QC proposed by Taguchi 
(1985) took the form L(y) = k(y – τ)2, where L(y) is a measure of the loss in quality 
related to the QC, y and τ are respectively the observed and target values, and k is a 
positive loss coefficient based on the magnitude of estimated losses. Moreover, it is well 
known that the expected value of the univariate squared-error loss function for NTB 
characteristics can be expressed as  
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 , (2.8) 
where E(L), μ and σ2 denote the expected quality loss, the actual mean of the QC and the 
variance of the QC, respectively. Therefore, in order to minimize the expected loss, the 
mean squared error and variance need to be reduced. In the literature, however, no formal 
research work integrating Taguchi loss function with scientific formulation optimization 
techniques has been found.  
 
 DF approaches 
As discussed earlier, it is common that drug designers are faced with an MRS 
formulation optimization problem. In the literature, researchers proposed various 
scientific techniques for solving MRS problems in the past thirty years. The usage of 
Taguchi‘s method (1986) for designing robust products or processes prevailed among 
earlier research work. Pignatiello (1993), Elsayed and Chen (1993), Vining (1998), and 
Ko et al. (2005) employed the expected Taguchi quality loss function approach to 
determine the optimal settings of input factors for products with multiple QCs. Some 
extensions to Taguchi‘s method were also made by researchers such as Chen (1997), Wu 
(2002), Fung and Kang (2005), and Kovach and Cho (2008). In practice, in addition to 
the approaches to MRS optimization problems mentioned above, some formulation 
scientists have demonstrated the effectiveness of the DF method in MRS formulation 
optimization problems (Abu-Izza et al., 1996; Paterakis et al., 2002; Rosas et al., 2011).  
The DF technique is useful to convert multiple characteristics with different units 
of measurement into a single commensurable objective by means of normalizing each 
   
2 2E L     
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estimated response variable to individual desirability, whose value varies between 0 and 
1, and the response becomes desirable as its desirability approaches 1. If  (i = 1, 2, …, 
m) is the i
th
 estimated response variable, the individual desirability for an LTB or STB 
characteristic is computed by  
, (2.9) 
where Li and Ui respectively represent acceptable minimum and maximum values, Ti is 
an allowable maximum or minimum value for the LTB or STB characteristic, and i is 
the shape parameter for the DF, which is determined based on how important to hit the 
value Ti. Similarly, if  is an NTB characteristic, its individual desirability is given by  
 , (2.10) 
where Ti is the target value, and the shape parameters are denoted by i1 and i2. 
Derringer (1994) also suggested using a weighted geometric mean function to convert the 
multiple individual desirability into a single measure of characteristic performance 
known as the overall desirability, D. Let Wi (i = 1, 2, …, m) be the pre-defined weight for 
the , D can be expressed as 
 . (2.11) 
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Hence, when applying the DF approach to optimizing a formulation, the overall 
DF value is always maximized so that the optimal settings of the ingredient amounts can 
ensure the best compromise among multiple characteristics of interest (Wang et al., 1996; 
Ficarra et al., 2002; Candioti et al., 2006; Holm et al., 2006; Zidan et al., 2007; Li et al., 
2011). In this traditional way, the estimated individual and overall DF can be obtained by 
fitting polynomial regression functions of x to the calculated desirability for the responses 
and therefore one may estimate the desirability for the formulation determined by the 
responses which in turn are at the same time determined by the factors. 
Furthermore, several innovative attempts have been made to improve the 
traditional DF approach. Del Castillo et al. (1996) proposed a differentiable DF method 
which allowed researchers to use more efficient gradient-based optimization methods for 
maximizing the overall desirability. Wu and Hamada (2000) suggested using the double-
exponential function as an alternative DF, and Wu (2004) extended the double 
exponential DF based on the Taguchi‘s loss function in order to optimize correlated 
multiple QCs. Moreover, Bashiri and Salmasnia (2009) and Goethals and Cho (2011) 
also presented new optimization procedures based on the DF method for correlated 
characteristics. However, the conventional DF method does not consider the variability of 
QCs, which is not adequately addressed in the literature and may affect its effectiveness 
of optimizing a formulation with multiple QCs. Several researchers also revealed 
additional shortcomings of the DF approach. Takayama et al. (1999) argued that one of 
the weaknesses of the DF was the subjectivity in the selection of acceptable interval for 
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each response. Kim and Lin (2000) pointed out that the DF value did not provide a clear 
interpretation except the basic principle that a higher value of desirability is preferred. 
 
2.5 Summary 
In Chapter 2, assessment of biopharmaceutical tests, including in vitro dissolution 
tests, in vivo bioavailability studies, and IVIVC, are discussed as a basis for 
understanding the development of pharmaceutical formulations. The levels of scale-up 
changes and required documentation tests for IR oral formulations are succinctly 
summarized. Various DOE techniques and common optimization methodologies applied 
to the formulation optimization are provided in detail. These investigations establish 
essential foundation for assessing dissolution and bioavailability of IR oral drugs and for 
developing a rigorous formulation optimization model when scale-up changes occur. The 
following chapters will cover the proposed models to achieve the equivalent performance 
in dissolution and bioequivalence between the pre-change and post-change formulations 
while all regulatory requirements are satisfied.  
 49 
 
CHAPTER 3 
DEVELOPING THE OPTIMAL FORMULATIONS FOR NEW TABLET DRUGS 
(DISSOLUTION COMPARISONS) 
 
3.1 Introduction 
Growth in clinical or market demand for tablet drugs often provides the impetus 
for increasing the scale of production. Pharmaceutical formulation optimization is 
conducted initially to find the optimal combination of inactive ingredients, but changes of 
formulations may occur as consequence of scale-up. In this case, in vitro dissolution 
comparisons may need to be performed so as to demonstrate the equivalent safety and 
efficacy of pre-change and post-change formulations. Therefore, the extended 
formulation optimization is necessary to determine the levels of composition aimed at 
ensuring the equivalent safety and efficacy for the changed formulation, while meeting 
all related regulatory constraints. This chapter is an attempt to propose formulation 
optimization models for the test formulation by incorporating all necessary FDA 
requirements and USP-National Formulary (USP-NF) specifications. In Section 3.2, the 
proposed optimization model is developed. Based on the FDA and USP-NF guidance, 
DOE, estimation, and optimization stages are discussed in Sections 3.2.1, 3.2.2, and 
3.2.3, respectively. In Section 3.3, the proposed optimization methodology is introduced. 
Numerical examples and analysis are presented in Section 3.4 in order to investigate the 
feasibility of the proposed methodology in solving the formulation optimization problem 
for scale-up changes in composition. Moreover, possible effects of constraints boundaries 
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on the behavior of the optimal input settings are studied by carrying out a sensitivity 
analysis in Section 3.4. Finally, conclusions are provided in Section 3.5. 
 
3.2 Development of Proposed Model 
An optimization procedure is used to seek the best combination of excipient levels 
of the test formulation in order to assure the closeness of dissolution characteristics 
between the test and reference formulations, while meeting various constraints. The 
following subsections are primarily centered on the development of the proposed 
optimization model consisting of three phases: experimental phase, estimation phase, and 
optimization phase. Furthermore, the input factors, output responses of interest, and 
related specifications have been identified and serve as a prior knowledge base for the 
proposed methodology. Figure 3.1 illustrates the development sequence of the proposed 
model.  
 
3.2.1 Experimental Phase 
Based on the FDA guidance (1995) associated with IR solid oral dosage forms, 
scale-up modifications to pharmaceutical formulations include changes in excipients 
rather than active ingredients. It is indicated by the FDA guidance (1995) that the APIs 
for the reference and test formulations remain the same. Consequently, for an extended 
formulation optimization problem, the input factors are the excipient amounts for the test 
formulation (typically measured in mg). The commonly used excipients for formulating 
an IR tablet include (1) filler, (2) starch (as a disintegrant), (3) binder, (4) magnesium 
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stearate (as a lubricant), (5) talc (as a glidant) and (6) film coat. Let xi (i = 1, 2, …, 6) 
denote the weight of each excipient in the test formulation. Moreover, the output 
responses are associated with the constraints in the optimization procedure. In the 
proposed procedure, they include dissolution, uniformity, disintegration, friability, 
compressibility, hardness, thickness and stability.  
Replicated observations can be taken for these characteristics in the experimental 
phase in order not only to evaluate the mean and variance of data in the estimation phase, 
but also to comply with the FDA or USP-NF regulations. A general DOE with r 
experimental runs for extended formulation optimization problems is illustrated in Table 
3.1, where Y
R
 represents the replicated response, and the sample mean  and variance 
 of  can be calculated from the corresponding replicated observations at the i
th
 
run for i = 1, 2, …, r. 
 
Figure 3.1 Development of Proposed Methodology 
 
3.2.2 Estimation Phase 
During the estimation phase, response functions that relate the levels of excipients
R
iY
2 ( )Ris Y
R
iY
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Construct and perform a 
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Estimation Phase
Obtain estimated response 
functions for the mean and the 
variance
Optimization Phase
Development of objective 
functions and constraints
Prior Knowledge
Control factors, responses, and 
specifications
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(x) and responses (Y
R
), including the sample averages and variances for the measures of 
interest, are obtained using linear or nonlinear regression techniques in order to 
implement the optimization phase. Generally, these experimental responses can be 
divided into two classes: time-sensitive and non-time-sensitive responses. In this chapter, 
the former includes dissolution data, which are related to the cumulative amounts 
dissolved at predetermined points in time, while the latter refers to the other responses. 
The following part focuses on the development of second-order models for time-sensitive 
responses. 
Table 3.1 General DOE Format 
Run Factors (x) Replicated Responses (Y
R
) 
Mean of 
Y
R
 
Variance 
of Y
R
 
1 
Input 
Factor 
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Referring to Table 3.1, let M = [
 
 … ] be the matrix of the means of 
the dissolution data, in which , , …, and  denote the mean vectors,  
( , , …, )k, at the k
th
 time point. Also let V = [
 
 … ] represent the 
matrix of the variances of the dissolution responses, where , , …, and  denote 
the variance vectors, [ , , ..., ]k, at the k
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 time point. It is reasonable 
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the input factors, x. Additionally, the second-order polynomial model for the 6-factor 
case is known to be 
 . (3.1) 
Hereafter, this equation will be referred to as Model (3.1). Hence, the predicted values at 
x can be obtained by the following equations: 
 and ,
 
where ω(x) = [ ] is the vector corresponding to the Model  
(3.1), and  and  are the ordinary least squares 
estimators of the parameters for the mean and variance matrices, respectively. Note that 
X is a matrix of data for the predictor variables; it is derived from the experimental 
design matrix  . The design matrix   is the r × 6 matrix whose rows and columns 
correspond to the r experimental runs and 6 factors, respectively. Finally, the functions 
describing the correlations of the means and variances with x over time t can be 
developed as follows: 
 and 
. 
 
3.2.3 Optimization Phase 
3.2.3.1 Definitions of Variables 
The decision variables in the extended formulation optimization problem are the 
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input factors mentioned in Section 3.2.1. In addition, the pre-identified weight of each 
excipient in the reference formulation can be expressed as τi (i = 1, 2, …, 6), and ai  
(i = 1, 2, ..., p)
 
is defined as the pre-identified weight of each active ingredient, where p is 
the number of APIs. 
 
3.2.3.2 Development of Objective Function 
According to the FDA (1995, 2000), the equivalent safety and efficacy of the test 
and reference formulations can be evaluated by conducting in vivo bioequivalence studies 
or in vitro dissolution comparisons when process scale-up changes occur. It is necessary 
to establish equivalence with respect to the average and variance of bioequivalence or 
dissolution characteristics for the test and reference formulations. In this chapter, the 
objective functions are set up based on Equation (2.8). 
Assume that multiple dissolution data are observed at the same point in time for 
each formulation, and let AT(ti) and AR(ti) denote the average cumulative amounts 
dissolved at time ti for the test and reference formulations, respectively, where  
i = 1, 2, …, n. As stated in Chapter 2, dissolution-time curves can be considered similar 
when f2 values are on the interval (50,100) according to the FDA guideline. Therefore, as 
proposed below, the objective function associated with dissolution comparisons 
minimizes the summation of squared deviations of f2 from the target value τ for each API:  
Minimize ,    
2
1 2
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where ATi(t,x) and ARi(t,x) are the average dissolution functions over time t for the i
th
 API 
in the test and reference formulations, respectively. Note that τ is typically set as 100, 
since two dissolution profiles become similar as τ approaches 100. 
However, the main shortcoming of the f2 method is that it is applicable to the 
dissolution data with low SDs only. In practice, because individual subjects may differ 
widely in their response to the drug release, it is essential to ensure the low variability of 
dissolution data. If the variability of the test formulation is relatively large, then the safety 
of the test formulation may be questionable. Incorporating E(L), an alternative objective 
function can be formulated to minimize the sum of the squared difference between AT(t,x) 
and AR(t,x) and the variance of AT(t,x) at each point in time. When the formulation 
contains p APIs, our objective function becomes: 
Minimize . 
 
3.2.3.3 Development of Constraints 
In this chapter, the constraints for the extended formulation optimization 
procedure can be divided into two classes: specific and common. The former is related to 
categories of scale-up changes, dissolution comparisons, bioequivalence studies and 
BCS, since a different objective function is selected, depending on the types of changes 
and the category of BCS. The latter refers to process knowledge and release 
characteristics. The constraints, associated with excipient changes, dissolution testing, 
uniformity, disintegration, friability, hardness, thickness, stability and design space, are 
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included. Recall that the BCS classifies APIs into four types: high solubility and high 
permeability (Class 1), low solubility and high permeability (Class 2), high solubility and 
low permeability (Class 3), and low solubility and low permeability (Class 4) (FDA, 
2000).  
 
 Constraints associated with excipient changes 
The FDA guidance (1995) defined different types of scale-up changes and 
different levels within each type. When a Level 1 change of any type occurs, neither in 
vitro dissolution comparisons nor in vivo bioequivalence studies are required. When a 
Level 2 change in excipients occurs, investigators should provide the documentation tests 
related to dissolution comparisons based on the BCS. Thus, it is of importance to develop 
the constraints related to excipient changes at Level 2. According to the limits on the 
percentage change in excipient amounts for Level 2 (FDA, 1995), the constraints for the 
test formulation are formulated in Table 3.2, where WR represents the pre-identified 
weight of the total reference dosage form, and (θ1, θ2, θ3, θ4, θ5, θ6) = (10%, 6%, 1%, 
0.5%, 2%, 2%). 
Table 3.2 Proposed Constraints on Excipient Changes at Level 2 
1.
 
 
2.
 
 
 
 Constraints associated with in vitro dissolution tests and comparisons 
The dissolution test is designed to determine compliance with the specific 
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dissolution requirements for a tablet or capsule dosage form (USP-NF, 2009b). The 
dissolution specification contains the three stages shown in Table 3.3, where the quantity, 
Q, is the amount of dissolved active ingredient, expressed as a percentage of the labeled 
content; the 5%, 15%, and 25% values also represent such percentages. 
Table 3.3 Acceptance Table for Dissolution 
Stage Number Tested Acceptance Criteria 
S1 6 Each unit ≥ Q + 5% 
S2 6 Average of 12 units (S1 + S2) ≥ Q, and no unit < Q − 15% 
S3 12 
Average of 24 units (S1 + S2 + S3) ≥ Q, not more than 2 
units < Q – 15%, and no unit < Q – 25% 
 
When setting dissolution specifications for a new drug, the FDA (1997b) 
recommended establishing a single-point specification for Class 1 and 3 APIs and a two-
point specification for Class 2 based on the BCS. Moreover, it is appropriate to set an 
upper limit on the RSD of dissolution data to substitute for the three-stage acceptance 
procedure in order to ensure the small variability of dissolution data, because the RSD is 
used extensively as a universal yardstick of variability (Torbeck, 2010). Therefore, the 
single- and two-point specifications for the i
th
 API (i = 1, 2, …, p) are modeled in Table 
3.4, where aUi and aLi are defined as the upper and lower bounds of a dissolution range 
for the i
th
 API, respectively, s[ ] denotes the sample SD of the characteristic of interest, 
λ1 is the upper bound of the RSD of dissolution data, and Q is generally set as 80%. 
When applying the f2 to comparing dissolution profiles, the FDA (2000) specified 
several requirements on the use of mean values. Accordingly, the constraint on the usage 
of f2 for each API can be expressed in Table 3.5 (i = 1, 2, …, p), where α = 1, 2, …, l and 
β = l + 1, l + 2, …, n. Note that tα and tβ represent the predefined earlier and later time 
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points, respectively, l is the demarcation point that distinguishes what is considered early 
and late, and tl is usually set as 10 minutes. 
Table 3.4 Proposed Constraints for Single- and Two-Point Specifications 
Single-point Two-point RSD 
 
  
 
Table 3.5 Proposed Constraints for the f2 Method 
1.  
2.  
3.  
4. 
 
 
 Constraints associated with uniformity acceptance criteria 
Generally, two methods, content uniformity and weight variation (WV), can be 
applied to testing uniformity. Since the input factors are associated with the weights of 
inactive ingredients, the following part focuses on the WV tests.  
The USP-NF (2009c) presents the approach to calculate acceptance value (AV) 
for WV by the following equation: 
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 , (3.2) 
where k is the acceptability constant, and Tc is the target content per dosage expressed as 
a percentage, which is usually set as 100%. Let χi (i = 1, 2, …, q) denote the individual 
APIs of the units tested expressed as a percentage of the label claim, where q is the 
sample size.  and s are the sample mean and SD of χi, respectively. Note that k is set as 
2.4 (2.0) when the sample size equals 10 (30) based on the USP-NF guidance. The 
uniformity requirements are met if the AV of the first 10 (q = 10) dosage units is no more 
than G%, which is the upper limit of the AV. If the AV is greater than G%, an additional 
20 units should be tested. The RSD should be no more than 2% based on the USP-NF 
guideline (2009c). Moreover, the requirements usually apply individually to each active 
ingredient. In our proposed optimization model, χij for the i
th
 active ingredient is 
estimated by:  
, 
where aij is the weight of the i
th
 API for the j
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 replication. Based on the USP-NF 
requirement, the constraints for the i
th
 active ingredient are proposed in Table 3.6. (x) 
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inactive ingredients. They can be calculated by the respective equations for the i
th
 active 
ingredient presented in Table 3.7. 
Table 3.6 Proposed Constraints on WV Tests 
1. Weight of API ≥ 25mg  
2. Ratio of API ≥ 25%  
3. RSD ≤ 2%  
4. AV ≤ G% (Referring to 
Equation (3.2)) 
 
 
Table 3.7 Proposed Estimating Equations for WV Tests 
1.  (3.3) 
2.    (3.4) 
3.  
 
 Constraints associated with disintegration acceptance criteria 
The disintegration time is the time taken for all six tablets to disintegrate 
completely. If one or two tablets out of the six fail to disintegrate sufficiently, 12 
additional tablets are tested (USP-NF, 2009a). The proposed constraints for disintegration 
time are described as: 
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where D(x) is the response function that relates the average disintegration time to the set 
of factors, x. dU and dL are the upper and lower disintegration time limits, respectively. 
Finally, s[D(x)] and λ2 denote the standard deviation of D(x) and the upper bound of the 
RSD, respectively.  
 
 Constraints associated with friability acceptance criteria 
Tablet friability is measured by evaluating the loss of mass for a tablet. According 
to USP-NF (2009e), the loss of mass for a single tablet should be no more than 1%. If the 
weight loss is greater than 1%, the test should be repeated twice and the mean loss of 
mass for the three tablets should be no more than 1%. Therefore, the constraints on 
friability, under two scenarios (1.1 and 1.2), are proposed in Table 3.8, in which F(x) is 
the response function that relates the average mass loss to the set of factors, x, and the 
subscript i (i = 1, 2, 3) represents the individual measure for the i
th
 sample. 
Table 3.8 Proposed Constraints on Friability 
Scenario 1.1  
Scenario 1.2 
 
 
 Constraints associated with compressibility acceptance criteria 
The compressibility index (CI) is determined by CI = 100×(V0 – Vf)/V0, where V0 
is the unsettled apparent volume and Vf is the final tapped volume (USP-NF, 2009d). 
Based on the USP-NF guideline (2009d), a CI value less than 25 is considered to be 
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acceptable; further, a value less than 10 is regarded as excellent. Therefore, the related 
constraint is developed as follows:  
, 
where V0(x) and Vf(x) are the response functions that relate the average volumes to the set 
of factors, x, and H denotes the upper limit of CI. 
 
 Constraints associated with hardness, thickness, and stability acceptance criteria 
Hwang et al. (2011) indicated that the hardness, thickness, and stability of a tablet 
were essential responses when conducting formulation optimization. Tablet hardness and 
thickness are usually measured in kilopascals (kp) and millimeters (mm), respectively. 
Stability usually refers to the degradation time of a tablet under certain environmental 
conditions. Let Ni(x) (i = 1, 2, 3) represent the related DOE response functions and ηLi 
and ηUi (i = 1, 2, 3) define the corresponding lower and upper limits for hardness, 
thickness, and degradation time. Therefore, the constraints can be described as: 
. 
 
 Constraints associated with design space 
Based on the type of DOE methods applied in the optimization procedure, the 
input factors should remain within the corresponding design space. The design space is 
the region explored by DOE that determines the levels of a formulation that are both 
optimal and feasible. For a factorial design or a Taguchi design, the design space for each 
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factor should be within the interval between the minimum and maximum coded values. 
That is, −1 ≤ xi ≤ 1 for i = 1, 2, …, 6. For a CCD, x
T
x≤ ρ2 where ρ is the distance in any 
direction from the center point and is analogous to the radius of a sphere. A CCD will be 
employed here since it is one of the most effective DOE methods for capturing the 
quadratic effects of input factors. 
 
3.3 Proposed Optimization Model 
In this section, the formulation optimization procedure is developed on the 
premises that (1) the factors, responses, and specifications of interest have been identified 
prior to the optimization study; (2) 12 individual units of the test and reference 
formulations, based on FDA requirements, are used in dissolution tests. 
The acceptance criteria of Level 2 excipient changes for different 
biopharmaceutics classes are presented in Table 3.9 (FDA, 1995). The proposed 
formulation optimization involves Level 2 excipient changes for three classes of drugs. 
Taking into consideration all the related acceptance criteria and constraints, the proposed 
optimization procedure is described in Table 3.10. It should be mentioned that the 
objective functions for Class 1 drugs exclude the term associated with the deviation from 
the target value because no target values for the mean can be identified based on Table 
3.9. In other words, the objective function for Class 1 drugs is established to minimize the 
summation of either the variance or SD of dissolution data for each API. Ensuring either 
the minimum variance or SD depends on which of the two is chosen as the response. 
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Note that the second-order response functions, which estimate the correlations of the 
variance and SD with the input factors, are different.  
 
3.4 Examples for Level 2 Excipient Changes 
Few formal numerical examples for the extended formulation optimization 
problem can be found in the literature; therefore, simulated data are used in this section. 
The data are obtained randomly using Microsoft® Excel. The statistical software used to 
evaluate the experimental design results is Minitab® 16. The optimization procedure is 
conducted using Wolfram Mathematica® 8. The formulation optimization procedure is 
performed to seek the optimal weights (mg) of five input factors including the amounts of 
filler (x1), disintegrant (x2), binder (x3), lubricant (x4) and glidant (x5). A five-factor CCD 
with a total of 32 (r = 32) experimental runs is used to evaluate the effects of these factors 
on the responses and to optimize the formulation. The uncoded values of five levels (−2, 
−1, 0, +1, +2) for each factor are provided in Table 3.11. In addition, the pre-identified 
weight of each excipient in the reference formulation is (τ1, τ2, τ3, τ4, τ5) = (190, 10.5, 20, 
15, 2.5),
 
measured in mgs. The number of APIs is p = 1, and the pre-identified weight of 
the API is a1 = 80mg. Thus, the total weight of the reference formulation turns out to be 
WR = 318mg. As for the parameters related to the USP-NF acceptance criteria, let Q = 
80%, λ1 = λ2 = 10%, G = 15,Tc = 100%, dL = 10min, dU = 11.8min, ηL1 = 9.5kp, ηU1 = 
10.5kp, aU = 50%, aL = 65% and H = 25. 
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Table 3.9 Acceptance Criteria of Level 2 Excipient Changes Based on the BCS 
Classification 
Acceptance Criteria 
Class 1 Class 2 Class 3 
Level 2 Excipient 
Changes 
Single point dissolution 
of 85% within 15 
minutes. 
Multi-point dissolution 
profile should be 
similar to the reference 
one. 
Multi-point dissolution 
profile should be 
similar to the reference 
one. 
 
Table 3.10 Proposed Optimization Scheme for the Formulation Optimization 
Problem 
Minimize  
 1. For Class 1 drugs 
 
(1)  
(2)  
 2. For Class 2 and 3 drugs 
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 Common constraints: 
 1. Disintegration time criteria 
  
 2. Dissolution criteria ( ) 
 
(1) For Class 1 and 3 drugs 
 
 
(2) For Class 2 drugs 
 
 
(3) For Class 1, 2, and 3 drugs
 
 
 3. Uniformity criteria 
 
 
 
 4. Friability criteria 
 
 
 5. Compressibility criteria 
  
 6. Hardness, thickness and stability criteria 
  
 7. Nonnegativity of regression functions 
 
 
    where  stands for all derived response regression equations. 
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Table 3.11 The Uncoded Values of Factors 
Factors 
Levels 
−2 −1 0 +1 +2 
x1 160 170 180 190 200 
x2 4.8 7.8 10.8 13.8 16.8 
x3 15 20 25 30 35 
x4 1 5 9 13 17 
x5 2 6 10 14 18 
 
3.4.1 Class 1 Drugs with Level 2 Changes 
Within each experimental run, 12, 10, and 6 formulations are prepared for single-
point dissolution tests, uniformity tests, and disintegration tests, respectively, and 3 
formulations for friability, compressibility and hardness tests. The means and variances 
of the responses of interest are provided in Table 3.12. Moreover, in order to calculate the 
responses associated with uniformity tests, replicated observations on the amount of the 
API are presented in Table 3.13. Note that the responses  and s1 can be obtained using 
Equations (3.3) and (3.4).  
The optimization procedures for minimizing the variance and SD of the 
dissolution data are performed; the composition and predicted responses for both 
scenarios (1.3 and 1.4) are listed in Table 3.14. It is concluded that the optimal solution in 
the second scenario provides a smaller s(AT) than that in the first one. Therefore, in terms 
of reducing the variability of dissolution data for the test formulation, the second scenario 
optimization procedure is preferred. 
 
 
1
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Table 3.12 Response Sets for Class 1 Drugs 
 
3.4.2 Class 2 and 3 Drugs with Level 2 Changes 
Similar to Section 3.4.1, the amounts of the input factors are considered as 
decision variables. Assume that the observations associated with disintegration, 
uniformity, friability, compressibility and hardness tests are still valid in this section. The 
dissolution means and SDs derived from the 12 replicated formulations at 8 time points 
are provided in Table 3.15. The output responses are simulated from 5 min to 60 min. 
Further, 5 min, 8 min, and 10 min are defined as earlier time points, and the two-point 
specification for dissolution performance is established at 15 min and 45 min. The 
amount (mg) dissolved for the reference formulation at each time point is set as follows: 
Run AT(tb) s
2[ AT(tb)] s[ AT(tb)] D s(D) CI N1 F1 F2 F3 
1 67.06 28.78 5.37 10.5 0.94 34.3 10.3 2.7 1.9 2.0 
2 64.09 14.79 3.85 11.2 1.06 15.1 10.7 2.6 1.8 2.7 
3 68.13 37.60 6.13 9.8 1.07 20.9 9.9 2.1 2.0 2.0 
4 65.88 52.52 7.25 11.9 0.96 23.1 10.9 3.7 1.9 2.2 
5 69.68 69.92 8.36 9.4 0.86 28.3 9.0 2.9 2.3 3.2 
6 64.62 50.52 7.11 11.5 1.23 28.5 11.6 2.6 2.9 3.4 
7 71.95 101.47 10.07 9.9 1.06 34.4 10.1 3.5 2.9 1.6 
8 69.94 110.05 10.49 11.8 1.17 20.2 10.5 2.5 2.8 2.9 
9 68.69 16.98 4.12 10.8 1.15 14.5 8.2 2.7 1.9 2.9 
10 68.16 16.72 4.09 10.0 0.86 27.7 10.2 2.9 3.1 1.9 
11 70.82 12.54 3.54 9.2 0.83 14.1 8.1 2.6 2.1 3.0 
12 65.98 15.67 3.96 12.0 0.98 24.0 9.7 2.5 3.7 2.9 
13 64.34 20.28 4.50 9.0 0.90 17.5 11.1 1.7 1.8 2.3 
14 71.90 101.34 10.07 11.0 1.03 25.9 9.7 3.5 1.9 2.5 
15 70.91 32.18 5.67 10.5 0.89 10.4 11.7 2.1 2.7 2.2 
16 69.87 48.82 6.99 10.6 0.94 32.1 10.9 2.5 2.5 2.2 
17 64.74 60.36 7.77 10.8 1.17 27.2 12.0 1.9 1.6 3.0 
18 66.06 15.71 3.96 9.1 0.84 18.0 10.8 2.4 2.7 1.8 
19 71.23 41.10 6.41 9.1 0.75 14.8 9.2 3.2 1.8 1.7 
20 64.49 50.32 7.09 9.3 0.96 33.6 8.2 2.9 2.3 3.2 
21 67.29 54.78 7.40 9.3 0.79 30.6 11.3 2.9 3.1 3.3 
22 66.90 54.15 7.36 10.9 0.93 27.8 11.9 3.7 2.9 2.6 
23 67.12 101.36 10.07 12.4 1.00 34.8 9.4 2.5 2.7 3.4 
24 68.80 38.34 6.19 10.9 1.17 30.8 8.7 2.4 1.6 1.9 
25 70.27 96.79 9.84 10.3 1.09 23.2 11.8 1.6 3.1 3.2 
26 71.38 32.61 5.71 10.7 0.99 14.9 8.8 2.4 3.6 2.9 
27 69.38 30.81 5.55 10.4 0.95 18.1 8.7 2.4 3.5 2.2 
28 66.59 99.78 9.99 12.0 1.22 16.5 11.3 2.4 2.9 2.9 
29 66.70 11.12 3.33 9.4 1.00 24.8 8.5 3.2 2.2 3.5 
30 68.08 29.66 5.45 10.2 1.07 13.9 9.6 2.2 2.1 1.7 
31 64.22 69.71 8.35 10.2 1.07 24.3 8.5 2.0 2.4 2.8 
32 65.98 10.88 3.30 11.4 1.21 25.3 10.6 2.9 2.9 1.6 
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AR(t1 = 5min) = 22 AR(t2 = 8min) = 33 AR(t3 = 10min) = 38 AR(t4 = 15min) = 48
 
AR(t5 = 30min) = 65 AR(t6 = 45min) = 74
 
AR(t7 = 55min) = 77 AR(t8 = 60min) = 78 
 
The proposed optimization procedures are performed for the two scenarios (1.5 
and 1.6). In the first one, similarity factor f2 with its related constraints are used. 
However, the second scenario does not take f2 into consideration. The optimal amounts of 
ingredients in both scenarios are achieved and summarized in Table 3.16. Note that 
within each scenario, there is no significant difference in the optimal settings between 
Class 2 and 3 drugs. The f2 value in Scenario 1.5 is greater than that in Scenario 1.6; thus, 
the optimal formulation in the former scenario is better than that in the latter, with respect 
to the FDA suggestion on the use of f2. However, for the test formulation, the mean of the 
dissolution data at each time point in Scenario 1.6 is generally closer to the reference 
value, except for AT(t6) and AT(t7). The dissolution rates at t6 and t7 decrease most sharply, 
which probably leads to these relatively large deviations from the corresponding 
reference values. Further investigations may be needed to penalize the dissolution data at 
certain points in time that have most sharp dissolution rates by assigning weights to the 
corresponding terms in the objective function. Additionally, the variability of dissolution 
data at each time point in the second scenario is generally smaller, except for s(t1), s(t4) 
and s(t8). It is important to mention that the differences of s(t1), s(t4) and s(t8) between 
both scenarios are insignificant with p-values of 0.919, 0.859 and 0.896 greater than α = 
0.05 based on the following two-sample F-test for the variance ratio for i = 1, 4, 8.  
H0:   (ti, x
*
) under Scenario 1.5 =   (ti, x
*
) under Scenario 1.6 
versus 
H1:   (ti, x
*) under Scenario 1.5 ≠   (ti, x
*
) under Scenario 1.6. 
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Table 3.13 API Levels and Responses Associated with Uniformity Tests 
Run 
API Levels Mean 
  
          
 
1 79.63 79.38 79.92 80.37 79.43 80.58 79.66 80.85 78.93 79.91 79.87 0.9989 0.010 
2 80.28 79.24 79.95 79.17 79.33 80.83 80.46 80.05 80.02 79.16 79.85 0.9987 0.013 
3 80.98 79.67 79.01 80.24 79.46 79.27 80.36 80.63 79.15 80.88 79.96 0.9997 0.012 
4 79.61 79.95 79.89 79.12 80.22 80.90 79.57 79.42 79.20 79.12 79.70 0.9973 0.013 
5 80.74 79.99 80.51 79.32 80.68 79.77 80.93 80.33 79.60 80.26 80.21 1.0019 0.022 
6 80.21 80.98 79.19 79.23 80.77 80.33 80.82 80.37 79.74 79.10 80.07 1.0007 0.014 
7 80.72 78.98 80.56 80.92 79.10 79.02 79.01 80.65 79.50 80.01 79.85 0.9987 0.018 
8 80.43 79.36 79.91 80.93 79.42 80.14 79.84 80.50 79.08 79.93 79.95 0.9996 0.013 
9 79.13 79.50 80.71 79.45 79.53 79.33 79.31 80.72 79.40 80.37 79.74 0.9977 0.020 
10 80.54 80.79 78.95 79.88 80.98 80.03 79.51 80.85 79.09 80.37 80.10 1.0009 0.021 
11 80.07 80.20 79.27 80.23 79.29 80.65 79.50 79.77 80.28 80.77 80.00 1.0000 0.021 
12 80.56 78.92 79.94 80.32 80.90 79.89 80.44 80.54 80.84 79.30 80.16 1.0015 0.012 
13 79.72 79.37 80.90 80.74 78.96 80.08 80.75 79.98 79.66 80.75 80.09 1.0008 0.017 
14 80.19 79.66 80.24 79.33 79.94 80.79 80.73 79.26 79.40 79.06 79.86 0.9987 0.012 
15 80.98 80.91 79.20 78.95 80.71 80.83 80.12 79.76 80.08 79.68 80.12 1.0011 0.011 
16 80.50 79.23 80.89 79.51 79.93 80.17 79.08 80.62 79.61 79.28 79.88 0.9989 0.021 
17 79.06 80.16 80.41 80.07 80.24 79.66 78.97 80.49 79.23 79.35 79.76 0.9979 0.022 
18 80.37 80.93 80.54 80.62 79.34 79.96 80.50 80.86 79.87 80.49 80.35 1.0032 0.019 
19 79.93 79.35 79.99 80.08 80.10 79.63 80.64 79.46 79.36 80.22 79.88 0.9989 0.018 
20 79.36 80.70 80.28 79.89 80.20 79.19 79.43 79.44 80.90 80.73 80.01 1.0001 0.014 
21 79.39 80.64 79.38 80.41 80.58 80.10 80.36 80.05 80.70 79.99 80.16 1.0015 0.012 
22 80.36 79.01 80.75 80.77 80.53 79.17 79.36 78.99 80.43 79.69 79.90 0.9991 0.011 
23 79.27 79.09 80.66 80.40 80.11 79.71 79.45 79.80 79.52 79.43 79.74 0.9976 0.014 
24 79.70 80.15 79.95 79.81 80.00 80.09 80.46 79.25 80.34 79.10 79.88 0.9989 0.017 
25 79.55 79.40 79.73 80.19 80.39 79.11 80.94 80.40 78.92 79.79 79.84 0.9985 0.022 
26 80.66 80.73 80.26 80.27 79.64 79.51 80.54 79.42 80.68 80.56 80.23 1.0021 0.013 
27 79.91 79.52 79.65 80.20 80.53 79.01 79.67 80.77 79.94 80.52 79.97 0.9997 0.022 
28 80.35 80.71 79.18 79.02 79.93 80.35 80.25 80.01 80.53 80.62 80.09 1.0009 0.020 
29 78.94 79.15 79.39 79.46 80.04 79.38 80.81 78.94 79.85 80.43 79.64 0.9966 0.012 
30 79.85 79.65 79.50 80.89 79.90 79.35 80.21 79.38 80.69 79.68 79.91 0.9991 0.012 
31 80.54 80.86 79.90 80.18 80.91 80.64 79.17 79.22 79.85 79.94 80.12 1.0011 0.018 
32 79.05 78.92 80.33 80.75 80.19 79.64 80.94 80.33 79.13 79.24 79.85 0.9986 0.018 
 
Therefore, the optimization model in Scenario 1.6 generally works better in terms of 
minimizing both deviations from the target values and variances. 
The three-dimensional response surfaces, shown in Figure 3.2, are drawn to 
estimate the effects of the input factors on the expected quality loss. x1, x2, and the values 
of the objective function in each scenario are included for each diagram. Additionally, the 
contour plots illustrating the simultaneous effect of x1 and x2 on the objective functions 
are provided in Figure 3.3. Note that in both Figures 3.2 and 3.3, x3, x4, and x5 are set at 
their optimal levels. 
1 1s
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Table 3.14 The Factors and Responses of the Optimal Formulation 
Scenario      AT s(AT) D s(D) CI N1 F1 AV1 
1.3 173.61 13.38 18.48 15.24 7.06 68.30 4.19 11.49 1.11 21.60 9.76 2.16 0.03 
1.4 169.10 12.45 20.18 16.51 8.77 68.79 3.97 11.56 1.15 17.30 9.50 1.91 0.04 
 
3.4.3 Sensitivity Analysis 
The behavior of the optimal solutions is further examined by varying associated 
constraint boundaries in order to validate the optimization results. The boundaries which 
are associated with dissolution performance, including the lower bounds of λ1 and f2, are 
respectively altered for the sensitivity analysis on the models in Sections 3.4.1 and 3.4.2, 
while additional boundaries remain the same. The results for Class 1 drugs with Level 2 
changes are summarized in Table 3.17. As λ1 increases from 0.2 to 0.4 with an increment 
of 0.1, the optimal input settings provided by the model in Scenario 1.4 always produce a 
smaller s(AT). In other words, the conclusion that the optimization model in Scenario 1.4 
is superior in terms of minimizing the variability is consistent with that stated in Section 
3.4.1. Similarly, a sensitivity analysis of the constraint boundary to the optimal solution is 
performed by varying the lower bound of f2 from 60 to 70 with an increment of 5, which 
is shown in Table 3.18. Note that no change occurs in the optimal solutions for Scenario 
1.5. Based on Table 3.18, it can be observed that (1) the means of the amounts dissolved 
at t6 and t7 in Scenario 1.6 deviate more significantly from the corresponding reference 
values, and (2) s(t1), s(t4) and s(t8) are smaller in the first scenario, while the differences 
of them between both scenarios are statistically insignificant. Hence again, the optimal 
solutions in the second scenario provide overall preferred outputs. 
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Table 3.15 Multi-Point Dissolution Data 
Run 
t1 t2 t3 t4 = tb t5 t6 = tc t7 t8 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
1 22.75 3.62 33.05 5.94 36.34 3.85 48.55 4.41 66.01 6.09 75.41 7.38 76.89 7.66 78.50 7.58 
2 22.07 3.93 32.99 5.65 38.04 3.70 46.34 4.48 63.55 6.08 72.72 7.31 76.84 7.62 78.09 7.76 
3 22.14 3.71 31.97 5.91 37.21 3.89 48.98 4.39 66.96 6.08 73.49 7.37 76.82 7.80 78.06 7.53 
4 20.24 3.97 33.67 5.67 37.48 3.86 47.30 4.57 66.43 6.06 75.04 7.21 77.70 7.61 78.00 7.60 
5 20.40 3.77 34.55 5.91 38.97 3.50 48.98 4.31 63.80 6.10 72.80 7.34 77.85 7.78 78.12 7.55 
6 20.77 3.97 31.64 5.97 37.26 3.60 46.03 4.44 63.79 6.14 75.06 7.39 76.66 7.60 78.89 7.70 
7 20.46 3.60 33.37 5.76 36.51 3.71 48.50 4.48 63.71 6.13 74.78 7.40 77.73 7.64 78.96 7.34 
8 21.26 4.01 31.74 5.71 36.89 3.80 46.30 4.44 63.27 6.09 74.52 7.22 77.85 7.62 78.93 7.71 
9 21.47 3.98 33.75 5.74 36.21 3.79 48.86 4.44 63.71 6.02 74.89 7.22 77.74 7.71 77.90 7.59 
10 22.43 3.90 34.34 5.69 37.79 3.75 48.96 4.47 64.49 6.03 74.50 7.21 77.58 7.70 78.77 7.74 
11 20.92 3.79 31.64 5.73 36.26 3.84 46.66 4.44 63.00 6.18 74.96 7.39 77.38 7.65 78.90 7.45 
12 20.98 3.76 33.59 5.86 37.71 3.87 48.23 4.40 65.51 6.16 72.70 7.26 76.94 7.61 78.70 7.27 
13 22.39 3.83 34.25 5.86 37.22 3.78 46.02 4.59 63.37 6.09 75.44 7.29 76.91 7.72 77.90 7.56 
14 22.68 4.04 34.74 5.75 38.65 3.64 46.89 4.56 65.47 6.02 75.82 7.25 77.57 7.78 78.87 7.78 
15 20.80 3.90 33.99 5.69 36.69 3.78 46.78 4.43 63.90 6.19 74.29 7.20 76.98 7.78 78.16 7.60 
16 20.95 4.05 31.84 5.97 36.89 3.58 48.29 4.49 66.62 6.05 73.59 7.22 77.62 7.73 78.71 7.60 
17 22.63 4.07 34.12 5.87 36.67 3.56 47.96 4.40 66.80 6.07 73.49 7.39 77.45 7.61 78.09 7.55 
18 20.34 3.97 34.81 5.77 36.25 3.72 46.13 4.44 65.63 6.06 73.93 7.25 77.83 7.64 78.72 7.27 
19 22.07 3.81 33.82 5.93 37.21 3.80 48.80 4.44 63.31 6.00 72.43 7.23 76.67 7.60 77.90 7.31 
20 22.37 3.72 34.65 5.63 36.14 3.55 48.45 4.60 65.87 6.08 75.42 7.37 77.90 7.77 78.66 7.64 
21 22.33 3.96 31.95 5.65 36.86 3.90 48.28 4.48 63.88 6.02 74.52 7.21 77.57 7.66 78.87 7.46 
22 20.06 4.01 32.38 6.00 38.99 3.71 48.41 4.36 64.64 6.18 74.10 7.40 77.55 7.61 78.30 7.75 
23 22.45 3.97 31.39 5.63 36.39 3.90 46.65 4.55 64.33 6.11 72.79 7.36 76.74 7.75 78.89 7.76 
24 20.30 3.74 33.09 5.83 36.73 3.81 48.22 4.49 64.10 6.16 75.05 7.27 76.53 7.60 78.11 7.38 
25 22.81 3.85 34.05 5.64 38.08 3.52 47.58 4.35 63.52 6.03 75.44 7.25 77.58 7.71 78.21 7.56 
26 22.62 3.71 32.45 5.65 38.02 3.69 48.99 4.37 64.79 6.20 73.07 7.30 77.44 7.61 77.96 7.53 
27 20.89 3.71 31.72 5.64 38.16 3.52 46.58 4.57 63.45 6.14 74.15 7.27 76.74 7.65 78.77 7.65 
28 21.41 3.75 32.18 5.87 36.58 3.58 47.18 4.32 65.47 6.21 74.25 7.32 76.88 7.59 78.26 7.78 
29 21.33 3.81 31.67 5.97 37.72 3.64 48.98 4.47 66.34 6.12 74.80 7.34 77.12 7.58 78.66 7.39 
30 21.67 3.98 33.02 5.85 36.13 3.50 47.81 4.53 65.87 6.18 74.11 7.10 77.64 7.68 78.76 7.51 
31 20.75 3.74 34.84 5.69 38.63 3.87 47.46 4.51 65.48 6.27 75.55 7.40 76.99 7.71 78.36 7.50 
32 21.28 3.94 33.06 5.65 38.12 3.56 48.81 4.60 65.87 6.25 75.41 7.39 76.89 7.68 78.54 7.20 
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Table 3.16 Summary of Optimal Formulations in Two Scenarios 
 Scenario 1.5 Scenario 1.6 
 178.02 190.05 
 
14.88 9.60 
 16.82 22.16 
 13.41 13.73 
 8.86 4.15 
 84.28 63.34 
 22 : 19.95 ± 3.82 21.85 ± 3.84 
 33 : 30.49 ± 5.72 33.35 ± 5.51 
 38 : 36.20 ± 3.90 37.26 ± 3.73 
 48 : 48.57 ± 4.39 48.51 ± 4.43 
 65 : 63.46 ± 6.22 63.92 ± 6.13 
 74 : 73.94 ± 7.35 74.51 ± 7.22 
 
77 : 77.28 ± 7.66 77.63 ± 7.66 
 
78 : 78.90 ± 7.43 78.71 ± 7.48 
 
Table 3.17 Sensitivity Analysis for Class 1 Drugs with Level 2 Changes 
λ1 Scenario      s(AT) 
0.2 
1.3 173.71 13.39 18.44 15.22 7.04 4.19 
1.4 168.50 12.29 20.40 16.66 8.90 3.95 
0.3 
1.3 173.70 13.39 18.44 15.22 7.04 4.19 
1.4 168.69 12.34 20.25 16.60 8.90 3.95 
0.4 
1.3 173.73 13.39 18.44 15.22 7.04 4.19 
1.4 169.51 12.32 16.82 16.27 8.08 3.98 
 
3.5 Conclusion 
Throughout the development of a new drug, it is frequent for a new product to 
encounter changes in composition due to scaling up production. In order to smooth the 
scale-up and to ensure the equivalent safety and efficacy of the product, the traditional 
pharmaceutical formulation optimization procedure can be extended to determine the 
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Table 3.18 Sensitivity Analysis for Class 2 and 3 Drugs with Level 2 Changes 
Optimal settings 
 f2 ≥ 60 f2 ≥ 65 f2 ≥ 70 
Scenario 1.5 Scenario 1.6 Scenario 1.6 Scenario 1.6 
 178.02 190.05 190.12 186.67 
 
14.88 9.60 9.58 11.62 
 16.82 22.16 21.82 20.58 
 13.41 13.73 13.50 13.41 
 8.86 4.15 4.89 5.80 
 
84.28 63.34 65.00 70.00 
 22 : 19.95 ± 3.82 21.85 ± 3.85 21.67 ± 3.86 21.04 ± 3.83 
 33 : 30.49 ± 5.72 33.35 ± 5.51 33.20 ± 5.53 32.16 ± 5.60 
 38 : 36.20 ± 3.90 37.26 ± 3.73 37.21 ± 3.72 36.86 ± 3.76 
 48 : 48.57 ± 4.39 48.51 ± 4.43 48.56 ± 4.44 48.68 ± 4.42 
 65 : 63.46 ± 6.22 63.92 ± 6.13 64.04 ± 6.13 64.26 ± 6.20 
 74 : 73.94 ± 7.35 74.51 ± 7.22 74.37 ± 7.22 74.11 ± 7.24 
 
77 : 77.28 ± 7.66 77.63 ± 7.66 77.61 ± 7.65 77.33 ± 7.64 
 
78 : 78.90 ± 7.43 78.71 ± 7.48 78.73 ± 7.48 78.71 ± 7.43 
 
  
Figure 3.2 Response Surface Plots Showing the Effects of x1 and x2 on the Objective 
Function 
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Figure 3.3 Contour Plots of x1 and x2 for the Dissolution Comparison Problem 
optimal settings of inactive ingredients when ingredient changes occur. The proposed 
optimization model can also be used to avoid duplicate submission of data to the FDA for 
excipient changes. Incorporating the quality loss concept, more comprehensive quality 
loss functions are developed and used as the objective functions in this chapter. The 
concept of quality loss is attractive because it evaluates the deviations from target profiles 
of both the mean and variance, while traditional methods only consider the mean. The 
variance is generally considered essential because large variability in the dissolution 
performance of the formulation may result in unpredictable safety and efficacy issues. 
Furthermore, the extended formulation optimization procedure is developed by 
investigating all related regulatory regulations and incorporating modern DOE and 
regression techniques into the optimization methodology. The numerical examples under 
different scenarios examine the feasibility of introducing the proposed approach to the 
practical optimization problem. Finally, a sensitivity analysis is conducted to study the 
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behavior of optimal input factor settings for varying associated constraint boundaries. In 
summary, implementing the extended formulation optimization methodology not only 
minimizes the quality loss, but also potentially achieves cost savings. 
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CHAPTER 4 
DEVELOPING THE OPTIMAL FORMULATIONS FOR NEW TABLET DRUGS 
(BIOEQUIVALENCE STUDIES) 
 
4.1 Introduction 
In the previous chapter, the extended formulation optimization procedure 
associated with dissolution comparisons was developed. This chapter is a continuous 
effort on optimizing pharmaceutical formulations for scale-up changes in excipients when 
bioequivalence studies are carried out. If a Level 3 change in excipients for Class 4 drugs 
(containing APIs with low solubility and low permeability) is detected, the FDA 
guidance (1995) for IR solid oral dosage forms requires establishing bioequivalence 
between the pre-change reference and post-change test formulations so as to avoid 
resubmission of data for excipient changes to the FDA. Note that Level 3 changes refer to 
those that are likely to have a significant impact on formulation quality. In that case, the 
in vivo bioequivalence study is generally performed to compare the critical bioavailability 
attributes for the two formulations. Bioavailability is a measurement of the rate and 
extent of the active ingredient which is absorbed and becomes available at the site of 
action (Shargel et al., 2004). Furthermore, ABE is concluded if the average 
bioavailability attributes of the test formulation is within 80% to 125% of those of the 
reference formulation at the 90% significance level (FDA, 2001). Additionally, 
bioequivalence studies may be excluded by establishing an IVIVC. 
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In order to determine the optimal setting of excipients and to ensure the 
bioequivalence of the test formulation, DOE and regression techniques can be 
incorporated into the optimization model. However, no formal research incorporating 
bioequivalence studies into DOE techniques has been found. However, several methods 
for evaluating the bioavailability characteristics for an individual profile exist in the 
literature (Shargel et al., 2004; Chow & Liu, 2009). The question remains as to which 
method is most appropriate for the integration of bioequivalence and DOE 
methodologies. In this chapter, we shall perform the following studies:  
 Describe the integration of bioequivalence studies into DOE methods, and 
develop assessment methods for the bioavailability characteristics of interest, 
when replicated profiles are sampled under the DOE framework.  
 Propose a formulation optimization procedure to identify the optimal levels of 
excipients for the test formulation, while satisfying bioequivalence criteria.  
The next section incorporates the bioequivalence study into DOE methodologies 
and introduces the associated methods for bioequivalence assessment. In Section 4.3, the 
optimization procedure is proposed. Sections 4.4 and 4.5 respectively present a numerical 
example and a sensitivity analysis for validation, and Section 4.6 finally provides 
conclusions. 
 
4.2 Integration of the In Vivo Bioequivalence Study into Experimental Designs 
The in vivo bioequivalence study is conducted in order to compare a test and its 
reference formulation with respect to critical bioavailability characteristics. On the other 
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hand, the DOE technique requires establishing the input factor settings related to the 
ingredient amounts of the test formulation. Therefore, a bioequivalence study should be 
performed under each input setting when integrated into DOE. This section introduces 
the bioequivalence assessment under both the standard and DOE format. 
 
4.2.1 Regular Bioequivalence Assessment 
The in vivo bioequivalence study generally utilizes a single-dose, two-treatment, 
two-period, two-sequence (2×2) crossover design to compare critical bioavailability 
attributes of the test and reference formulations. An equal number of subjects is randomly 
assigned to each of the two sequences (FDA, 1995). Within the first sequence, the 
reference formulation is administered to subjects first, while the test formulation is 
administered first within the second one. The general framework of the study design is 
shown in Table 4.1 (Chow & Liu, 2009), in which Yijk denotes the bioavailability 
characteristic, i, j and k are the numbers of subjects, periods, and sequences, respectively, 
for i = 1, 2, …, nk, j and k = 1, 2, with nk defined as the number of subjects within 
sequence k. Also note that n1 is always equal to n2, since both sequences have the same 
number of subjects. The main advantage of crossover designs is that they exclude the 
inter-subject variability from the comparison between formulations. 
Table 4.1 2×2 Crossover Design Format for the Bioequivalence Study 
Sequence Period 1 Period 2 
1 Reference formulation: Yi11 Test formulation: Yi21 
2 Test formulation: Yi12 Reference formulation: Yi22 
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The standard bioavailability responses after a single-dose administration are the 
maximum plasma concentration (Cmax), the time to reach Cmax 
(tmax), and the area under 
the plasma concentration-time curve (AUC0-t) from time 0 to time t (FDA, 2003). In order 
to assess the means and variances of these responses for the test and reference 
formulations, while at the same time complying with the USP and FDA regulations, an 
unreplicated experiment should be conducted. In other words, a single-dose 2×2 
crossover design is performed at each experimental run.  
 
4.2.1.1 Continuous Computational Method for Assessment 
The continuous method refers to fitting a smooth curve to the discrete 
concentration data. When drug absorption has been completed, Equation (2.3) reduces to 
the following expression (Shargel et al., 2004): 
  (4.1) 
where tz is the critical time point at which absorption ends. AUC0-t can be derived by
, which is clearly dependent on time t. Generally, t is set to a specific 
value (denoted by t0), or infinity during the bioequivalence study. Since it has been 
widely accepted that the function in Equation (2.3) is always concave with Ka > Ke, Cmax 
and tmax exist and can be obtained by setting the rate of concentration change to zero. 
Moreover, the rate of concentration change can be achieved by differentiating Equation 
(2.3) with respect to t. Note that Equations (2.4) and (2.5) can be used to calculate Cmax 
and tmax; neither Cmax 
nor tmax are functions of t. AUC0-t is given by 
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, 
where . 
It is important to note that the estimators of K and Ke, denoted respectively by  
and , can be obtained by performing an ordinary linear regression analysis with the 
natural logarithm transformation of Equation (4.1). The method of residuals for fitting a 
curve to the experimental data of  a drug can be used to estimate Ka (Gibaldi & Perrier, 
1982). Instead of plotting a fitted curve, we propose a method to estimate Ka using 
regression techniques. First,  and 
 
are substituted into Equation (2.3) as follows: 
  (4.2) 
which has only one unknown parameter, Ka. Subsequently, Equation (4.2) can be 
simplified to 
 , 
in which . Let [C
*
(ti), ti] denote the observed value of [C
*
(t), t] on 
the i
th
 trial, where i = 1, 2, …, n, and n is the number of time points. Thus, the estimator 
for Ka,  can be derived by minimizing the following equation: 
 . (4.3) 
By differentiating Equation (4.3) with respect to Ka and then setting the derivative equal 
to zero, we obtain 
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 . (4.4) 
Q′(Ka) can be considered a linear combination of n bi-exponential functions, so the shape 
of its function curve is similar to the one shown in Figure 4.1. Additionally, 
,  
and 
. 
Therefore, it is concluded that Equation (4.4) has a unique solution on the interval  
( ,∞); the general shape of the function Q′(Ka) curve is illustrated in Figure 4.1. 
 
Figure 4.1 General Shape of Q′(Ka) Curve 
Let C = [C(t1), C(t2), …, C(tn)]′ 
and T = [t1, t2, …, tn]′ be the n × 1 vectors for the 
concentration levels and time points. The matrix exponential of T, exp(T), is given by 
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exp(T) = [ , , …, ]′. Furthermore, Td denotes a diagonal matrix with dimension n 
× n for the time points, where  
. 
Hence, Equation (4.4) can be rewritten in matrix notation as 
 . (4.5) 
In order to solve for  in Equation (4.5), the bisection procedure can be applied to 
iteratively converge on the solution which lies inside the interval [ , ]. Note that  
denotes the pre-determined upper bound of the interval. Alternatively, a numerical 
computing environment, such as MATLAB® 2009, can be used to solve for . 
 
4.2.1.2 Discrete Computational Method for Assessment 
In addition to the continuous method above, the FDA recommends the use of a 
discretization method, specifically the linear trapezoidal technique, to approximate the 
AUC. In this method, the AUC can be estimated based on Equations (2.6) and (2.7); Ke 
can be obtained by using regression analysis based on Equation (4.1). Note that  
Cmax = max{C1, C2, …, Cn}, and the estimate of tmax is established as the corresponding 
point in time at which Cmax occurs. 
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4.2.2 Bioequivalence Assessment under the Experimental Design Structure 
The input factors are the amounts of excipients in the test formulation. Let x and 
  denote the vector of input factors and design matrix, respectively. An unreplicated 
DOE format with r experimental runs for the bioequivalence study is illustrated in Table 
4.2, where Y
U
 represents the unreplicated response, and Cijkhu denotes the plasma 
concentration level at time point h of the u
th
 run, with j and k = 1, 2, h = 1, 2, …, n and u 
=1, 2, …, r. Note that the subscript u denotes the characteristic of interest for the uth 
design point and s
2[•] is the sample variance of the characteristic of interest. Log-
transformations of Cmax 
and AUC0-t are recommended by the FDA, since the transformed 
data appear to be approximately normally distributed and achieve a relatively 
homogeneous variance (Chow et al., 1991). Hence, let 
 
and  denote 
the means of log-transformed Cmax 
and AUC0-t at the u
th
 run, respectively. The pooled 
sample SD of period differences from both sequences, denoted by , is useful to 
evaluate the 90% confidence interval (CI) of the bioavailability characteristics 
differences. According to (Chow & Liu, 2009),  is calculated by 
, 
where diku = (Yi2ku – Yi1ku)/2 and  for i = 1, 2, …, nk and k = 1, 2. Note that 
no specific CI related to tmax is provided in the FDA guidance, as tmax is not often used 
because of its high inter-individual variability (Qiu et al., 2009). Therefore, Y denotes 
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either lnAUC0-t or lnCmax. Moreover, the intra-subject variability between the test and 
reference formulations at the u
th
 run, denoted by , can be estimated by  
 , (4.6) 
where , , and . Again, Y is either lnAUC0-t or 
lnCmax in Equation (4.6). 
When multiple concentration profiles are collected at each design point under the 
framework of a 2×2 crossover design, equations for calculating the sample means and 
variances of AUC0-t, Cmax, 
and tmax for the test formulation at the u
th
 experimental run 
must be developed; theses equations are listed in Table 4.3, where AUC0-t,ijku, Cmaxijku, and 
tmaxijku denote the corresponding bioavailability characteristic at the u
th
 run with i 
concentration profiles, j periods, and k sequences. Moreover, u = 1, 2, …, r, , 
and the subscript T represents the test formulation. It should be mentioned that 
characteristic variances for the reference formulation are not chosen as responses under 
the DOE format, because they are not considered the target values of the variances for the 
test formulation when applying the Taguchi quality loss concept to the optimization 
procedure. Similarly, the mean estimators for the reference formulation at the u
th
 design 
point are found using the formulas in Table 4.4, where the subscript R represents the 
reference formulation. 
2
inus
22 22 2 2 2 2 2
2 2
1 1 1 1 1 1 1 11 2
1
2 2 2
k kn n
jkui ku ku
inu ijku
k j i k i k j kk k
YY Y
s Y
n n n n       
 
        
   
2
1
i ku ijku
j
Y Y


1
kn
jku ijku
i
Y Y


2
1 1
kn
ku ijku
i j
Y Y
 

1, 2
2, 1
j k
j k
 

 
 86 
 
Table 4.2 DOE Format for the Bioequivalence Study 
 
Table 4.3 Mean and Variance of Characteristics for the Test Formulation 
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Table 4.4 Mean of Characteristics for the Reference Formulation 
 
 
 
 
Additionally, for the continuous computational method, the estimation of K, Ka, 
and Ke can be achieved by extending the dimension of the matrix presented in Section 
2.1.1. Let us define vectors , K, Ke, Ka, and β as follows: 
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= [ , , , …, , , , …, , , , 
…, , , , …, ], 
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where the subscripts i, j, k and r denote the related parameter for the i
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j
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 design point, and lnK denotes the vector that 
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is obtained after taking the natural logarithm of each element of K. Moreover, the matrix 
containing the concentration data from time tz to tn, denoted by Creduce, is defined as 
. 
The regression coefficient vector, β, for the natural logarithm transformation of Equation 
(4.1) can be calculated by 
. 
Based on the equations above, the values of K and Ke can now be determined. Moreover, 
each element of the vector Ka can be obtained by solving Equation (4.5), and MATLAB 
code has been provided in Appendix 2.1 for this purpose. 
Finally, the estimated second-order response function, shown below, can be 
obtained by using the ordinary least squares method. 
, 
where X is a matrix for the predictor variables. Moreover, when the Y
U
 includes AUC0-t, 
the estimated response function becomes 
. 
 
4.3 Proposed Optimization Model 
4.3.1 Objective Function 
The Taguchi quality loss concept is the basis for the objective function, which 
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ensures that the optimal solution provides minimum deviations from the target values of 
bioavailability characteristics for the test formulation, including AUC0-t, Cmax and tmax. 
Referring to the univariate squared-error loss function (Taguchi, 1985), the objective of 
the optimization procedure is to minimize the summation of squared differences between 
characteristics of interest for the test formulation and their target values. The target values 
for the mean and variance are chosen as the means for the reference formulation and zero, 
respectively. Although tmax is not a common measurement when assessing 
bioequivalence, Shargel et al. (2004) indicated that drug products were generally tested in 
chemically equivalent doses in bioequivalence studies, and tmax could be very useful in 
comparing the respective rates of absorption of a drug from chemically equivalent drug 
products. Hence, in order to capture the performance of tmax in addition to AUC0-t and 
Cmax, we propose the following objective function:  
Minimize
 
, 
in which a function of x denotes the estimated response surface function for either the 
mean or variance, and a function of t and x is the response function over time t. 
 
4.3.2 Constraints on Excipient Changes 
According to the FDA (1995), the ranges of Level 3 changes in the excipient are 
beyond those of Level 2. Hence, the constraints on Level 3 excipient changes are 
proposed by incorporating all possible combinations of the following seven inequalities, 
where (θ1, θ2, θ3, θ4, θ5, θ6) = (10%, 6%, 1%, 0.5%, 2%, 2%). 
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 and . 
 
4.3.3 Constraints Associated with In Vivo Bioequivalence Studies 
Based on the FDA (2006a) and Chow and Liu (2009), the 90% CI for the 
difference in means of log-transformed data is provided in Table 4.5, where Y denotes 
either Cmax or AUC0-t. Then, constraints on the CIs for Cmax and AUC0-t are developed, 
which are shown in Table 4.6. 
Table 4.5 90% Confidence Interval for Assessing Bioequivalence 
Upper bound  
Lower bound  
 
Table 4.6 Proposed Constraints for the Bioequivalence Study 
Y = Cmax 
Upper 
bound 
 
Lower 
bound 
 
Y = AUC0-t 
Upper 
bound 
 
Lower 
bound 
 
 
4.3.4 Intra-Subject Variability Constraints 
For a standard 2×2 crossover design, Chow and Liu (2009) pointed out that the 
difference in total variability between test and reference formulations is the difference in 
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intra-subject variability between the two formulations, since the crossover design 
removes the inter-subject variability. However, there is no universal agreement on how 
much difference in variability would be considered to be of clinically meaningful 
significance. Let γA and γC be the upper limits of intra-subject variations ( ) for AUC0-t 
and Cmax, respectively. Therefore, the constraints on  are proposed as 
 and . 
 
4.3.5 Other Constraints 
Additional constraints that were developed (in Chapter 3) for disintegration time, 
uniformity, friability, compressibility, hardness, thickness, stability, nonnegativity and 
design space, also need to be taken into consideration in this optimization model. 
 
4.4 Numerical Examples 
The formulation optimization is performed for Class 4 Drugs with Level 3 
excipient changes. Plasma concentration profiles for the bioequivalence study are 
simulated under a standard 2×2 crossover design framework. The number of subjects 
within each sequence for the crossover study is n1 = n2 = 3. The vector of points in time, 
measured in hours, is set as T = [0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12]′. The input factors 
(treated as decision variables) include x1 and x2 in this case; therefore, a two-factor CCD 
with 13 experimental runs (i.e., r = 13) is analyzed using Minitab® 16. Table 4.7 
provides the plasma concentration data under a DOE format. The uncoded values of two 
2
ins
2
ins
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2
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levels (−1, +1) for x1 and x2 are set as (170, 190) and (7.8, 13.8), respectively. The design 
format with coded factor values is described in Table 4.8. 
We will adopt the estimated response functions associated with disintegration, 
uniformity, friability, compressibility, and hardness tests from Chapter 3, and let the 
weights of x3, x4, and x5 be 20mg, 15mg, and 2.5mg, respectively. The target weight of 
each excipient in the reference formulation is (τ1, τ2) = (150, 10.5) measured in mg. The 
pre-identified average weight of the API is 80mg. Therefore, the total weight of the 
reference formulation is WR = 278mg. In addition, let the upper bounds of intra-subject 
variability be γA = γC = 0.1.  
We compare the AUCs from time 0 to infinity, AUC0-∞, for the test and reference 
formulations in this numerical example. The bioavailability characteristics, tmax, Cmax,  
and AUC0-∞, can be derived by the discrete (Scenario 2.1) and continuous (Scenario 2.2) 
methods; the results for the two scenarios are listed in Table 4.9. Note that the data 
calculated by the continuous method are presented in bold in the table. Referring to 
Equation (4.1), the regression coefficients of the concentration-time function were 
estimated under the condition that tz = 4h. 
Running a regression analysis with Minitab, we obtain the estimated response 
surface functions for both scenarios, which are then used to implement the optimization 
procedure with respect to the objective function and constraints. The optimal solutions 
and critical characteristics which are associated with assessing bioequivalence for both 
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Table 4.7 Plasma Concentration Data Set under a 2-Factor CCD Structure 
Run Sequence Period Subject 
Time point 
0 0.5 1 1.5 2 3 4 6 8 10 12 
1 
1 1 1 0 8.60 12.91 16.00 16.08 14.31 12.36 8.15 5.63 3.87 2.41 
  2 0 9.48 12.96 15.73 16.42 14.58 12.79 8.53 5.10 4.02 2.69 
  3 0 9.10 12.79 15.27 15.94 14.56 12.55 8.50 5.44 3.87 2.47 
1 2 1 0 9.23 12.96 15.95 15.61 14.27 12.23 8.19 5.22 3.75 2.28 
  2 0 9.13 12.76 15.32 16.23 14.87 12.32 8.08 5.04 3.87 2.84 
  3 0 9.17 12.55 15.56 15.54 14.18 12.74 8.86 5.63 4.46 3.00 
2 1 1 0 9.32 12.91 15.56 16.24 14.30 12.89 8.88 5.28 4.00 2.43 
  2 0 9.24 12.78 15.04 16.31 14.60 12.77 8.80 5.37 4.03 3.00 
  3 0 8.57 12.96 15.16 15.77 14.49 12.88 8.61 5.20 3.93 2.27 
2 2 1 0 8.84 12.89 15.16 16.27 14.84 12.45 8.95 5.85 3.86 2.46 
  2 0 8.51 12.90 15.49 16.34 14.03 12.54 8.23 5.10 3.85 2.79 
  3 0 8.66 12.92 15.86 15.88 14.28 12.59 8.48 5.08 4.05 2.17 
2 
1 1 1 0 9.43 12.59 15.46 16.35 14.73 12.81 8.94 5.57 4.43 2.57 
  2 0 8.77 12.97 15.40 15.89 14.07 12.03 8.38 5.08 3.88 2.76 
  3 0 8.75 12.79 15.12 16.47 14.64 12.68 8.20 5.12 3.60 2.95 
1 2 1 0 9.04 12.96 15.66 15.68 14.88 12.30 8.71 5.62 4.44 2.87 
  2 0 9.48 12.80 15.01 15.69 14.06 12.75 8.50 5.16 4.13 2.02 
  3 0 9.11 12.81 15.88 15.97 14.18 12.12 8.24 5.63 3.94 2.23 
2 1 1 0 9.06 12.98 15.08 15.93 14.58 12.26 8.40 5.64 4.26 2.41 
  2 0 9.01 12.78 15.57 16.31 14.99 12.31 8.52 5.50 4.15 2.36 
  3 0 9.00 12.81 15.78 16.31 14.77 12.84 8.99 5.96 4.03 2.34 
2 2 1 0 8.62 12.95 15.17 16.04 14.66 12.00 8.10 5.41 4.20 2.74 
  2 0 9.11 12.57 15.26 16.31 14.57 12.41 8.64 5.00 3.96 2.61 
  3 0 9.05 12.84 15.99 15.85 14.92 12.93 8.23 5.63 4.12 2.03 
3 
1 1 1 0 9.11 12.63 15.67 15.63 14.43 12.29 8.00 5.70 4.25 2.04 
  2 0 8.87 13.00 15.85 15.75 14.96 12.83 8.11 5.36 4.15 2.23 
  3 0 9.26 13.00 15.32 15.54 14.30 12.20 8.69 5.07 4.47 2.67 
1 2 1 0 8.90 12.72 15.20 15.51 14.85 12.68 8.18 5.70 3.79 2.28 
  2 0 9.33 12.56 15.31 15.54 14.01 12.51 8.18 5.68 4.04 2.08 
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  3 0 9.30 12.55 15.74 16.37 14.95 12.74 8.00 5.88 3.92 2.63 
2 1 1 0 8.80 12.83 15.96 16.47 14.87 12.26 8.37 5.21 4.31 2.31 
  2 0 8.66 12.86 15.18 16.38 14.12 12.50 8.12 5.19 4.42 2.94 
  3 0 8.61 12.64 15.08 16.17 14.52 12.78 8.87 5.00 3.97 2.66 
2 2 1 0 8.76 12.67 15.13 16.01 14.04 12.33 8.37 5.12 4.49 2.69 
  2 0 8.86 12.83 15.81 16.32 14.66 12.46 8.43 5.94 3.50 2.62 
  3 0 9.11 12.76 15.88 16.09 14.77 12.79 8.69 5.37 3.75 2.87 
4 
1 1 1 0 8.82 12.95 15.51 16.43 14.70 12.51 8.24 5.63 4.15 2.08 
  2 0 8.50 12.97 15.15 16.09 14.89 12.22 8.59 5.74 4.05 2.99 
  3 0 9.05 12.55 15.09 16.40 14.65 12.94 8.25 5.41 4.31 2.59 
1 2 1 0 9.18 12.95 15.02 16.42 14.11 12.92 8.90 5.09 4.25 2.65 
  2 0 9.11 12.70 15.22 15.85 14.97 12.02 8.97 5.27 3.77 2.68 
  3 0 9.24 12.58 15.78 16.02 14.61 12.12 8.71 5.45 3.51 2.78 
2 1 1 0 8.64 12.79 15.88 16.03 14.85 12.99 8.22 5.08 4.32 2.96 
  2 0 8.61 12.55 15.18 16.14 14.49 12.81 8.55 5.84 4.46 2.20 
  3 0 9.27 12.96 15.03 16.19 14.35 12.27 8.30 5.63 3.76 2.19 
2 2 1 0 9.42 12.99 15.12 15.60 14.95 12.88 8.66 5.30 3.51 2.89 
  2 0 8.90 12.79 15.76 15.98 14.21 12.48 8.44 5.59 3.84 2.10 
  3 0 8.74 12.71 15.29 16.49 14.82 12.47 8.12 5.37 4.47 2.11 
5 
1 1 1 0 8.98 12.81 15.23 16.42 14.42 12.13 8.51 5.72 4.41 2.98 
  2 0 8.65 12.71 15.79 15.59 14.64 12.20 8.97 5.58 3.97 2.79 
  3 0 8.77 12.57 15.25 15.78 14.94 12.57 8.06 5.31 3.61 2.62 
1 2 1 0 9.24 12.95 15.19 16.21 14.76 12.38 8.93 5.56 3.66 2.12 
  2 0 8.61 12.78 15.57 16.47 14.12 12.03 8.72 5.42 4.16 2.16 
  3 0 8.72 12.76 15.52 16.34 14.27 12.09 8.21 5.87 4.24 2.98 
2 1 1 0 9.33 12.62 15.26 15.54 14.34 12.68 8.26 5.22 3.65 2.91 
  2 0 8.58 12.70 15.48 16.05 14.27 12.01 8.50 5.71 3.61 2.32 
  3 0 8.96 12.71 15.76 15.92 14.35 12.19 8.60 5.99 3.72 2.62 
2 2 1 0 9.02 12.71 15.08 15.65 14.02 12.99 8.90 5.09 3.79 2.40 
  2 0 8.77 12.91 15.15 16.46 14.34 12.72 8.16 5.28 4.10 2.88 
  3 0 9.12 12.83 15.46 15.51 14.17 12.15 8.75 5.83 4.37 2.15 
6 
1 1 1 0 8.55 12.70 15.03 16.37 14.21 12.48 8.07 5.18 3.93 2.10 
  2 0 9.43 12.57 15.60 16.43 14.24 12.40 8.47 5.28 4.33 2.66 
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  3 0 8.66 12.74 15.24 16.06 14.06 12.32 8.88 5.81 3.58 2.06 
1 2 1 0 8.69 12.66 15.55 15.59 14.41 12.73 8.09 5.69 4.28 2.94 
  2 0 9.15 12.76 15.85 16.16 14.90 12.92 8.13 5.69 3.57 2.99 
  3 0 8.91 12.66 15.33 16.35 14.48 12.17 8.36 5.82 3.51 2.25 
2 1 1 0 8.93 12.76 15.44 16.24 14.01 12.09 8.02 5.83 4.41 2.44 
  2 0 9.05 12.98 15.78 15.72 14.58 12.95 8.80 5.70 4.22 2.06 
  3 0 8.90 12.90 15.16 15.95 14.12 12.53 8.09 5.36 4.50 2.17 
2 2 1 0 8.75 12.87 16.00 16.23 14.93 12.52 8.51 5.68 3.77 2.27 
  2 0 8.76 12.75 15.97 16.38 14.88 12.92 8.02 5.64 3.77 2.26 
  3 0 9.09 12.95 15.86 15.78 14.54 12.05 8.94 5.68 4.25 2.64 
7 
1 1 1 0 9.45 12.89 15.56 15.69 14.54 12.80 9.00 5.69 4.15 2.54 
  2 0 9.28 12.50 15.70 15.81 14.83 12.38 8.90 5.24 3.94 2.61 
  3 0 9.01 12.56 15.69 16.04 14.16 12.68 8.76 5.94 4.20 2.80 
1 2 1 0 8.87 12.76 15.54 15.61 14.93 12.92 8.54 5.48 3.83 2.98 
  2 0 8.84 12.88 15.92 15.64 14.88 12.83 8.26 5.81 3.76 2.76 
  3 0 8.59 12.72 15.28 16.02 14.83 12.03 8.20 5.39 4.34 2.00 
2 1 1 0 9.33 12.54 15.96 16.44 14.86 12.96 8.95 5.90 4.27 2.30 
  2 0 9.02 12.51 15.61 15.72 14.18 12.47 8.53 5.24 4.10 2.93 
  3 0 8.79 12.52 15.47 15.90 14.02 12.04 8.14 5.09 4.33 2.25 
2 2 1 0 8.95 12.95 15.20 15.68 14.44 12.46 8.11 5.77 3.50 2.00 
  2 0 9.33 12.59 15.03 16.28 14.12 12.66 8.79 5.27 3.78 2.24 
  3 0 9.50 12.81 15.70 16.47 14.69 12.65 8.91 5.74 4.26 2.33 
8 
1 1 1 0 9.44 12.90 15.02 15.57 14.01 12.61 8.78 5.79 4.23 2.07 
  2 0 8.98 12.96 15.93 15.76 14.97 12.66 8.60 5.40 4.08 2.90 
  3 0 9.12 12.77 15.83 15.66 14.77 12.57 8.84 5.02 3.76 2.35 
1 2 1 0 9.34 12.58 15.11 16.27 14.97 12.21 8.05 5.39 3.85 2.09 
  2 0 9.36 12.67 15.26 15.95 14.45 12.81 8.24 5.66 4.49 2.44 
  3 0 8.64 12.67 15.05 16.44 14.18 12.36 8.22 5.11 3.57 2.31 
2 1 1 0 8.69 12.96 15.49 16.22 14.85 12.63 8.64 5.88 4.43 2.98 
  2 0 9.06 12.84 15.10 16.27 14.04 12.34 8.78 5.63 3.94 2.05 
  3 0 8.55 12.74 15.61 15.66 14.10 12.94 8.08 5.61 3.67 2.48 
2 2 1 0 8.54 12.83 15.04 16.45 14.71 12.56 8.73 5.21 4.45 2.79 
  2 0 9.15 12.66 15.86 15.52 14.55 12.43 8.16 5.59 4.26 2.52 
 96 
 
  3 0 8.60 12.87 15.60 16.24 15.00 12.42 8.23 5.03 4.33 2.90 
9 
1 1 1 0 9.09 12.98 15.43 16.27 14.44 12.23 8.15 5.14 4.50 2.79 
  2 0 8.93 12.82 15.22 15.80 14.84 12.10 8.92 6.00 3.86 2.09 
  3 0 8.56 12.77 15.76 16.41 14.44 12.74 8.83 5.21 4.09 2.88 
1 2 1 0 8.79 12.71 15.13 16.22 14.87 12.50 8.30 5.52 3.72 2.06 
  2 0 9.10 12.64 15.60 15.51 14.08 12.34 8.78 5.85 4.12 2.02 
  3 0 8.91 12.82 15.74 15.62 14.91 12.04 8.36 5.22 4.27 2.88 
2 1 1 0 9.05 12.64 15.16 15.79 14.80 12.28 8.98 5.35 3.96 2.04 
  2 0 8.54 12.61 15.94 16.19 14.78 12.38 8.02 5.95 4.01 2.62 
  3 0 9.27 12.96 15.15 15.52 14.56 12.64 8.31 5.87 3.87 2.53 
2 2 1 0 9.21 12.96 15.74 16.33 14.38 13.00 8.44 5.42 3.62 3.00 
  2 0 8.71 12.79 15.70 16.46 14.74 12.18 9.00 5.95 4.09 2.32 
  3 0 9.43 12.54 15.10 16.10 14.34 12.82 8.11 5.92 3.92 2.85 
10 
1 1 1 0 9.29 12.84 15.06 15.50 14.84 12.76 8.69 5.77 3.50 2.63 
  2 0 9.07 12.89 15.31 16.46 14.94 12.38 8.06 5.13 4.36 2.03 
  3 0 9.21 12.50 15.34 15.74 14.03 12.05 8.31 5.86 3.56 2.31 
1 2 1 0 9.26 12.86 15.06 15.91 14.08 13.00 8.21 5.91 4.39 2.62 
  2 0 8.64 12.70 15.82 16.24 14.27 12.90 8.41 5.48 4.30 2.16 
  3 0 9.35 12.89 15.00 16.34 14.12 12.30 8.91 5.34 4.46 2.06 
2 1 1 0 9.15 12.88 15.13 16.07 14.53 12.51 8.48 5.36 4.44 2.37 
  2 0 8.84 12.96 15.53 15.78 14.85 12.57 8.34 5.88 3.69 2.91 
  3 0 9.02 12.98 15.47 15.97 14.97 12.84 8.12 5.10 3.72 2.77 
2 2 1 0 8.55 12.77 15.80 16.19 14.39 12.89 8.52 5.12 3.78 2.08 
  2 0 8.63 12.78 15.89 16.24 14.65 12.27 8.48 5.03 3.96 2.49 
  3 0 8.81 12.67 15.56 15.78 15.00 12.15 8.41 5.71 4.01 2.22 
11 
1 1 1 0 8.66 12.87 15.82 15.70 14.37 12.83 8.28 5.45 4.36 2.08 
  2 0 8.54 12.63 16.00 15.98 14.81 12.55 8.13 5.85 3.60 2.20 
  3 0 9.16 12.65 15.80 15.74 14.20 12.01 8.32 5.00 3.89 2.36 
1 2 1 0 9.21 12.50 15.99 15.93 14.60 12.59 8.61 5.40 3.85 2.16 
  2 0 8.52 12.85 15.16 15.67 14.79 12.65 8.29 5.31 4.44 2.08 
  3 0 8.97 12.68 15.69 16.09 14.73 12.69 8.68 5.43 4.14 2.01 
2 1 1 0 9.24 12.61 15.47 16.08 14.36 12.26 8.42 5.94 3.95 2.58 
  2 0 8.55 12.97 15.64 15.72 14.21 12.07 8.89 5.71 3.74 2.83 
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  3 0 8.50 12.76 15.44 15.61 14.20 12.85 8.11 5.14 4.24 2.25 
2 2 1 0 9.31 12.52 15.13 16.32 14.75 12.17 8.91 5.62 3.90 2.89 
  2 0 8.64 12.70 15.41 16.15 14.52 12.56 8.31 5.67 3.55 2.51 
  3 0 9.28 12.69 15.35 15.58 14.02 13.00 8.16 5.77 3.86 2.05 
12 
1 1 1 0 9.22 12.67 15.87 15.72 14.11 12.88 8.11 5.03 3.63 2.97 
  2 0 9.45 12.72 15.14 16.28 14.02 12.54 8.15 5.31 3.69 2.60 
  3 0 9.09 12.72 15.66 15.50 14.29 12.67 8.56 5.40 3.50 2.17 
1 2 1 0 9.44 12.74 15.31 15.57 14.61 12.16 8.90 5.14 4.24 2.31 
  2 0 9.17 12.98 15.54 15.63 14.77 12.67 8.09 5.38 3.71 2.57 
  3 0 8.65 12.62 15.42 16.12 14.07 12.03 8.16 5.84 3.92 2.95 
2 1 1 0 8.74 13.00 15.02 15.74 14.58 12.84 8.35 5.32 4.16 2.45 
  2 0 8.70 12.94 15.55 15.87 14.33 12.97 8.88 5.27 4.19 2.43 
  3 0 9.10 12.51 15.21 16.16 14.09 12.36 8.97 5.95 4.04 2.04 
2 2 1 0 9.46 12.66 15.53 15.51 14.98 12.28 8.55 5.28 4.03 2.25 
  2 0 8.89 12.71 15.11 16.12 14.34 12.71 8.74 5.00 3.93 2.37 
  3 0 8.95 12.75 15.94 16.50 14.14 12.03 8.25 5.25 4.08 2.54 
13 
1 1 1 0 9.47 12.82 15.70 16.28 14.13 12.29 8.12 5.18 4.44 2.81 
  2 0 9.08 12.94 15.85 15.69 14.14 12.09 8.06 5.83 3.79 2.48 
  3 0 9.50 12.54 15.02 16.12 14.87 12.47 8.90 5.99 3.70 2.33 
1 2 1 0 8.69 12.94 15.20 15.95 14.03 12.06 8.36 5.85 3.73 2.61 
  2 0 9.39 12.61 15.28 16.29 14.31 12.95 8.91 5.67 3.77 2.45 
  3 0 9.04 12.81 15.74 16.50 14.21 12.55 8.81 5.32 4.01 2.99 
2 1 1 0 9.46 12.92 15.32 15.58 14.97 12.81 8.03 5.66 4.21 2.85 
  2 0 9.39 12.55 15.69 16.21 14.74 12.39 8.53 5.00 4.01 2.35 
  3 0 9.16 12.58 15.78 15.68 14.64 12.27 8.04 5.18 4.18 2.43 
2 2 1 0 8.97 12.81 15.64 15.99 14.70 12.30 8.74 5.56 3.73 2.66 
  2 0 9.30 12.76 15.77 15.77 14.21 12.50 8.85 5.06 4.07 2.96 
  3 0 8.67 12.97 15.79 16.44 14.48 12.03 8.44 5.30 3.99 2.96 
 98 
 
Table 4.8 The Coded CCD Design Format 
Run 
Factors 
x1 x2 
1 170.000 7.8000 
2 190.000 7.8000 
3 170.000 13.8000 
4 190.000 13.8000 
5 165.858 10.8000 
6 194.142 10.8000 
7 180.000 6.5574 
8 180.000 15.0426 
9 180.000 10.8000 
10 180.000 10.8000 
11 180.000 10.8000 
12 180.000 10.8000 
13 180.000 10.8000 
 
scenarios are found using Mathematica; they are summarized in Table 4.10. According to 
the objective function values in Table 4.10, the optimal levels of excipients in the second 
scenario result in less quality loss. Based on the following two-sample t-test with 
unknown population variances, the lnAUC values in both scenarios are statistically 
equivalent with a p-value of 0.75 (greater than α = 0.05). 
H0:  ln    (∞, x
*
) under Scenario 2.1 =  ln     (∞, x
*
) under Scenario 2.2 
versus 
H1:  ln     (∞, x
*) under Scenario 2.1 ≠  ln     (∞, x
*
) under Scenario 2.2. 
Hence, it can be concluded that the AUC is not particularly sensitive to the method used 
(discrete or continuous) during the estimation phase. However, the deviations of Cmax 
and 
tmax between both scenarios are significant. There are two main reasons underlying 
causes. First, it is observed that in Scenario 2.1 (which uses the discrete method), Cmax 
and tmax are sensitive to the time at which the observation is taken. The true Cmax 
and tmax 
can be overlooked due to a long observation interval. Second, the major advantage of the 
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Table 4.9 Parameters and Responses Related to the Bioequivalence Study 
Run 
Reference Test 
  
   tmaxR   s
2(lnCmaxT) tmaxT s
2(tmaxT)  
s2(lnAUC0-
∞T) 
1 
2.782151 2 4.741269 2.773065 0.000358 1.833333 0.066667 4.753819 0.001247 
0.0005988 0.0000199 0.02261 0.003633 
2.744712 1.893755 4.733302 2.739993 0.000231 1.887438 0.006731 4.74422 0.001134 
2 
2.783381 1.916667 4.750856 2.771314 0.000308 2 0 4.742571 0.000928 
0.0004463 0.0001023 0.029875 0.014303 
2.734822 1.862566 4.73917 2.749241 0.000167 1.924573 0.004165 4.73923 0.000779 
3 
2.767023 1.833333 4.745939 2.776852 0.000747 2 0 4.742459 0.000684 
0.0002493 0.0004283 0.02233 0.029268 
2.740561 1.88373 4.739395 2.737923 0.000227 1.897756 0.005612 4.734738 0.000461 
4 
2.782659 2 4.744578 2.779277 0.000142 2 0 4.75147 0.000565 
0.0004735 0.0001656 0.030772 0.018198 
2.744083 1.912908 4.736324 2.740232 0.000093 1.900239 0.006397 4.741138 0.000397 
5 
2.768252 1.916667 4.754009 2.777915 0.000433 2 0 4.742185 0.000796 
0.0016708 0.0003927 0.056322 0.026031 
2.731869 1.896427 4.744763 2.737605 0.000319 1.895376 0.005261 4.733489 0.000661 
6 
2.786269 1.916667 4.732484 2.773179 0.000332 1.916667 0.041667 4.744774 0.000832 
0.0006898 0.0004163 0.037142 0.028854 
2.749011 1.923233 4.726806 2.741245 0.000309 1.907178 0.00595 4.739313 0.000575 
7 
2.772103 2 4.745118 2.768383 0.000323 1.916667 0.041667 4.749261 0.001085 
0.0016925 0.0005759 0.058181 0.033937 
2.753132 1.953868 4.739915 2.739653 0.000421 1.903634 0.003714 4.741486 0.000757 
8 
2.771177 1.75 4.755942 2.780863 0.000309 2 0 4.734519 0.001545 
0.0004325 0.0003790 0.029412 0.02753 
2.738077 1.887436 4.746859 2.742229 0.000068 1.925901 0.002097 4.72888 0.001588 
9 
2.786663 2 4.76211 2.762604 0.000348 1.833333 0.066667 4.735141 0.000764 
0.0005943 0.0001304 0.034477 0.016148 
2.741727 1.887007 4.751459 2.740857 0.000228 1.926366 0.010238 4.727862 0.000626 
10 
2.771432 2 4.723731 2.775742 0.00017 2 0 4.748185 0.000414 
0.0000107 0.0002820 0.004613 0.023277 
2.746066 1.92329 4.716238 2.745198 0.000096 1.919142 0.004561 4.74271 0.000297 
11 
2.769029 1.75 4.728223 2.763722 0.000188 1.916667 0.041667 4.731403 0.000464 
0.0002061 0.0001599 0.020302 0.017883 
2.744255 1.928227 4.721642 2.74523 0.000199 1.944836 0.002282 4.726819 0.000351 
12 
2.771945 1.75 4.731515 2.762962 0.000245 2 0 4.741492 0.000273 
0.0006430 0.0004033 0.03586 0.0284 
2.739869 1.879108 4.721926 2.739748 0.000283 1.925679 0.007764 4.735026 0.000187 
13 
2.77716 1.916667 4.758695 2.775622 0.000459 1.916667 0.041667 4.752271 0.000605 
0.0007606 0.0005001 0.039001 0.031625 
2.735566 1.839498 4.747834 2.739958 0.000156 1.873638 0.004121 4.74353 0.000491 
 
Table 4.10 Optimal Settings in Both Scenarios for Bioequivalence Assessment 
Scenario   
Objective 
value
 lnAUCR lnAUCT lnCmaxR lnCmaxT tmaxR tmaxT 
2.1 184.05 10.31 0.066 4.738 4.742 2.779 2.765 1.892 1.935 
2.2 177.80 8.06 0.025 4.730 4.738 2.748 2.735 1.921 1.919 
 2ins AUC  
2
maxins C  ˆ AUC  maxˆ C
maxln RC 0ln RAUC  maxln TC 0ln TAUC 
*
1x
*
2x
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continuous method over the discrete one is the complete smoothness of the fitted curve. 
Theoretically, the existence of experimental errors will result in the discontinuity of data. 
Since errors are experimentally inevitable, it is believed that the continuous method may 
become less effective. Also, the estimation of K, Ke and Ka in Scenario 2.2 only utilizes 
the concentration data at the later time intervals, which potentially causes biases in these 
regression coefficients and consequently in the estimated characteristics. Furthermore, 
the values of  and  in Scenario 2.1 are greater than those in Scenario 2.2, which 
potentially results in more input material costs. 
Table 4.11 Comparisons of Scenarios 2.1 and 2.2 
Scenario 
CI Variance 
 ratio of AUC ratio of Cmax AUCT CmaxT tmaxT 
2.1 [99.65%, 100.50%] [98.33%, 100.70%] 0.000 0.013 0.050 102.3% 
2.2 [99.46%, 100.88%] [98.50%, 100.50%] 0.012 0.000 0.013 99.86% 
 
Additionally, Table 4.11 compares the bioavailability characteristics for the test 
and reference formulations within both scenarios and presents the related variances for 
the test formulation. Based on Table 4.11, the CIs for the ratios of AUC and Cmax stay 
strictly within the regulatory limit [80%, 125%] in both scenarios. Further, the tmax for the 
test formulation in the second scenario is much closer to the reference value than that in 
the first. Finally, characteristic variances for the test formulation in both scenarios are 
close to zero. Note that the summation of these variances in Scenario 2.2 is even less than 
that in Scenario 2.1. Figure 4.2 illustrates the response surfaces of the objective functions 
in both scenarios. The contour plots depicting the effect of x1 and x2 on the objective 
functions in the two scenarios are presented in Figure 4.3. 
*
1x
*
2x
max maxT Rt t
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In summary, the continuous computational method generally works better for this 
formulation optimization problem. It turns out that the continuous method is superior in 
assessing Cmax and tmax, since it results in (1) a smaller CI for the ratio of Cmax, (2) a 
smaller deviation of tmax, and (3) smaller variances of Cmax and tmax for the test 
formulation. By comparison, the discrete method produces a smaller CI for the ratio of 
AUC and a reduced AUC variance for the test formulation. Additionally, the optimal 
input factor amounts are less in Scenario 2.2 (which uses the continuous method), leading 
to lower input costs. 
 
Figure 4.2 Response Surface Plots of the Two Scenarios 
 
4.5 Sensitivity Analysis 
As presented in the previous section, the proposed approach in Scenario 2.2 is not 
preferred for evaluating AUC. In order to validate this result, a sensitivity analysis of the 
constraint boundary to the optimal ingredient amounts is performed by varying ηL1 from 
9.7 to 10.1 with an increment of 0.2. The results are provided in Table 4.12. The same  
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Figure 4.3 Contour Plots of x1 and x2 for the Bioequivalence Studies 
Problem 
Table 4.12 Sensitivity Analysis for the Bioequivalence Studies Problem 
ηL1 
Scenario  
CI Variance 
 ratio of AUC ratio of Cmax AUCT CmaxT tmaxT 
9.7 
2.1 (184.06, 10.28) [99.65%, 100.50%] [98.32%, 100.70%] 0.000 0.013 0.050 102.24% 
2.2 (177.80, 8.26) [99.49%, 100.85%] [98.50%, 100.53%] 0.012 0.000 0.013 99.98% 
9.9 
2.1 (184.05, 10.32) [99.65%, 100.50%] [98.33%, 100.70%] 0.000 0.013 0.050 102.31% 
2.2 (177.80, 8.77) [99.55%, 100.79%] [98.49%, 100.59%] 0.011 0.000 0.013 100.26% 
10.1 
2.1 (184.00, 10.45) [99.66%, 100.49%] [98.34%, 100.71%] 0.000 0.013 0.050 102.42% 
2.2 (177.80, 9.33) [99.61%, 100.72%] [98.48%, 100.66%] 0.011 0.000 0.013 100.53% 
 * *1 2,x x max maxT Rt t
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conclusion as that in Section 4.4 can be reached. That is, the discrete computational 
method works better for assessing AUC, while the continuous method results in lower 
input costs and more desirable performance related to Cmax and tmax. 
 
4.6 Conclusion and Future Study 
In this chapter, we propose an experimental design integrating in vivo 
bioequivalence studies and the formulation optimization procedure in order to seek the 
optimal levels of excipients that ensure bioequivalence between formulations when Level 
3 excipient changes are detected. Two bioequivalence assessment methods, designated as 
continuous and discrete, are developed for this research. Furthermore, a numerical 
example shows that the continuous methodology generally performs better than the 
discrete one.  
Finally, recall that if IVIVC is not established, then an in vivo bioequivalence 
study is mandated; otherwise, a dissolution test may serve as the surrogate for this 
comparatively expensive study. While the former was the subject of this chapter, the 
latter has yet to be considered (to the same extent). The motivation for a future 
investigation of the dissolution test is identical to that of the current study. That is, the 
objective would be to determine a test formulation whose performance is deemed 
equivalent to that of the reference drug, while at the same time minimizing the associated 
costs. 
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CHAPTER 5 
QUALITY BY DESIGN STUDIES ON MULTI-RESPONSE PHARMACEUTICAL 
FORMULATION MODELING AND OPTIMIZATION  
 
5.1 Introduction 
Pharmaceutical formulation is the process that combines active and inactive 
ingredients to produce a final drug product. Formulation designers seek optimal 
ingredient amounts in order to maximize the clinical benefit of ingredients. Beyond its 
significant role in drug delivery, formulation optimization has gained increasing attention 
over the years because of the desirable benefits of building drug quality in early design 
phases, in contrast to the traditional quality control philosophy of inspecting finished 
products (FDA, 2006b).  
It is widely acknowledged that the formulation optimization can be implemented 
by the use of a combination of analytical approaches, such as DOE, RSM, and 
optimization (Holm et al., 2006; Huang et al., 2009; Rosas et al., 2011). DOE combined 
with RSM permits the mathematical modeling of a QC associated with the clinical 
benefit, such as friability, hardness, thickness, and dissolution performance, as a function 
of the ingredient amounts. Based upon the established response surface function, 
optimization techniques are then utilized to determine optimal settings of the ingredients 
so that the desirable performance of the characteristic can be achieved. In practice, during 
the formulation optimization, designers are usually faced with multiple pharmaceutical 
QCs, namely an MRS problem. In this case, it is difficult to determine the optimal factor 
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settings for all the responses, because (1) these characteristics may have different scales 
of measurement and different types of optimality, and (2) as one characteristic is 
optimized, it is usually at the expense of one or more others (Derringer, 1994; Xu et al., 
2004). Therefore, it is necessary to develop an optimization model for pharmaceutical 
formulation that simultaneously considers multiple characteristics in order to find the best 
compromise among them. 
Despite the existing research efforts on solving an MRS optimization problem for 
formulation optimization, there remain several issues which have not been 
comprehensively studied in the literature. First, in addition to the response mean, 
formulation researchers need to take into account the variance, since individual subjects 
may differ widely in their responses to a drug and variability may potentially lead to 
safety and efficacy issues. The correlation between responses is frequently overlooked 
when multiple QCs are evaluated. For instance, the optimization of the dissolution profile 
is a usual routine for developing a new formulation, where the associated responses, 
including the amounts dissolved at multiple points in time, are believed to be correlated 
over time. Their covariance is most likely to influence the dissolution performance over 
time; hence, additional response variables regarding the variance and covariance are 
considered in our proposed model. Second, one of the most popular methods for solving 
MRS problems is the DF approach, originally developed by Harrington (1965) and later 
improved by Derringer and Suich (1980). In this chapter, the conventional DF method is 
modified and incorporated into the formulation optimization as enhanced empirical and 
mechanistic DF approaches. Third, the commonly-used RSM, which calls for fitting the 
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response desirability or response variable to a first- or second-order polynomial 
regression function to predict the response surface, may be less effective for estimation 
than a higher-order model (Shaibu & Cho, 2009). Since the precision in the model fit 
heavily influences the effectiveness in finding optimal factor settings, the solution 
resulting from the traditional low-order response surface functions may be less accurate. 
In order to improve the accuracy of the estimated response surface, we propose the use of 
higher-order (up to fourth order) models, incorporating the best subsets regression 
method. Finally, despite the fact that the weight-based overall DF is extensively treated 
as an objective function for simultaneously optimizing multiple QCs, there are potential 
shortcomings, which include the high sensitivity of the optimal solution resulting from 
the weights assigned and the subjectivity in determining the weights of subjects. A 
priority-based optimization scheme that is based upon a priority, rather than a numerical 
weight for each individual characteristic, can be a more effective alternative. Since goal 
programming is one of the most popular approaches to finding good solutions to a multi-
objective problem (Rardin, 1998), a priority-based goal programming model is proposed 
to optimize individual desirability of the multiple characteristics with the purpose of 
determining the best formulation. 
The rest of this chapter is organized as follows. Section 5.2 provides modified 
DFs as a basis of the proposed DF methods. The development of the proposed multi-
response formulation optimization model, integrated with two modified DF methods and 
the well-investigated goal programming technique, is given in Section 5.3. A numerical 
example to demonstrate the effectiveness of the proposed model in optimizing a 
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dissolution profile and comparative conclusions are presented in Sections 5.4 and 5.5, 
respectively. 
 
5.2 Analysis of DF 
In the literature, researchers proposed various scientific techniques for solving 
MRS problems in the past thirty years. The usage of Taguchi‘s method (1986) for 
designing robust products or processes prevailed among earlier research work. Pignatiello 
(1993), Elsayed and Chen (1993), Vining (1998), and Ko et al. (2005) employed the 
Taguchi quality loss function approach to determine the optimal settings of input factors 
for products with multiple QCs. Some extensions to Taguchi‘s method were also made by 
researchers such as Chen (1997), Wu (2002), Fung and Kang (2005), and Kovach and 
Cho (2008). In practice, in addition to the approaches mentioned above, some 
formulation scientists applied the DF method to formulation optimization for optimizing 
multiple characteristics simultaneously (Abu-Izza et al., 1996; Paterakis et al., 2002; 
Rosas et al., 2011).  
The DF technique is useful to convert multiple characteristics with different units 
of measurement into a single commensurable objective by means of normalizing each 
estimated response variable to individual desirability. Its value varies between 0 and 1, 
and the response becomes desirable as its desirability approaches 1. Derringer (1994) also 
suggested using a weighted geometric mean function to convert multiple individual 
desirability into a single measure of characteristic performance known as the overall 
desirability, D. Hence, when applying the DF approach to formulation optimization, the 
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overall DF value is always maximized so that the optimal settings of the ingredient 
amounts can ensure the best compromise among multiple characteristics of interest 
(Wang et al., 1996; Ficarra et al., 2002; Candioti et al., 2006; Holm et al., 2006; Zidan et 
al., 2007; Li et al., 2011). Adopting this traditional approach, the estimated DF can be 
obtained by fitting polynomial regression functions of x to the calculated desirability for 
the responses. As a result, one may estimate the desirability for the formulation 
determined by the h responses which in turn are at the same time determined by the k 
factors. 
Furthermore, several innovative attempts have been made to improve the 
traditional DF approach. Del Castillo et al. (1996) proposed a differentiable DF method 
which allowed researchers to use more efficient gradient-based optimization methods for 
maximizing the overall desirability. Wu and Hamada (2000) suggested using the double-
exponential function as an alternative DF, and Wu (2004) extended the double 
exponential DF based on the Taguchi‘s loss function in order to optimize correlated 
multiple QCs. Moreover, Bashiri and Salmasnia (2009) and Goethals and Cho (2011) 
also presented new optimization procedures based on the DF method for correlated 
characteristics. However, several researchers also revealed some shortcomings of the DF 
approach. Takayama et al. (1999) argued that one of the weaknesses of DF was the 
subjectivity associated with the selection of an acceptable interval for each response. Kim 
and Lin (2000) pointed out that it was difficult to assign meaning to a DF value, beyond 
the basic principle that a higher value of desirability is preferred. 
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In this chapter, we propose a modified DF which allows the formulation designer 
to incorporate correlations between QCs. Suppose that h QCs of interest concerning the 
mean, variance, and covariance, denoted by  ω for ω = 1, 2, …, h, are determined by a 
set of k factors, x = [x1, x2, …, xk] . Referring to Equations (2.9) and (2.10), if the ω
th
 
response is a LTB or STB characteristic, the individual desirability is computed by the 
transformation 
 , (5.1) 
where Lω and Uω respectively represent acceptable minimum and maximum values, Tω is 
an allowable maximum or minimum value for the LTB or STB response, and ω is the 
shape parameter for the DF. ω is determined by the importance of hitting the value Tω. If 
 ω is a NTB response, its individual desirability is given by the transformation 
 , (5.2) 
where Tω is the target value, and the shape parameters are denoted by ω1 and ω2. Based 
upon Equation (2.11), let Wω (ω = 1, 2, …, h) be the predefined weight for the πω; then, 
D can be expressed as 
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 . (5.3) 
This modified DF will be the basis of the proposed mechanistic and empirical DF models 
developed in the next section. 
 
5.3 Proposed Model Development 
Figure 5.1 illustrates the phases of model development. During the first phase, 
DOE is performed based upon the prior knowledge of the factors, responses, and 
experimental space of interest. The second phase, which incorporates higher-order 
polynomial functions, least squares regression, and best subsets model selection method, 
is designed to obtain estimated DFs by proposing two separate DF methods- mechanistic 
and empirical. First, we develop the estimated mechanistic DF, which employs the 
piecewise form of the traditional DF method utilizing the higher-order estimated response 
surface function for each response variable. Second, we propose the use of least squares 
method to develop estimated empirical DFs that take the higher-order polynomial form 
for evaluating the response variance and covariance in addition to the mean. Finally, by 
means of incorporating goal programming techniques and related constraints into the 
optimization procedure, the optimal settings of ingredient amounts that minimize the 
deviations of responses from their respective goals can be determined. Each phase is 
discussed in greater detail in the following sections. 
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Figure 5.1 Development of Proposed Optimization Scheme 
 
5.3.1 Experimentation Phase 
In this chapter, the ingredient amounts, x, are chosen as input factors, and the QCs 
of interest, y, are the amounts or percentages dissolved at multiple points in time. Since 
the dissolution data are classified as time series data, the responses are correlated over 
time; the behavior of the covariance between responses is considered in the proposed 
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model. Commonly, factorial designs, CCDs, and mixture designs with replications can be 
performed in order to evaluate the response surfaces of related characteristics in terms of 
the mean, variance, and covariance. Let yijs be the j
th
 (j = 1, 2, …, m) observation for the 
i
th
 (i = 1, 2, ..., n) characteristic (i.e., i
th
 point in time) on the s
th
 (s = 1, 2, …, r) 
experimental run, then the mean and variance of the i
th
 response as well as the covariance 
between the w
th
 and g
th
 (1 ≤ w < g ≤ n) responses on the sth run are respectively given by 
 .  
It should be mentioned that (1) since a small response variance is always desired, 
we consider      to be a STB characteristic, and (2) it is also reasonable to treat        as a 
NTB characteristic since the covariance to be optimized should be close to its target 
value. A general experimental format with r runs and m replications for each run is 
provided in Table 5.1, where   is the factor settings for k factors. It can be easily shown 
that the total number of response variables, h, is equal to 2n + nC2.  
Table 5.1 A General Experimental Format 
Run 
Factors 
(x) 
y1   1   
   ... yn   n   
   ...    
   ...        
  
1 
Input 
factor 
settings 
( ) 
y111 … y1m1   11    
   … yn11 … ynm1   n1    
   …      
  ...          
  
2 y112 … y1m2   12    
   … yn12 … ynm2   n2    
   …      
  ...          
  
        …       …   ...   
s y11s … y1ms   1s    
   … yn1s … ynms   ns    
   …      
  ...          
  
        …       …   ...   
r y11r … y1mr   1r    
   … yn1r … ynmr   nr    
   …      
  ...          
  
 
    
2
2 2
,
1 1 1
1 1 1
ˆ ˆ ˆ ˆ, , and
1 1
m m m
is ijs is ijs is wg s wjs ws gjs gs
j j j
y y y y
m m m
     
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5.3.2 DF Prediction Phase 
As discussed earlier, the traditional DF is implemented by plugging the response 
mean into Equations (5.1) ‒ (5.3). Alternatively, the mechanistic model can be 
established by utilizing the estimated response surface function based upon the 
underlying mechanism of the DF approach. Moreover, the empirical desirability model 
can be developed by modifying the traditional method, which employs the variance, 
covariance, and mean of the individual desirability for m observations on each of the 
experimental runs. The use of higher-order regression functions is proposed for modeling 
the responses and desirability; then, the best subsets model selection method is extended 
to identify the estimated functions that most precisely approximate both the proposed 
mechanistic and empirical desirability. Hereafter, we use the subscripts M and E to 
differentiate their related terms.  
 
5.3.2.1 Proposed Mechanistic Desiraiblity Model 
In order to obtain the estimated mechanistic DFs, ordinary least squares 
regression techniques are initially utilized to develop the estimated response surface 
functions in terms of the mean, variance, and covariance. Hereafter, a regression function 
with ψ parameters or ψ – 1 predictor variables is considered a full model; 
correspondingly, a reduced model is regarded as a regrssion function containing less than 
ψ – 1 predictors. Let   i(x) and    (x) be the higher-order (up to fourth-order) regression 
functions for the mean and variance of the i
th
 (i = 1, 2, …, h) response, respectively. Their 
full models can be expressed by the following equations: 
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  (5.4) 
and 
 , (5.5) 
where Yi = [  i1,   i2, …,   ir]  is the vector of the i
th
 response means, and Σi = [   
  ,    
  , …, 
    ]  is the vector of the i
th
 response variances. Additionally, XF is an r × ψ matrix of data 
for the predicator variables in the full model: 
 , 
in which XF,s (s = 1, 2, …, r) is the data vector for the full model on the s
th
 experimental 
run. In a reduced model with v – 1 (1 ≤ v ≤ ψ) predictors, the r × v data matrix for the 
predictors is denoted by XR,v = [XR,1,v XR,2,v, …, XR,r,v]  in which XR,s,v is the data vector 
for the reduced model on the s
th
 experimental run; especially, XF = XR,ψ. Subsequently, 
the full model for the covariance between the w
th
 and g
th
 (1 ≤ w < g ≤ n) repsonses is 
given by 
 , (5.6) 
where Σwg = [     
 ,      
 , …,       ]  is the vector of the covariances between the w
th
 and 
g
th
 responses. When employing a higher-order regression model, an increase in the 
number of predictors may result in multicollinearity between predictors. Variance 
Inflation Factor (VIF) is widely used to diagnose the multicollinearity. The VIF is 
defined as VIFf = 1/(1 −   
 ), where   
  is the coefficient of multiple determination when 
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the f
th
 predictor is regressed on the v – 1 other predictors in the model (Kutner et al., 
2004). A maximum of these VIF values greater than 10 indicates that the 
multicollinearity may impact the least squares estimates. In this case, the correlated 
predictors can be removed from the estimated function.  
If  ω(x) denotes any estimated response surface function for ω = 1, 2, …, h whose 
predictors are considered appropriate for the estimation of the related response variable 
based upon the best subsets critieria, the estimated mechanistic individual DF, d[ ω(x)], 
and overall DF,   M(x), can be finally expressed using Equations (5.4) – (5.6) under the 
traditional DF mechanism. Hereafter, we use   M,ω(x) instead of d[ ω(x)] for the sake of 
simplicity; more specifically, we have 
 . (5.7) 
 
5.3.2.2 Proposed Empirical Desiraiblity Model  
If d(yijs) is the individual DF value for yijs, its formulas categorized by the 
characteristic type are developed in Table 5.2. The estimated empirical individual DF for 
the response mean can be derived from the raw observations by using the ordinary least 
squares method. Let   E,ω(x) (ω = i) be the esimated empirical fourth-order individual DF 
of x for the the ωth response mean. Then its full model can be expressed as  
 , (5.8) 
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where dω = [dω1, dω2, …, dωr]  is the vector of the mean values for the ω
th
 individual 
desiraiblity and dω  can be calculated by     
 
 
        
 
    for s = 1, 2, …, r. Efforts 
are also made to extend the application of Equation (5.8) for expressing the full model of 
the estimated individual DFs for the response variance and covariance. If ω = n + i, the 
dω  represents the desiraiblity of      that is calculated by d(    ); otherwise, it is the 
desiraiblity of        that is calculated by d(      ). In a similar fashion, the full model of 
the estimated empirical fourth-order overall DFs of x, denoted by   E(x), is given by 
 , (5.9) 
where D = [D1, D2, …, Dr]  is the vector of overall DF values. Note that Ds (s = 1, 2, …, 
r) is defined as the overall desirability value on the s
th
 run. It is the weighted geometric 
mean of dω  and can be computed by 
 . (5.10) 
However, some of the yijs may go beyond the allowable maximum or minimum 
value of desirability potentially resulting in that the proposed dω  and consequently the 
overall desirability on the corresponding experimental run becomes zero. If the overall 
desiraiblity for many of the runs appears to be zero, the appropriateness of using the least 
squares method to obtain the estimated overall DF can be questionable. As a supplement 
to Table 5.1, Table 5.3 shows an extended experimental format from the perspective of 
desirability concerning the mean, variance, and covaraince of each response, in which 
  ω(x) denotes either the mechanistic or empirical desirability model.  
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Table 5.2 Formulas for Calculating d(yijs) 
Characteristic 
Type
 
Formula
 
LTB
 
 
STB
 
 
NTB
 
 
 
Table 5.3 An Extended Experimental Format Concerning Desirability 
Run y1   1   
   ... yn   n   
      
      
   ...        
  
1 d(y111) … d(y1m1) 
     
  
   
 
   
  
… d(yn11) … d(ynm1) 
   
  
  
   
 
  
  
   
 
 
   
  
   
 
 
   
  
... 
   
  
  
2 d(y112) … d(y1m2) … d(yn12) … d(ynm2) ... 
    …   ... 
s d(y11s) … d(y1ms) … d(yn1s) … d(ynms) ... 
    …   ... 
r d(y11r) … d(y1mr) … d(yn1r) … d(ynmr) ... 
 
5.3.2.3 Model Selection of Estimated Empirical DFs 
In addtion to seeking the appropriate subset of predictor variables for  ω(x), 
which has been well studied in the literature, we focus on the identification of the proper 
subsets of predictors under the empirical models for estimating DF values which 
necessitates the development of different subset selection criteria. Cruz-Monteagudo et 
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al. (2008) proposed the desirability‘s determination coefficient,   
 , and adjusted   
  (adj. 
  
 ) for the traditional desiraiblity method to measure the effect of a specific set of 
predictors on reducing the uncertainty when predicting desirability. The both critiera as 
well as three alternative criteria, including Akaike information criterion (AIC), Bayesian 
information criterion (BIC), and prediction sum of squares (PRESS), need to be further 
investigated for examining the estimated empirical individual and overall DFs with 
different sizes of predictors. Each subset selection criterion is delineated in terms of 
desirability in Table 5.4, where the subscripts d and v (1 ≤ v ≤ ψ) indicate that the statistic 
is related to desirability and there are v – 1 predictor variables in the model. The 
following paragraphs provide the development of these statistics. 
Table 5.4 Subset Selection Criteria for Desirability Models with v – 1 Predictors 
Criterion Fomula Description 
  
SSRd,v and SSTOd denote regression sum of squares (SSR) and total sums of 
sqaures (SSTO) for the DF with v – 1 predictors. Large     
  values are 
preferred.     
  always increases as v increases, so it is not appropriate to 
compare desirability models with different sizes. 
adj.   
SSEd,v denotes error sum of squares (SSE) for the DF with v – 1 predictors. 
Large adj.     
  values are preferred. This criterion can be used to compare 
desirability models with different sizes, since this criteria provides penalty for 
adding predictors. 
AICd,v rln(SSEd,v) – rln(r) +  2v 
Small values of AICd,v are preferred. Similar to adj.     
 , this criteria 
penalizes desirability models have large numbers of predictors and can be 
used to compare desirability models with different sizes. 
BICd,v 
rln(SSEd,v) – rln(r) + 
vln(r) 
By analogy with AICd,v, small values of BICd,v are sought. However, the 
BICd,v gives more penalty for over-fitting than AICd,v when r ≥ 8. This 
indicates that the BICd,v tends to favor more simple models. 
PRESSd,v  
        is the s
th residual term and hss,v is the s
th diagnal element of the r × r hat 
matrix             
      
      
  for the esimated desirability model with v 
– 1 predictors. Desirability models with small PRESSd,v values fit well in the 
sense of having small prediction errors (also known as residuals). 
 
 Analysis of variance for estimated empirical DFs 
Let SSTOd,ω be the SSTO of the ω
th
 individual desirability model, which can be 
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written as Equation (5.11) incorporating the unity matrix, J = 11 , and the identity matrix, 
I. 
 , (5.11) 
where   ω is the mean of dω  for s = 1, 2, …, r. Similarly, if the SSTO for the overall 
desirability model is denoted by SSTOD and    is the mean of Ds, SSTOD can be 
computed by  
 . (5.12) 
Using the fact that               
      
      
        , in which   v,ω = 
[  E,ω(XR,1,v),   E,ω(XR,2,v), …,   E,ω(XR,r,v)]  is the vector of the ω
th
 estimated empirical DF 
values at XR,s,v (s = 1, 2, …, r), it can be shown that the SSE and SSR of the ω
th
 empirical 
individual desirability model with v – 1 predictors, denoted by SSEd,v,ω and SSRd,v,ω, are 
given by 
  (5.13) 
and 
 .  (5.14) 
In the same manner as in Equations (5.13) and (5.14), the formulas of the SSE and SSR 
for the empirical overall desirability with v – 1 predictors, denoted by SSEDE,v and 
SSRDE,v, are given by 
  (5.15) 
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and  
 . (5.16) 
Furthermore, let ev,ω and ev denote the residual vectors for the ω
th
 empirical 
individual and overall desirability, then they can be developed as linear combinations of 
dω and D, respectively: 
  (5.17) 
and  
 , (5.18) 
where   d,s,v,ω and   D,s,v correspond to the residual terms of the ω
th
 individual DF and 
overall DF with v – 1 predictors on the sth experimental run.  
 
 Subset selection criteria development 
As shown in Table 5.5, the selection criteria for the individual and overall DFs 
under empirical models can be obtained based upon Equations (5.11) – (5.18). In our 
proposed model, one may need to consider more than one criterion when selecting the 
ideal estimated function. Since the number of possible regression functions, 2
v-1
, 
increases dramatically as v increases, it is an overwhelming task for a data analyst to 
examine all possible subsets of predictors. Commonly, we use the best subsets regression 
technique to simply the task. This technique requires the calculation of only a small 
fraction of all the possible regression models, so that a small group of regression 
functions that are considered desirable candidates according to these criteria can be 
, ,
1
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identified. A detail examination can then be made, leading to the selection of the final 
estimated DF to be employed in the optimization phase.  
Table 5.5 Subset Selection Criteria for the Individual and Overall Desirability 
Criterion 
Formula with v – 1 predictors 
ωth Individual DF  Overall DF 
 
  
adj.  
  
AICd   
BICd 
  
PRESSd   
 
5.3.3 Optimization Phase 
At this stage, we need to solve an MRS optimization problem; namely, the 
optimal settings of ingredient amounts of a pharmaceutical formulation need to be 
determined in order to ensure that the dissolution data at multiple points in time have 
most desirable performance referencing the target profile. Traditionally, the MRS 
optimization problem can be simplified into a single-objective optimization problem in 
which the overall DF is maximized subject to a rigid set of constraints. It can 
alternatively be viewed as a multi-objective optimization problem.  
2
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5.3.3.1 Proposed Optimization Model 
Goal programming, as one of the most widely applied tools of multi-objective 
optimization, is constructed in terms of specific goals to be achieved rather than 
quantities to be maximized or minimized (Rardin, 1998). According to the basic thread of 
goal programming, prior to formulating an objective function for each of the individual 
DFs by means of introducing nonnegative deficiency variables to model the extent of 
violation in their respective goals that need not to be rigidly enforced, a specific 
numerical target is established for each of them. Since the response performance becomes 
more desirable as its DF value approaches 1, the numerical target of the individual DF is 
usually set to 1. Subsequently, each of the individual DFs can be expressed in an 
equality-form mathematical format with the target value and deficiency variables:   ω(x) 
−   
  +   
  = 1, in which   
  and   
  are the nonnegative deficiency variables associated 
with the underachievement and overachievement of the ωth desirability. Since the 
allowable maximum of desirability is 1,   
  does not exist in this case and therefore the 
equality reduces to 
 . (5.19) 
In order to ensure that all desirability values are as close as possible to 1, involved 
deficiency variables should be minimized. Generally, non-preemptive and preemptive 
optimization schemes can be utilized to facilitate the minimization of the deficiency 
variables (Hillier & Lieberman, 2001). The objective of the former is to satisfy all goals 
by minimizing a weighted sum of the deficiency variables. However, it is believed that 
the subjectivity in assigning the weights of subjects may impact the resulting optimal 
 ˆ 1d 
  x
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solution which is highly sensitive to the different weights. In the latter scheme, there is 
hierarchy of priority levels for the goals, so that deficiency in the DF of primary 
importance is minimized, deficiency in the DF of secondary importance is minimized 
subject to an additional constraint that the first achieve its minimum, and so forth. 
Therefore, with the purpose of overcoming the weaknesses of weight-based goal 
programming, we propose a priority-based approach for optimizing multiple individual 
DFs.  
Based on the pre-identified shape parameters for the DFs, the procedural steps for 
the algorithm of our proposed optimization model are illustrated in Figure 5.2 and 
described below in greater detail: 
(1) Determine the priority hierarchy of the ω individual DFs based on importance 
levels of the dissolved amounts or percentages at different points in time. For 
example, the half-life of dissolution is critical to a dissolution profile because 
it establishes the time to promote the dissolution of 50% of the drug (Chazel et 
al., 1998); hence, the half-life dissolution performance in terms of the mean 
and variance can be the highest ranked responses in the priority hierarchy. 
Suppose that    individual DFs are categorized as the  
th
-priority goals to be 
achieved with        = ω, and   is initially set to 1. 
(2) Formulate the objective function of the  th optimization model by minimizing 
the summation of    deficiency variables in the  
th–priority individual DFs 
while satisfying the following constraints: 
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a) Let  ω be the specification region of  ω(x) for ω = 1, 2, …, h. For an 
estimated function in terms of either the mean or covariance (NTB), the 
lower and upper bounds of its specification region are the corresponding 
acceptable minimum and maximum values; meanwhile, for an estimated 
function related to the variance (STB), the target and acceptable maximum 
values are considered the lower and upper bounds.  
b) The input factors should remain within the design space which is explored 
by DOE and ensures the optimality and feasibility of a pharmaceutical 
formulation. The design space for each of the k factors should be within 
the interval between the minimum and maximum coded values. That is, −1 
≤ x1,  x2, …, xk ≤ 1 for a factorial design, Taguchi design, or mixture 
design; x
T
x ≤ ρ2 for a CCD, where ρ is the distance in any direction from 
the center point and is analogous to the radius of a sphere.  
c) Nonnegativity of deficiency variables involved in the  th optimization 
model should be satisfied. It is introduced by the constraint form:   
  ≥ 0, 
where   
  denotes any of the involved underachievement deficiency 
variables. 
d) Referring to Equation (5.19), the constraints associated with the goals of 
involved individual DFs needs to be included. For the sake of simplicity, 
these constraints are established in an equality form:    (x) +   
  = 1, 
where    (x) represents any of the  
th–priority individual DFs in the  th 
optimization model.  
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e) If   > 1 and the resulting optimal solution of deficiency variables in the (  
− O)th optimization model is denoted by       
 , extra constraints with the 
expression of        (x) +       
  = 1 for O = 1, 2, …,   – 1 are added to 
the  th optimization model, which guarantees that all the preceding goals 
are achieved in the  th optimization model. 
f) The values of all the estimated DFs should vary from 0 to 1, so that the 
validity of these DFs can be ensured at each iteration of the proposed 
optimization model.   
g) Additional constraints specified by the FDA may be added to the 
optimization model as appropriate, such as hardness, thickness, and 
stability requirements for the formulation. Any of these estimated response 
functions, denoted by   (x), can be obtained by the RSM discussed in the 
previous subsections. In a similar fashion to Step (a),   (x) should remain 
within the associated regulatory region,   . 
(3) If the  th optimization model yields a unique solution, the routine is 
terminated and this optimal solution vector (  
 ,   
 )  is finalized as the most 
desirable settings of both the factors and deficiency variables without 
considering any lower-priority goals. Note that   
  is the vector of optimal 
factor settings for the  th optimization model. Otherwise, Step (4) is executed. 
(4) If (  + 1)th-priority goals exist,   is increased by one and the procedure returns 
to Step (2). Otherwise, we adopt the (  
 ,   
 )  immediately. 
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Figure 5.2 Flowchart for the Algorithm of the Proposed Optimization Model 
Moreover, based upon Step (2), Table 5.6 outlines the proposed  th optimization scheme 
for the priority-based goal programming methodology to the formulation optimization 
problem.  
5.3.3.2 Comparative models 
As references for comparison with the proposed model, optimization models that 
maximize the overall DF under both mechanistic and empirical models are developed in 
Table 5.7, in which the optimal settings of deficiency variables under both models are 
expressed as:   
  and   
 . 
 
Determine the 
priority hierarchy 
of individual DFs
ξ = 1
Solve the ξth 
optimization 
model
Unique 
optimal 
solution?
ξ = ξ + 1
 ,x Δ   
Store the 
optimal solution
 ,x Δ   
End.
Final optimal 
solutionYes
Does ξ + 1 
exist?
Yes
No No
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Table 5.6 Proposed Optimization Scheme for the  th-Priority Individual DFs 
Minimize    
  
Subject to Constraints: 
 
1. Specification region of estimated response surface functions (ω = 1, 2, …, h): 
 ω(x)    ω 
2. Design space of factors: 
−1 ≤ x1,  x2, …, xk ≤ 1 (for a factorial design, Taguchi design, or mixture design) 
or 
xTx ≤ ρ2 (for a CCD) 
3. Nonnegativity of deficiency variables: 
   ≥ 0 
4. Goals of present individual DFs: 
   (x) +   
  = 1 
5. Goals of preceding individual DFs (applicable if    > 1): 
       (x) +       
  = 1 for O = 1, 2, …,   – 1 
6. Individual DF (ω = 1, 2, …, h): 
0 ≤   ω(x) ≤ 1  
7. Additional constraints specified by the FDA: 
  (x)      
Find Optimal solution (  
 ,   
 )  
 
Table 5.7 Comparative Optimization Schemes Using the Overall DF 
 Mechanistic Model Empirical Model 
Maximize   
Given Predefined weights for each individual DF  
Subject to Common constraints:  
 
1. Specification region of estimated response surface functions (ω = 1, 2, …, h): 
 ω(x)    ω 
2. Design space of factors: 
−1 ≤ x1,  x2, …, xk ≤ 1 (for a factorial design, Taguchi design, or mixture design) 
or 
xTx ≤ ρ2 (for a CCD) 
3. Additional constraints specified by the FDA: 
  (x)      
 Specific constraints: 
 
 
1. Individual DF (ω = 1, 2, …, h): 
 
2. Overall DF: 
 
1. Overall DF: 
 
 
Find Optimal solution x
* Optimal solution x* 
 
 ˆ xMD  ˆ xED
 ,ˆ0 1xMd  
 ˆ0 1xMD 
 ˆ0 1xED 
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5.4 Numerical Example 
To demonstrate the effectiveness of the proposed optimization scheme and 
compare its resulting performance with that of the comparative scheme using the 
mechanistic and empirical desirability models, a numerical example is studied in the 
following paragraphs. Employing second-order estimated response surface functions, 
Huang et al. (2004) conducted a formulation optimization study to develop propranolol 
extended release formulations containing two inactive ingredients: HPMC and avicel. 
HPMC as a pH-independent material is widely used to prepare extended release dosage 
forms while avicel incorporating with HPMC can modify the dissolution performance of 
a drug. A randomized 3
2
 full factorial design with additional two center point runs (r = 
11) was performed in their experiment where two factors, including the HPMC/drug ratio 
(x1) and content percentage of avicel (x2), were measured on the five output responses: 
drug dissolution percentages (y1, y2, y3, y4, and y5) at 1.5, 4, 8, 14, and 24h. Note that the 
center runs were primarily used to provide a measure of pure error. Furthermore, FDA 
(2000) recommends the use of the equally-weighted similarity factor, f2, to evaluate the 
equivalence between two dissolution profiles if the following requirements are satisfied: 
(1) at least 12 units should be used for both profile determination; (2) the RSD at the 
earlier point of time should not be more than 20% and at other points should not be more 
than 10%; and (3) no more than 85% dissolved in 15 minutes. The f2 can be calculated by 
Equation (2.1). Dissolution-time curves are considered similar when f2 is greater than 50, 
and they become similar when f2 approaches 100. The f2 method is utilized as an 
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additional reference for model comparison in order to validate our comparative 
conclusions from the perspective of FDA suggestions.  
Therefore, given the experimental data set in terms of the mean and variance 
provided by Huang et al. (2004), we initially regard y1 as the dissolution data at the 
earlier point of time and the other four responses as those at the later points. In other 
words, these response variances should meet their respective requirements on RSD 
mentioned earlier. Subsequently, it is feasible and necessary to simulate normally 
distributed observations with 12 replicates (m = 12) on each experimental run using 
Microsoft® Excel, so that   i(x) (i = 1, 2, …, h) represents the estimated mean dissolution 
of 12 units at each point of time in accordance with one of the f2 requirements. The factor 
settings, target dissolution profile against priority, and specifications of each variance and 
covariance measures are summarized in Table 5.8. The highest priority pertaining to the 
individual DFs is given to   2 and   3 along with their variances, since both points in time 
are adjacent to the half-life of the dissolution; meanwhile, the second priority is assigned 
for the other response means and variances and the third for the covariance terms. The 
corresponding weights in the overall DF are also identified in Table 5.8 so as to 
implement the comparative optimization study, and the shape parameters of the DFs are 
all set to 1. Moreover, in order to obtain the best regression functions for estimating the 
mean, variance, covariance, and desirability, all possible combinations of predictors up to 
fourth order are examined by using the software program Minitab® 16, and only those 
contributing to the regression analysis are kept for further study. In Table 5.9, a 
comparison of estimated functions related to the response means is displayed, and the 
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fourth-order regression functions concerning response variance, covariance, and 
empirical individual desirability with the highest R
2
 (or   
 ) and adj. R
2
 (or adj.   
 ) are 
selected out of the results of the best subsets screening. Finally, these candidate functions 
are evaluated against the various selection criteria developed in the previous section. 
Since the adj. R
2
 is generally utilized to compare the regression function with different 
sizes of predictors, the best models that achieve desirable values for most of the criteria 
and maintain higher adj. R
2
 or adj.   
  values are identified and given in bold in Table 5.9. 
It should be noted that because the majority of Ds for s = 1, 2, …, r are equal to zero, the 
  E(x) cannot be obtained in this particular example and thereby we perform the 
comparative optimization scheme using the mechanistic overall desirability model. The 
differences in the estimation of the response means under the second- and proposed 
fourth-order models can be illustrated by the contour plots for x1 and x2 with 
corresponding contour labels (see Figure 5.3). The contour plots, shown in Figure 5.4, are 
drawn to compare the resulting estimated fourth-order DFs related to the response mean 
by using the traditional and proposed empirical desirability models. 
Using the results of Table 5.9, the proposed priority- and comparative overall DF-
based optimization procedures can be performed. The resulting optimal settings under the 
different models along with the weighted overall desirability and f2 are obtained by 
Mathematica® 8.0 and summarized in Table 5.10, in which the ideal desirability and f2 
values are highlighted in bold. Note that because both of the solutions to the achievement 
of the 1
st
-priority goals using the empirical and mechanistic DF methods are unique, their 
respective priority-based optimization procedures are then terminated, with (  
 ,   
 ) = 
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(0.138, 1.000) and (  
 ,   
 ) = (0.589, –0.968) as the corresponding optimal factor settings. 
The Mathematica programming code is provided in Appendix 3. Moreover, Figure 5.5 
describes a comparison of the resulting optimal desirability against ω. The impact of the 
assigned weights or priorities on the optimal desirability under the associated 
optimization models can be observed in Figure 5.6, which shows a comparison of the 
optimal individual desirability under each of the models in Table 5.10 (solid line) and 
that under the respective equally-weighted optimization model (dashed line). In Figure 
5.5 and 5.6, the lines marked with ●, ▲, and ■ describe the resulting desirability under the 
empirical, mechanistic, and overall DF models, respectively. 
 
Figure 5.3 Comparison of Contour Plots between Second- (---) and Fourth-Order 
(—) Models for the Response Means 
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Table 5.8 Experimental Factor Settings and Target Dissolution Profile 
Factors 
Actual values under coded levels 
−1 0 +1 
x1 1 : 1 1.5 : 1 2 : 1 
x2 8% 14% 20% 
Characteristic 
Acceptable 
minimum (%) 
Target (%) 
Acceptable 
maximum (%) 
Priority Weight 
  1 0 12.5 25 2
nd 10 
  2 35 42.5 50 1
st 100 
  3 55 62.5 70 1
st 100 
  4 75 82.5 90 2
nd 10 
  5 95 102.5 110 2
nd 10 
  
   − 0 25 2
nd 10 
  
   − 0 25 1
st 100 
  
   − 0 49 1
st 100 
  
   − 0 81 2
nd 10 
  
   − 0 121 2
nd 10 
Covariance −5 0 +5 3rd 1 
 
 
Figure 5.4 Comparison of Contour Plots between Estimated Traditional (---) and 
Proposed Empirical (—) Desirability Models for the Response Means 
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Table 5.9 Model Selection for the Mean, Variance, Covariance, and Individual Desirability 
 
Estimated Response Surface Function Estimated Empirical Individual Desirability 
Characteristic v R2 adj. R2 AIC BIC PRESS ω v
 
 adj.  AICd BICd PRESSd 
S
eco
n
d
-
o
rd
er  
  1 3 0.607 0.508 24.64 25.83 117.38 1 3 0.382 0.228 −36.34 −35.14 0.45 
  2 4 0.770 0.672 26.62 28.21 143.11 2 4 0.349 0.070 −23.88 −22.89 1.83 
  3 3 0.789 0.736 29.14 30.33 183.45 3 3 0.246 0.057 −28.92 −27.73 0.68 
  4 4 0.764 0.662 30.34 31.92 248.26 4 4 0.112 0 −27.80 −26.21 1.18 
  5 5 0.710 0.517 27.29 29.27 291.94 5 5 0.653 0.422 −31.09 −29.10 1.60 
P
ro
p
o
sed
 fo
u
rth
-o
rd
e
r 
  1 9 0.996 0.978 −14.83 −12.44 0 1 
8 0.994 0.980 −78.80 −75.62 0 
9 0.996 0.978 −80.34 −76.75 0 
  2 
6 0.973 0.947 13.33 15.72 58.38 
2 
6 0.936 0.873 −45.47 −43.08 0 
9 0.984 0.919 8.57 12.15 0 9 0.953 0.763 −42.70 −39.12 0 
  3 
6 0.938 0.877 21.60 23.99 102.5 
3 
7 0.871 0.677 −40.34 −37.55 0 
9 0.967 0.836 20.65 24.23 0 9 0.880 0.401 −37.15 −33.57 0 
  4 
8 0.949 0.830 21.47 24.65 0 
4 
7 0.871 0.678 −42.96 −40.17 0 
9 0.961 0.803 20.65 24.23 0 9 0.877 0.383 −35.86 −39.44 0 
  5 
8 0.974 0.915 6.57 9.75 0 
5 
7 0.946 0.864 −47.49 −44.71 0.19 
9 0.974 0.872 8.57 12.15 0 9 0.953 0.767 −45.21 −41.63 0 
  
   
7 0.970 0.926 8.44 11.23 0 
6 
7 0.970 0.926 −62.38 −59.59 0 
9 0.973 0.865 11.33 14.91 0 9 0.973 0.865 −59.48 −55.90 0 
  
   
4 0.373 0.105 43.74 45.33 617.5 
7 
4 0.373 0.105 −27.08 −25.48 0.988 
7 0.468 0 47.94 50.73 0 7 0.468 0 −22.87 −20.09 0 
  
   
2 0.137 0.041 57.63 58.43 2243.9 
8 
2 0.137 0.041 −28.00 −27.20 0.93 
8 0.272 0 67.77 70.95 0 8 0.271 0 −17.86 −14.68 0 
  
   
3 0.260 0.076 59.37 60.56 2259.4 
9 
2 0.237 0.152 −38.95 −38.15 0.28 
9 0.440 0 68.32 70.90 0 9 0.440 0 −28.35 −24.77 0 
  
   
7 0.828 0.569 68.80 71.59 496.5 
10 
7 0.828 0.569 −61.08 −58.30 0.03 
8 0.830 0.433 70.90 74.08 0 8 0.830 0.433 −59.22 −56.04 0 
   
   
5 0.600 0.333 0.44 2.43 0 
11 
4 0.612 0.446 −41.72 −40.13 0.21 
9 0.670 0 0.63 4.21 0 9 0.630 0 −32.24 −28.66 0 
   
   
8 0.965 0.884 −1.96 1.22 0 
12 
7 0.959 0.898 −45.75 −42.96 0.15 
9 0.974 0.871 −3.22 0.36 0 9 0.961 0.807 −42.37 −38.79 0 
   
   
4 0.739 0.627 3.68 5.27 15.75 
13 
6 0.803 0.607 −41.84 −39.46 0 
9 0.818 0.008 9.72 13.30 0 9 0.842 0.210 −38.25 −34.67 0 
   
   
5 0.891 0.818 3.20 5.19 48.76 
14 
7 0.929 0.822 −42.89 −40.11 0 
7 0.923 0.807 3.40 6.19 0 9 0.930 0.648 −39.03 −35.44 0 
   
   
7 0.937 0.843 −6.24 −3.45 0 
15 
7 0.783 0.458 −46.36 −43.58 0.14 
9 0.964 0.819 −8.27 −4.69 0 9 0.807 0.037 −43.68 −40.09 0 
   
   
4 0.386 0.123 23.26 24.85 118.39 
16 
3 0.526 0.408 −29.99 −28.80 0.60 
9 0.722 0 24.52 28.11 0 9 0.651 0 −21.37 −17.79 0 
   
   
4 0.537 0.338 18.27 19.86 69.87 
17 
4 0.484 0.262 −23.52 −21.92 0.88 
9 0.635 0 25.65 29.24 0 9 0.603 0 −16.41 −12.83 0 
   
   
5 0.700 0.501 19.46 21.45 44.71 
18 
5 0.663 0.438 −26.54 −24.55 0.75 
9 0.748 0 25.56 29.146 0 9 0.721 0 −20.63 −17.05 0 
   
   
4 0.602 0.432 19.27 20.86 54.61 
19 
6 0.911 0.821 −41.11 −38.72 0.31 
9 0.674 0 27.08 30.66 0 9 0.937 0.683 −38.87 −35.29 0 
   
   
7 0.934 0.835 6.17 8.95 10.88 
20 
5 0.672 0.453 −27.55 −25.56 0.67 
8 0.934 0.782 8.08 11.27 0 9 0.806 0.028 −25.31 −21.73 0 
2
dR
2
dR
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Table 5.10 Comparison of Optimal Settings 
Optimal Settings 
Proposed Priority-Based Optimization Comparative Model 
Proposed Empirical 
DF 
Proposed Mechanistic 
DF 
Overall DF 
x* (0.138, 1.000) (0.589, –0.968) (1.000, –0.799) 
f2 62.71 68.88 70.63 
D
esirab
ility
 
ω = 1   1 0.277 0.449 0.410 
2   2 0.796 1.000 0.714 
3   3 0.815 0.632 0.988 
4   4 0.795 0.300 0.727 
5   5 0.168 0.931 0. 659 
6   
   0.370 0.997 0.956 
7   
   0.840 0.833 0.853 
8   
   0.861 0.999 0.978 
9   
   0.920 0.729 0.732 
10   
   0.952 0.939 0.864 
11    
   0.563 0.993 0.990 
12    
   0.047 0.660 0.721 
13    
   0.305 0.763 0.759 
14    
   0.600 0.995 0.990 
15    
   0.805 0.687 0.687 
16    
   0.506 0.897 0.653 
17    
   0.618 0.847 0.492 
18    
   0.655 0.966 0.859 
19    
   0.873 0.801 0.428 
20    
   0.569 0.388 0.457 
Overall 0.762 0.822 0.847 
 
5.5 Conclusion 
One of the strengths of the proposed optimization model is that higher-order (up 
to fourth-order) rather than second-order regression functions are combined with the best 
subset approach to provide a more precise approximation to the characteristics of interest, 
which is considered critical to a pharmaceutical formulation optimization problem, 
because the error in estimating these characteristics may result in the additional error in 
the optimal settings of ingredient amounts. In Table 5.9, the proposed higher-order
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Figure 5.5 Comparison of Resulting Individual Desirability 
 
 
Figure 5.6 Impacts of Assigned Weights or Priorities on the Optimal Desirability 
Settings under Different Models 
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functions fit the observation data better than the second-order since they achieve more 
desirable values for the model selection criteria, including R
2
, adj. R
2
, AIC, BIC, and 
PRESS; meanwhile, these higher-order estimated response surface functions with 
different subsets of predictors are evaluated against the criteria in order to identify the 
ideal regression models that most appropriately estimate the true response mean, 
variance, and covariance. Moreover, in order to solve an MRS formulation optimization 
problem where multiple QCs are correlated over time, efforts are made to develop DFs 
under the empirical and mechanistic models that evaluate the desirability of the response 
covariance in addition to the mean and variance. It is essential to ensure small variability 
of these responses, since large variability may lead to the safety and efficacy issue of the 
formulation. By analogy with the ordinary model selection criteria for responses, we 
propose the desirability-related criteria for screening the higher-order estimated DFs 
under the empirical model with different sizes of predictors. The appropriate estimated 
desirability models, which most accurately approximate the associated desirability, are 
finally determined according to the proposed criteria. However, it is not necessary that 
the ideal higher-order estimated function contains higher-order terms, for instance   
  (x) 
and   E,8(x), both of which are the functions of x
2
. Considering the large number of the 
candidate regression functions, the extent of enhanced accuracy in the estimation of the 
response and desirability is considerably significant. 
Another insight of applying our model to the formulation optimization with 
multiple QCs is that we propose a priority-based optimization procedure incorporated 
with the modified DF approaches. As shown in Table 5.10 and Figure 5.5, it can be 
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observed that (1) the optimal factor settings of the comparative optimization model using 
the mechanistic overall DF approach results in the highest weighted overall desirability 
value and the highest f2 value that demonstrates that the resulting equally-weighted 
optimal dissolution profile is the most similar to the target profile according to the FDA 
regulation; and (2) for the priority-based model using the mechanistic DF approach, the 
majority of its resulting individual desirability values are larger than those of the other 
models. Moreover, in Figure 5.6, the optimal solution resulting from the optimization 
model using the empirical approaches significantly improves the performance of the 1
st
-
priority response variables compared with its equally-weighted model, which can 
observed by examining the overlapping plot of desirability against ω. Therefore, first, the 
optimal desirability settings of the optimization model using the empirical DFs are 
comparatively sensitive to the assigned priorities and less desirable than those using the 
mechanistic and overall DF approaches. Despite the fact that one main advantage of the 
empirical model over the others is the complete smoothness of the fitted curve, it may 
lead to errors as a consequence of the discontinuity of DF that is mechanistically 
expressed in a piecewise form. Recall that it may be infeasible to obtain an empirical 
overall DF by using the least squares method; hence, it is believed that the empirical 
model may become less effective in the optimization procedure. Second, although the 
comparative model produces the most desirable f2 and overall desirability, its optimal 
solution appears to be sensitive to the numerical weight assigned to each of the individual 
DFs (see Figure 5.6 (c)), which may also result in further errors of the solution. Third, in 
this numerical example, the optimal solution of the comparative model fails to provide a 
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desirable value of   2 although the heaviest weight is assigned for it in the objective 
function. Finally, the priority-based optimization model integrated with the mechanistic 
DF approach works best among all the models when simultaneously taking into account 
the performance related to the f2, overall desirability, and sensitivity to the assigned 
priorities. 
In summary, the proposed priority-based optimization model is a competitive 
alternative to solve an MRS problem in the formulation optimization. Higher-order 
regression models combined with the best subsets technique are utilized to improve the 
estimation of the response and desirability in terms of the mean, variance, and 
covariance. Identified priorities can significantly reduce the potential sensitivity and 
undesirable subjectivity associated with the weight-based optimization method. Based 
upon the numerical example, it is concluded that by comparison the mechanistic 
desirability model is the most effective method to implement the proposed priority-based 
optimization procedure. Finally, a future investigation of more rigorous multi-objective 
optimization techniques, such as Tchebycheff method, may be needed to develop 
alternative multi-response formulation optimization models. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE RESEARCH 
 
Pharmaceutical formulation optimization is the area in which the optimal settings 
of ingredient amounts are determined prior to scaling up a manufacturing process. The 
optimal formulation is able to fulfill the desirable performance of QCs specified by the 
FDA. Process scale-up always results in various modifications, such as ingredients, in 
order to meet the mounting clinical and market demand. In this case, the current 
formulation optimization approaches need to be extended to determine the optimal post-
change formulation which achieves the desirable performance in regulatory 
documentation tests including dissolution comparisons and bioequivalence studies. The 
establishment of similarity in dissolution profiles and bioequivalence for the pre-change 
and post-change formulations can not only ensure the equivalent safety and efficacy of 
the two formulations, but also eliminate the need for submitting the duplicate data to the 
FDA for approval after the scale-up changes occur. Nevertheless, the formulation 
optimization for scale-up changes is not adequately documented in the previous 
investigations. Hence, the objective of this research is to improve the existing formulation 
optimization techniques by expanding their ability to solve the optimization problem 
when scale-up changes occur. Following a review of current formulation optimization 
methods in Chapter 2, the proposed models are developed in Chapters 3, 4, and 5 with 
focus on dissolution comparisons, bioequivalence studies, and MRS problems, 
respectively.  
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6.1 Contributions 
Several academic contributions as a result of this research are summarized as 
follows: 
1. Traditionally, drug designers only consider the mean of a QC; however, the 
variability of the QC of interest can be essential, since individual subjects may 
differ widely in their responses to a drug, which may result in large variability of 
the QC and thereby unpredictable safety and efficacy issue. In the proposed 
models, both the mean and variability of the QCs are taken into account. The 
Taguchi quality loss concept appears to be attractive because it describes the 
deviations from target profiles of the mean as well as variance. In Chapters 3 and 
4, the Taguchi quality loss functions for the dissolution comparison and 
bioequivalence study are developed and then incorporated into the proposed 
optimization models, while the current methods, such as the f2 equation for 
comparing dissolution profiles, do not consider the variance. Further, in Chapter 
5, the traditional DF method is modified to evaluate the desirability associated 
with the variance and correlation of the QCs rather than solely the mean. 
2. The standard 2×2 crossover design, which is a special type of DOE and typically 
performed for the evaluation of bioequivalence between formulations, is 
integrated into the ordinary experimental scheme in order to estimate the 
functional relationship between the ingredient amounts and the characteristic 
related to bioequivalence (see Chapter 4). In addition, the traditional evaluation 
method for bioequivalence is compared with the proposed method in Chapter 4, 
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and it turns out that the proposed one generally performs better based upon the 
numerical example and sensitivity analysis.  
3. No formal research work for solving formulation optimization problems, where 
all related FDA and USP requirements are included, can be found in the literature. 
Therefore, as many regulatory regulations associated with the formulation 
optimization as possible are considered and mathematically formulated as 
constraints in the proposed optimization models, in an effort to enable the QCs to 
satisfy all the related requirements in an efficient manner. The development of 
various constraints, including disintegration, dissolution, friability, hardness, 
thickness, stability, and uniformity, are offered in Chapters 3 and 4. 
4. It is common that formulation professionals are faced with multiple characteristics 
to be optimized. In the literature, the DF approach is extensively combined with 
the optimization technique to seek the best compromise among multiple 
characteristics. Traditionally, the weight-based overall DF is considered as an 
objective function to solve the MRS problems. However, this approach has a 
potential shortcoming: the optimal solutions are extremely sensitive to the weights 
assigned and these weights are subjective in nature. In order to overcome this 
weakness, two proposed DF approaches- mechanistic and empirical, which 
consider the mean as well as the variability of a QC, are incorporated into the 
priority-based goal programming procedure to solve MRS formulation 
optimization problems. Moreover, efforts are made to extend the traditional 
second-order estimators to higher-order in Chapter 5 as a way to reduce the error 
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in the characteristic prediction and therefore improve the precision of the resulting 
optimal solutions. 
In summary, it is believed that the methodologies proposed in this dissertation can 
provide a significant support for modeling and optimizing pharmaceutical formulations. 
 
6.2 Future Research 
As stated in Chapter 4, the proposed formulation optimization model for 
bioequivalence studies relies on the assumption that the IVIVC is not established. 
However, the establishment of IVIVC may minimize the need for conducting costly and 
time-consuming bioequivalence studies. One of the motivations for a future investigation 
is to relax this assumption when conducting formulation optimization. Hence, a more 
comprehensive optimization procedure can be developed based upon the identified 
critical characteristics relevant to the IVIVC and associated constraints. The objective 
would be to seek an optimal post-change formulation whose bioequivalence studies can 
be substituted by dissolution comparisons as a consequence of an acceptable IVIVC.  
Moreover, although the establishment of IVIVC can save considerable costs of 
developing a new drug for a drug company, it is not necessarily desirable for customers 
who are exposed to the potential risk of unpredictable safety and efficacy issue due to the 
relatively simple testing conducted during the R&D stage. Finding the best trade-off 
regarding the costs between the drug company and customers may deserve further 
considerations. 
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Finally, further research into the extended formulation optimization problem 
when multiple scale-up changes occur would be of great value. However, the FDA 
guidance does not adequately address associated requirements for this situation. It would 
be possible that dissolution comparisons and bioequivalence studies need to be performed 
simultaneously as required documentation tests for multiple changes. In this case, the 
existing formulation optimization methods should be further improved by expanding their 
ability to solve more realistic problems. 
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APPENDICES 
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APPENDIX 1 
Mathematica Codes for the Examples in Chapter 3 
 
1.1 Estimated Response Functions 
vara[x1_,x2_,x3_,x4_,x5_]=-644+8.6x1+8.2x2-12.9x3-22.3x4+21.6x5-
0.009x1*x2+0.104x1*x3+0.173x1*x4-0.124x1*x5+0.039x2*x3-
0.957x2*x4+0.555x2*x5-0.18x3*x4-0.368x3*x5-0.269x4*x5-0.0318x1*x1-
0.14x2*x2+0.037x3*x3+0.298x4*x4+0.218x5*x5 
 
sa[x1_,x2_,x3_,x4_,x5_]=-26+0.56x1+0.18x2-1.12x3-
1.97x4+0.62x5+0.0011x1*x2+0.0076x1*x3+0.0133x1*x4-0.0033x1*x5-0.0011x2*x3-
0.0619x2*x4+0.0361x2*x5-0.006x3*x4-0.0253x3*x5-0.0221x4*x5-0.00237x1*x1-
0.0018x2*x2+0.0056x3*x3+0.0205x4*x4+0.015x5*x5 
 
a[x1_,x2_,x3_,x4_,x5_]=28+0.84x1+1.34x2-2.02x3-3x4-0.7x5-
0.019x1*x2+0.0126x1*x3+0.021x1*x4-0.0002x1*x5+0.0389x2*x3-
0.031x2*x4+0.0716x2*x5-0.0239x3*x4-0.0522x3*x5-0.0077x4*x5-
0.00324x1*x1+0.0322x2*x2+0.0039x3*x3+0.0197x4*x4+0.0645x5*x5 
 
w[x1_,x2_,x3_,x4_,x5_]=x1+x2+x3+x4+x5+80 
 
d[x1_,x2_,x3_,x4_,x5_]=-17.9+0.309x1-0.5x2-
0.24x3+0.57x4+0.22x5+0.00604x1*x2+0.00162x1*x3-0.00422x1*x4-
0.00016x1*x5+0.0063x2*x3+0.0036x2*x4-0.0057x2*x5-0.0003x3*x4+0.0016x3*x5-
0.0277x4*x5-0.00095x1*x1-0.0314x2*x2-0.00232x3*x3+0.0206x4*x4+0.0026x5*x5 
 
sd[x1_,x2_,x3_,x4_,x5_]=-1.03+0.021x1+0.175x2-0.107x3+0.186x4-0.041x5-
0.00027x1*x2+0.000987x1*x3-0.000703x1*x4-0.000016x1*x5+0.00087x2*x3-
0.00245x2*x4-0.00078x2*x5-0.00109x3*x4+0.00266x3*x5-0.00215x4*x5-
0.000102x1*x1-0.0053x2*x2-0.00186x3*x3+0.00061x4*x4-0.00009x5*x5 
 
xbar[x1_,x2_,x3_,x4_,x5_]=1.04-0.00075x1+0.00157x2+0.00162x3-0.00064x4-0.00003x5-
0.000004x1*x2-0.000008x1*x3+0.000005*x1*x4+0.000002x1*x5-
0.000026x2*x3+0.000042x2*x4-0.000058x2*x5-0.000021x3*x4-
0.000005x3*x5+0.000023x4*x5+0.000003x1*x1-0.000001x2*x2+0.000008x3*x3-
0.000019x4*x4+0.000013x5*x5 
 
s[x1_,x2_,x3_,x4_,x5_]=0.328-0.00336x1-0.00359x2+0.00441x3+0.00052x4-
0.00817x5+0.000013x1*x2-
0.000005x1*x3+0.000009x1*x4+0.000028x1*x5+0.000017x2*x3-
0.00001x2*x4+0.000156x2*x5-
0.0001x3*x4+0.000013x3*x5+0.000117x4*x5+0.000008x1*x1-0.000035x2*x2-
0.000058x3*x3-0.000028x4*x4+0.000004x5*x5 
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av1[x1_,x2_,x3_,x4_,x5_]=2.4*s[x1,x2,x3,x4,x5] 
 
av2[x1_,x2_,x3_,x4_,x5_]=0.985-xbar[x1,x2,x3,x4,x5]+2.4*s[x1,x2,x3,x4,x5] 
 
av3[x1_,x2_,x3_,x4_,x5_]=xbar[x1,x2,x3,x4,x5]-1.015+2.4*s[x1,x2,x3,x4,x5] 
 
f1[x1_,x2_,x3_,x4_,x5_]=-22.9+0.298x1-0.251x2-0.131x3-0.257x4+0.259x5-0.00146x1*x2-
0.00087x1*x3+0.00328x1*x4-0.00016x1*x5-0.00042x2*x3-0.0109x2*x4+0.0255x2*x5-
0.00406x3*x4-0.00844x3*x5-0.0137x4*x5-
0.000761x1*x1+0.0165x2*x2+0.00845x3*x3-0.00007x4*x4-0.0071x5*x5 
 
f2[x1_,x2_,x3_,x4_,x5_]=-62.8+0.608x1+0.712x2+0.457x3-0.144x4-0.099x5-0.00125x1*x2-
0.00275x1*x3+0.00375x1*x4+0.00063x1*x5+0.00417x2*x3+0.00833x2*x4-
0.0188x2*x5-0.0163x3*x4+0.0025x3*x5-0.00547x4*x5-0.00151x1*x1-
0.0196x2*x2+0.00245x3*x3-0.00945x4*x4+0.0093x5*x5 
 
f3[x1_,x2_,x3_,x4_,x5_]=-10.1+0.173x1-0.22x2-0.345x3+0.978x4-
0.254x5+0.00271x1*x2+0.00237x1*x3-0.00516x1*x4+0.00016x1*x5-
0.0129x2*x3+0.0172x2*x4+0.0036x2*x5-0.0116x3*x4+0.00031x3*x5+0.002x4*x5-
0.00061x1*x1-0.0054x2*x2+0.00305x3*x3+0.00007x4*x4+0.00632x5*x5 
 
ci[x1_,x2_,x3_,x4_,x5_]=351-1.38x1-7.7x2-5.16x3-
25.3x4+1.87x5+0.0354x1*x2+0.0125x1*x3+0.132x1*x4+0.027x2*x3+0.014x2*x4+0.02
1x2*x5-0.0387x3*x4+0.0094x3*x5-0.075x4*x5-
0.0014x1*x1+0.029x2*x2+0.0606x3*x3+0.151*x4*x4-0.0639x5*x5 
 
n[x1_,x2_,x3_,x4_,x5_]=129-1.35x1+1.15x2-0.34x3+0.36x4-0.49x5-0.00292x1*x2-
0.00525x1*x3-0.00469x1*x4+0.00344x1*x5+0.0108x2*x3+0.0073x2*x4-
0.0385x2*x5+0.0244x3*x4+0.0056x3*x5-0.007x4*x5+0.00427x1*x1-
0.0275x2*x2+0.0191x3*x3-0.01x4*x4+0.0095x5*x5 
 
a1[x1_,x2_,x3_,x4_,x5_]=26.8+0.055x1+0.44x2-0.792x3-1.08x4+1.03x5-
0.00381x1*x2+0.00396x1*x3+0.00448x1*x4-0.00673x1*x5+0.007x2*x3-0.0179x2*x4-
0.0266x2*x5+0.0167x3*x4-0.0008x3*x5+0.0094x4*x5-0.00029x1*x1+0.0172x2*x2-
0.00407x3*x3-0.0035x4*x4+0.0174x5*x5 
 
s1[x1_,x2_,x3_,x4_,x5_]=21-0.169x1-0.041x2-0.189x3+0.248x4-
0.191x5+0.00031x1*x2+0.000637x1*x3-0.00145x1*x4+0.00105x1*x5+0.00062x2*x3-
0.0013x2*x4+0.00224x2*x5+0.00084x3*x4-
0.00053x3*x5+0.00059x4*x5+0.000439x1*x1-
0.00221x2*x2+0.0014x3*x3+0.00016x4*x4-0.00101x5*x5 
 
a2[x1_,x2_,x3_,x4_,x5_]=113-1.19x1-1.33x2+2.82x3-0.51x4+0.1x5+0.00367x1*x2-
0.013x1*x3+0.00591x1*x4+0.00059x1*x5-0.0041x2*x3-
0.0236x2*x4+0.0103x2*x5+0.0059x3*x4-0.0135x3*x5-
0.0175x4*x5+0.00392x1*x1+0.0371x2*x2-0.00734x3*x3-0.0103x4*x4+0.0055x5*x5 
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s2[x1_,x2_,x3_,x4_,x5_]=20.8-0.116x1-0.176x2-0.171x3-0.253x4-
0.072x5+0.00106x1*x2+0.000788x1*x3+0.0012x1*x4+0.000453x1*x5-
0.00213x2*x3+0.00328x2*x4-
0.00234x2*x5+0.00022x3*x4+0.00197x3*x5+0.0002x4*x5+0.000186x1*x1+0.00096x2
*x2+0.000795x3*x3-0.00024x4*x4-0.00157x5*x5 
 
a3[x1_,x2_,x3_,x4_,x5_]=-61.5+0.948x1+1.05x2+1.12x3-1.08x4-0.54x5-0.00146x1*x2-
0.00587x1*x3+0.00628x1*x4+0.00138x1*x5-
0.0255x2*x3+0.001x2*x4+0.0099x2*x5+0.0029x3*x4-0.0063x3*x5+0.0095x4*x5-
0.00232x1*x1-0.0199x2*x2+0.00535x3*x3-0.013x4*x4+0.0103x5*x5 
 
s3[x1_,x2_,x3_,x4_,x5_]=6.05-0.0203x1-0.02x2-
0.122x3+0.052x4+0.185x5+0.00025x1*x2+0.00005x1*x3-0.000563x1*x4-
0.000687x1*x5-0.00008x2*x3-0.0026x2*x4-0.00365x2*x5+0.00069x3*x4-
0.00031x3*x5-
0.00102x4*x5+0.000078x1*x1+0.00184x2*x2+0.00196x3*x3+0.00385x4*x4-
0.00006x5*x5 
 
a4[x1_,x2_,x3_,x4_,x5_]=39.1+0.547x1-1.98x2-0.146x3-3.07x4-2.08x5+0.00706x1*x2-
0.00069x1*x3+0.0205x1*x4+0.0105x1*x5+0.0145x2*x3-0.0102x2*x4+0.0103x2*x5-
0.0105x3*x4+0.0026x3*x5-0.0024x4*x5-0.00258x1*x1+0.0152x2*x2+0.00266x3*x3-
0.0101x4*x4+0.00322x5*x5 
 
s4[x1_,x2_,x3_,x4_,x5_]=-3.65+0.0715x1+0.017x2+0.0437x3+0.077x4+0.103x5-
0.000083x1*x2-0.00015x1*x3-0.0005x1*x4-0.000406x1*x5-0.00025x2*x3-
0.00281x2*x4+0.00104x2*x5+0.00156x3*x4+0.00025x3*x5-0.00047x4*x5-
0.000157x1*x1+0.00104x2*x2-0.000627x3*x3+0.000582x4*x4-0.00192x5*x5 
 
a5[x1_,x2_,x3_,x4_,x5_]=207-1.24x1-0.42x2-0.607x3-3.61x4-
1.11x5+0.00802x1*x2+0.00509x1*x3+0.018x1*x4+0.00908x1*x5-0.0128x2*x3-
0.0064x2*x4-0.0053x2*x5+0.0345x3*x4+0.0027x3*x5-0.0136x4*x5+0.00218x1*x1-
0.021x2*x2-0.0108x3*x3-0.0177x4*x4-0.0186x5*x5 
 
s5[x1_,x2_,x3_,x4_,x5_]=-6.58+0.112x1+0.164x2+0.0911x3+0.0577x4+0.0876x5-
0.000396x1*x2-0.000213x1*x3-0.000297x1*x4-0.000266x1*x5-
0.000625x2*x3+0.00245x2*x4-0.0012x2*x5-0.000594x3*x4-0.000031x3*x5-
0.00043x4*x5-0.000272x1*x1-0.00371x2*x2-0.000736x3*x3-0.000604x4*x4-
0.000916x5*x5 
 
a6[x1_,x2_,x3_,x4_,x5_]=20.7+0.506x1+1.17x2-1.08x3+1.76x4+1.43x5-
0.00256x1*x2+0.00684x1*x3-0.00598x1*x4-0.0042x1*x5-0.0025x2*x3-0.0362x2*x4-
0.0042x2*x5+0.005x3*x4-0.0146x3*x5-0.0233x4*x5-0.00155x1*x1-0.0113x2*x2-
0.00021x3*x3-0.0064x4*x4-0.0012x5*x5 
 
s6[x1_,x2_,x3_,x4_,x5_]=7.48-0.0065x1+0.171x2-0.0305x3-0.069x4+0.089x5-
0.000792x1*x2+0.000275x1*x3+0.000312x1*x4-0.000531x1*x5-
0.00142x2*x3+0.00167x2*x4+0.0001x2*x5-
0.00062x3*x4+0.00081x3*x5+0.00016x4*x5+0.00002x1*x1-0.00033x2*x2-
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0.000068x3*x3+0.00005x4*x4-0.00058x5*x5 
 
a7[x1_,x2_,x3_,x4_,x5_]=134-0.549x1-x2-0.135x3+0.183x4-
0.406x5+0.00404x1*x2+0.00147x1*x4+0.00131x1*x5+0.00583x2*x3-
0.0143x2*x4+0.0198x2*x5-0.0075x3*x4-
0.00794x3*x5+0.0025x4*x5+0.00135x1*x1+0.00509x2*x2+0.00458x3*x3-
0.00729x4*x4+0.00638x5*x5 
 
s7[x1_,x2_,x3_,x4_,x5_]=10.4-0.0123x1+0.031x2-0.0252x3-0.154x4-0.13x5-
0.000271x1*x2+0.000112x1*x3+0.000609x1*x4+0.000641x1*x5-0.00038x2*x3-
0.00078x2*x4+0.00016x2*x5+0.00122x3*x4-0.000469x3*x5+0.0009x4*x5-
0.000003x1*x1+0.00163x2*x2+0.000086x3*x3+0.00076x4*x4+0.000526x5*x5 
 
a8[x1_,x2_,x3_,x4_,x5_]=70.9+0.048x1+0.799x2-0.437x3-0.359x4+0.878x5-
0.00404x1*x2+0.00257x1*x3+0.003x1*x4-0.0035x1*x5+0.00242x2*x3+0.00354x2*x4-
0.00188x2*x5-0.009x3*x4-0.00325x3*x5-0.00195x4*x5-0.000125x1*x1-
0.00486x2*x2+0.0013x3*x3+0.0007x4*x4-0.00578x5*x5 
 
s8[x1_,x2_,x3_,x4_,x5_]=5.7+0.043x1+0.117x2-0.201x3+0.073x4-0.121x5-
0.00092x1*x2+0.00065x1*x3-0.00091x1*x4+0.00072x1*x5+0.002x2*x3-
0.00177x2*x4-0.0001x2*x5+0.00206x3*x4-0.00206x3*x5+0.00172x4*x5-
0.000128x1*x1+0.00038x2*x2+0.00144x3*x3+0.0017x4*x4+0.00131x5*x5 
 
v1[x1_,x2_,x3_,x4_,x5_]=150-1.33x1-0.33x2-1.49x3+1.87x4-
1.45x5+0.00244x1*x2+0.00504x1*x3-0.011x1*x4+0.00794x1*x5+0.0053x2*x3-
0.0103x2*x4+0.0176x2*x5+0.0066x3*x4-0.004x3*x5+0.0041x4*x5+0.00343x1*x1-
0.017x2*x2+0.0109x3*x3+0.0013x4*x4-0.0078x5*x5 
 
v2[x1_,x2_,x3_,x4_,x5_]=207-1.32x1-2.05x2-1.99x3-2.94x4-
0.85x5+0.0123x1*x2+0.00917x1*x3+0.0139x1*x4+0.00535x1*x5-
0.0246x2*x3+0.0384x2*x4-
0.0272x2*x5+0.0027x3*x4+0.0229x3*x5+0.0023x4*x5+0.00211x1*x1+0.0112x2*x2+0
.0093x3*x3-0.0029x4*x4-0.0182x5*x5 
 
v3[x1_,x2_,x3_,x4_,x5_]=30.6-0.142x1-0.16x2-
0.901x3+0.37x4+1.36x5+0.00201x1*x2+0.00039x1*x3-0.00407x1*x4-0.00501x1*x5-
0.0011x2*x3-0.019x2*x4-0.027x2*x5+0.0051x3*x4-0.0024x3*x5-
0.0074x4*x5+0.00054x1*x1+0.0134x2*x2+0.0145x3*x3+0.0285x4*x4-0.0005x5*x5 
 
v4[x1_,x2_,x3_,x4_,x5_]=-53.2+0.645x1+0.15x2+0.404x3+0.687x4+0.918x5-0.00066x1*x2-
0.00138x1*x3-0.00444x1*x4-0.00361x1*x5-0.0025x2*x3-
0.0252x2*x4+0.0094x2*x5+0.014x3*x4+0.00216x3*x5-0.0041x4*x5-
0.00142x1*x1+0.0092x2*x2- 
 
v5[x1_,x2_,x3_,x4_,x5_]=-118+1.37x1+2.01x2+1.11x3+0.71x4+1.07x5-0.00486x1*x2-
0.00259x1*x3-0.00363x1*x4-0.00323x1*x5-0.0076x2*x3+0.0299x2*x4-0.0146x2*x5-
0.00726x3*x4-0.00042x3*x5-0.0053x4*x5-0.00334x1*x1-0.0455x2*x2-0.00904x3*x3-
0.00752x4*x4-0.0112x5*x5 
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v6[x1_,x2_,x3_,x4_,x5_]=55.7-0.093x1+2.51x2-0.45x3-x4+1.29x5-
0.0116x1*x2+0.00403x1*x3+0.00455x1*x4-0.00773x1*x5-
0.0206x2*x3+0.0243x2*x4+0.0015x2*x5-
0.0092x3*x4+0.0118x3*x5+0.0022x4*x5+0.00029x1*x1-0.0049x2*x2-
0.00099x3*x3+0.0006x4*x4-0.0085x5*x5 
 
v7[x1_,x2_,x3_,x4_,x5_]=101-0.189x1+0.49x2-0.39x3-2.37x4-2x5-
0.0042x1*x2+0.00173x1*x3+0.00938x1*x4+0.00988x1*x5-0.0059x2*x3-
0.012x2*x4+0.0024x2*x5+0.0188x3*x4-0.0072x3*x5+0.0138x4*x5-
0.00005x1*x1+0.0251x2*x2+0.00132x3*x3+0.0117x4*x4+0.0081x5*x5 
 
v8[x1_,x2_,x3_,x4_,x5_]=27+0.65x1+1.81x2-3x3+1.09x4-1.77x5-0.0141x1*x2+0.0097x1*x3-
0.0135x1*x4+0.0106x1*x5+0.0302x2*x3-0.0268x2*x4-0.0016x2*x5+0.0308x3*x4-
0.0309x3*x5+0.0256x4*x5-
0.00194x1*x1+0.0056x2*x2+0.0215x3*x3+0.0256x4*x4+0.0191x5*x5 
 
1.2 Optimization Models for Class 1 Drugs with Level 2 Changes 
Minimize[{sa[x1,x2,x3,x4,x5],a[x1,x2,x3,x4,x5]/80>=0.85,10<=d[x1,x2,x3,x4,x5]<=11.8,Abs[(x
1-190)/318]<=0.1,Abs[(x2-10.5)/318]<=0.06,Abs[(x3-20)/318]<=0.01,Abs[(x4-
15)/318]<=0.005,Abs[(x5-2.5)/318]<=0.02,Abs[(x1-190)/318]+Abs[(x2-
10.5)/318]+Abs[(x3-20)/318]+Abs[(x4-17)/318]+Abs[(x5-
2.5)/318]<=0.1,sd[x1,x2,x3,x4,x5]/d[x1,x2,x3,x4,x5]<=0.1,sa[x1,x2,x3,x4,x5]/a[x1,x2,x
3,x4,x5]<=0.1,80/w[x1,x2,x3,x4,x5]>=0.25,s[x1,x2,x3,x4,x5]/xbar[x1,x2,x3,x4,x5]<=0.0
2,f1[x1,x2,x3,x4,x5]/w[x1,x2,x3,x4,x5]<=0.01,ci[x1,x2,x3,x4,x5]<=25,sd[x1,x2,x3,x4,x
5]>=0,d[x1,x2,x3,x4,x5]>=0,vara[x1,x2,x3,x4,x5]>=0,a[x1,x2,x3,x4,x5]>=0,w[x1,x2,x3,
x4,x5]>=0,0.985<=xbar[x1,x2,x3,x4,x5]<=1.105,0<=av1[x1,x2,x3,x4,x5]<=0.15,s[x1,x2,
x3,x4,x5]>=0,f1[x1,x2,x3,x4,x5]>=0,ci[x1,x2,x3,x4,x5]>=0,9.5<=n[x1,x2,x3,x4,x5]<=1
0.5,sa[x1,x2,x3,x4,x5]>=0,160<=x1<=200,4.8<=x2<=16.8,15<=x3<=35,1<=x4<=17,2<
=x5<=18},{x1,x2,x3,x4,x5}] 
 
Minimize[{vara[x1,x2,x3,x4,x5],a[x1,x2,x3,x4,x5]/80>=0.85,10<=d[x1,x2,x3,x4,x5]<=11.8,Abs[
(x1-190)/318]<=0.1,Abs[(x2-10.5)/318]<=0.06,Abs[(x3-20)/318]<=0.01,Abs[(x4-
15)/318]<=0.005,Abs[(x5-2.5)/318]<=0.02,Abs[(x1-190)/318]+Abs[(x2-
10.5)/318]+Abs[(x3-20)/318]+Abs[(x4-17)/318]+Abs[(x5-
2.5)/318]<=0.1,sd[x1,x2,x3,x4,x5]/d[x1,x2,x3,x4,x5]<=0.1,sa[x1,x2,x3,x4,x5]/a[x1,x2,x
3,x4,x5]<=0.1,80/w[x1,x2,x3,x4,x5]>=0.25,s[x1,x2,x3,x4,x5]/xbar[x1,x2,x3,x4,x5]<=0.0
2,f1[x1,x2,x3,x4,x5]/w[x1,x2,x3,x4,x5]<=0.01,ci[x1,x2,x3,x4,x5]<=25,sd[x1,x2,x3,x4,x
5]>=0,d[x1,x2,x3,x4,x5]>=0,vara[x1,x2,x3,x4,x5]>=0,a[x1,x2,x3,x4,x5]>=0,w[x1,x2,x3,
x4,x5]>=0,0.985<=xbar[x1,x2,x3,x4,x5]<=1.105,0<=av1[x1,x2,x3,x4,x5]<=0.15,s[x1,x2,
x3,x4,x5]>=0,f1[x1,x2,x3,x4,x5]>=0,ci[x1,x2,x3,x4,x5]>=0,9.5<=n[x1,x2,x3,x4,x5]<=1
0.5,sa[x1,x2,x3,x4,x5]>=0,160<=x1<=200,4.8<=x2<=16.8,15<=x3<=35,1<=x4<=17,2<
=x5<=18},{x1,x2,x3,x4,x5}] 
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1.3 Optimization Models for Class 2 and 3 Drugs with Level 2 Changes 
obj1[x1_,x2_,x3_,x4_,x5_]=(50*(Log[10,(1+1/8*((a1[x2,x2,x3,x4,x5]-
22)^2+(a2[x1,x2,x3,x4,x5]-33)^2+(a3[x1,x2,x3,x4,x5]-38)^2+(a4[x1,x2,x3,x4,x5]-
48)^2+(a5[x1,x2,x3,x4,x5]-65)^2+(a6[x1,x2,x3,x4,x5]-74)^2+(a7[x1,x2,x3,x4,x5]-
77)^2+(a8[x1,x2,x3,x4,x5]-78)^2))^(-0.5)*100])-100)^2 
 
Minimize[{obj1[x1,x2,x3,x4,x5],s1[x1,x2,x3,x4,x5]/a1[x1,x2,x3,x4,x5]<=0.2,s1[x1,x2,x3,x4,x5]
>=0,a1[x1,x2,x3,x4,x5]>=0,s2[x1,x2,x3,x4,x5]/a2[x1,x2,x3,x4,x5]<=0.2,a2[x1,x2,x3,x4,
x5]>=0,s2[x1,x2,x3,x4,x5]>=0,s3[x1,x2,x3,x4,x5]/a3[x1,x2,x3,x4,x5]<=0.2,a3[x1,x2,x3,
x4,x5]>=0,s3[x1,x2,x3,x4,x5 >=0,s4[x1,x2,x3,x4,x5]/a4[x1,x2,x3,x4,x5]<=0.1,s4[x1,x2,
x3,x4,x5]>=0,a4[x1,x2,x3,x4,x5]>=0,s5[x1,x2,x3,x4,x5]/a5[x1,x2,x3,x4,x5]<=0.1,s5[x1,
x2,x3,x4,x5]>=0,a5[x1,x2,x3,x4,x5]>=0,s6[x1,x2,x3,x4,x5]/a6[x1,x2,x3,x4,x5]<=0.1,s6[
x1,x2,x3,x4,x5]>=0,a6[x1,x2,x3,x4,x5]>=0,s7[x1,x2,x3,x4,x5]/a7[x1,x2,x3,x4,x5]<=0.1,
s7[x1,x2,x3,x4,x5]>=0,a7[x1,x2,x3,x4,x5]>=0,s8[x1,x2,x3,x4,x5]/a8[x1,x2,x3,x4,x5]<=0
.1,s8[x1,x2,x3,x4,x5]>=0,a8[x1,x2,x3,x4,x5]>=0,a4[x1,x2,x3,x4,x5]/80<=0.85,sd[x1,x2,
x3,x4,x5]/d[x1,x2,x3,x4,x5]<=0.1,Abs[(x4-15)/318]<=0.005,Abs[(x1-
190)/318]<=0.1,Abs[(x2-10.5)/318]<=0.06,Abs[(x3-20)/318]<=0.01,Abs[(x5-
2.5)/318]<=0.02,Abs[(x1-190)/318]+Abs[(x2-10.5)/318]+Abs[(x3-20)/318]+Abs[(x4-
15)/318]+Abs[(x5-
2.5)/318]<=0.1,a4[x1,x2,x3,x4,x5]/80<=0.85,sd[x1,x2,x3,x4,x5]/d[x1,x2,x3,x4,x5]<=0.1,
10<=d[x1,x2,x3,x4,x5]<=11.8,sd[x1,x2,x3,x4,x5]>=0,a6[x1,x2,x3,x4,x5]/80>=0.85,80/w
[x1,x2,x3,x4,x5]<=0.25,w[x1,x2,x3,x4,x5]>=0,s[x1,x2,x3,x4,x5]/xbar[x1,x2,x3,x4,x5]<=
0.02,0.985<=xbar[x1,x2,x3,x4,x5]<=1.105,s[x1,x2,x3,x4,x5]>=0,0<=av1[x1,x2,x3,x4,x5
]<=0.15,f1[x1,x2,x3,x4,x5]>=0,ci[x1,x2,x3,x4,x5]>=0,9.5<=n[x1,x2,x3,x4,x5]<=10.5,f1[
x1,x2,x3,x4,x5]/w[x1,x2,x3,x4,x5]<=0.01,ci[x1,x2,x3,x4,x5]<=25,d[x1,x2,x3,x4,x5]>=0,
160<=x1<=200,4.8<=x2<=16.8,15<=x3<=35,1<=x4<=17,2<=x5<=18,0.50<=a4[x1,x2,x
3,x4,x5]/80<=0.65,factor[x1,x2,x3,x4,x5]>=50},{x1,x2,x3,x4,x5}] 
 
obj2[x1_,x2_,x3_,x4_,x5_]=(a1[x1,x2,x3,x4,x5]-22)^2+v1[x1,x2,x3,x4,x5]+(a2[x1,x2,x3,x4,x5]-
33)^2+v2[x1,x2,x3,x4,x5]+(a3[x1,x2,x3,x4,x5]-
38)^2+v3[x1,x2,x3,x4,x5]+(a4[x1,x2,x3,x4,x5]-
48)^2+v4[x1,x2,x3,x4,x5]+(a5[x1,x2,x3,x4,x5]-
65)^2+v5[x1,x2,x3,x4,x5]+(a6[x1,x2,x3,x4,x5]-
74)^2+v6[x1,x2,x3,x4,x5]+(a7[x1,x2,x3,x4,x5]-
77)^2+v7[x1,x2,x3,x4,x5]+(a8[x1,x2,x3,x4,x5]-78)^2+v8[x1,x2,x3,x4,x5] 
 
Minimize[{obj2[x1,x2,x3,x4,x5],s4[x1,x2,x3,x4,x5]/a4[x1,x2,x3,x4,x5]<=0.1,s4[x1,x2,x3,x4,x5]
>=0,a4[x1,x2,x3,x4,x5]>=0,s6[x1,x2,x3,x4,x5]/a6[x1,x2,x3,x4,x5]<=0.1,s6[x1,x2,x3,x4,
x5]>=0,a6[x1,x2,x3,x4,x5]>=0,Abs[(x1-190)/318]<=0.1,Abs[(x2-
10.5)/318]<=0.06,Abs[(x3-20)/318]<=0.01,Abs[(x4-15)/318]<=0.005,Abs[(x5-
2.5)/318]<=0.02,Abs[(x1-190)/318]+Abs[(x2-10.5)/318]+Abs[(x3-20)/318]+Abs[(x4-
7)/318]+Abs[(x5-
2.5)/318]<=0.1,sd[x1,x2,x3,x4,x5]/d[x1,x2,x3,x4,x5]<=0.1,10<=d[x1,x2,x3,x4,x5]<=11.
8,sd[x1,x2,x3,x4,x5]>=0,0.50<=a4[x1,x2,x3,x4,x5]/80<=0.65,a6[x1,x2,x3,x4,x5]/80>=0.
85,80/w[x1,x2,x3,x4,x5]>=0.25,w[x1,x2,x3,x4,x5]>=0,s[x1,x2,x3,x4,x5]/xbar[x1,x2,x3,
x4,x5]<=0.02,0.985<=xbar[x1,x2,x3,x4,x5]<=1.105,s[x1,x2,x3,x4,x5]>=0,0<=av1[x1,x2,
x3,x4,x5]<=0.15,f1[x1,x2,x3,x4,x5]>=0,ci[x1,x2,x3,x4,x5]>=0,9.5<=n[x1,x2,x3,x4,x5]<
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=10.5,f1[x1,x2,x3,x4,x5]/w[x1,x2,x3,x4,x5]<=0.01,ci[x1,x2,x3,x4,x5]<=25,d[x1,x2,x3,x
4,x5]>=0,160<=x1<=200,4.8<=x2<=16.8,15<=x3<=35,1<=x4<=17,2<=x5<=18,factor[x
1,x2,x3,x4,x5]>=50},{x1,x2,x3,x4,x5}] 
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APPENDIX 2 
MATLAB and Mathematica Codes for the Example in Chapter 4 
 
2.1 MATLAB Code for Estimating Ka 
C=xlsread('filename',sheet,'range'); 
T=xlsread('filename',sheet,'range'); 
TD=xlsread('filename',sheet,'range'); 
Ke=xlsread('filename',sheet,'range'); 
K=xlsread('filename',sheet,'range'); 
%Read vectors C, T, TD, Ke and K from a Microsoft® Excel file. 
 
syms Ka 
KA=[]; 
for m=1:1:x  %x=2*i*r. 
    C_temp=[]; 
    for o=1:1:y  %y=n. 
        C_temp(o)=C(m,o);  
    end 
    C_vector=C_temp'; 
    f1=exp((-Ka*T).')*TD; 
    f2=exp(-Ke(m)*T)-C_vector/K(m)-exp(-Ka*T); 
    f=f1*f2; 
    KA(m)=solve(f,Ka);  
end 
KA=KA' 
xlswrite('filename',KA,sheet,'range');  %output vector KA into an Excel file. 
 
2.2 Estimated Response Functions 
rauc[x1_,x2_]=4.95-0.0025x1+0.0061x2-0.000091x1*x2+0.000009x1*x1+0.000503x2*x2 
 
rauc1[x1_,x2_]=5.14-0.0043x1+0.0016x2-0.000074x1*x2+0.000013x1*x1+0.000572x2*x2 
 
tauc[x1_,x2_]=5.78-0.0094x1-0.0345x2+0.000169x1*x2+0.000021x1*x1+0.000147x2*x2 
 
tauc1[x1_,x2_]=5.45-0.00672x1-0.0206x2+0.000095x1*x2+0.000016x1*x1+0.000112x2*x2 
 
rtmax[x1_,x2_]=14.8-0.119x1-0.408x2+0.00208x1*x2+0.000271x1*x1+0.00069x2*x2 
 
rtmax1[x1_,x2_]=3.71-0.0138x1-0.112x2+0.000503x1*x2+0.000025x1*x1+0.00087x2*x2 
 
ttmax[x1_,x2_]=3.21-0.0294x1+0.232x2-0.00139x1*x2+0.000125x1*x1+0.00139x2*x2 
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ttmax1[x1_,x2_]=-1.96+0.0388x1+0.0598x2-0.000289x1*x2-0.000097x1*x1-0.000329x2*x2 
 
rcmax[x1_,x2_]=3.59-0.00831x1-0.0206x2+0.00012x1*x2+0.000021x1*x1-0.000079x2*x2 
 
rcmax1[x1_,x2_]=2.61+0.0027x1-0.0245x2+0.000112x1*x2-0.00001x1*x1+0.000173x2*x2 
 
tcmax[x1_,x2_]=4.08-0.0138x1-0.0129x2+0.000035x1*x2+0.000037x1*x1+0.000362x2*x2 
 
tcmax1[x1_,x2_]=2.28+0.00433x1+0.0106x2-0.000058x1*x2-0.00001x1*x1-0.000024x2*x2 
 
dauc[x1_,x2_]=1.83-0.0191x1-0.0124x2+0.00001x1*x2+0.000052x1*x1+0.000417x2*x2 
 
dcmax[x1_,x2_]=-0.73+0.0063x1+0.0324x2-0.000181x1*x2-0.000012x1*x1+0.00005x2*x2 
 
lauc[x1_,x2_]=(tauc[x1,x2]-rauc[x1,x2])-2.132*dauc[x1,x2]*Sqrt[1/3+1/3] 
 
lauc1[x1_,x2_]=(tauc1[x1,x2]-rauc1[x1,x2])-2.132*dauc[x1,x2]*Sqrt[1/3+1/3] 
 
uauc[x1_,x2_]=(tauc[x1,x2]-rauc[x1,x2])+2.132*dauc[x1,x2]*Sqrt[1/3+1/3] 
 
uauc1[x1_,x2_]=(tauc1[x1,x2]-rauc1[x1,x2])+2.132*dauc[x1,x2]*Sqrt[1/3+1/3] 
 
lcmax[x1_,x2_]=(tcmax[x1,x2]-rcmax[x1,x2])-2.132*dcmax[x1,x2]*Sqrt[1/3+1/3] 
 
lcmax1[x1_,x2_]=(tcmax1[x1,x2]-rcmax1[x1,x2])-2.132*dcmax[x1,x2]*Sqrt[1/3+1/3] 
 
ucmax[x1_,x2_]=(tcmax[x1,x2]-rcmax[x1,x2])+2.132*dcmax[x1,x2]*Sqrt[1/3+1/3] 
 
ucmax1[x1_,x2_]=(tcmax1[x1,x2]-rcmax1[x1,x2])+2.132*dcmax[x1,x2]*Sqrt[1/3+1/3] 
 
s2auc[x1_,x2_]=0.0767-0.000766x1-
0.00099x2+0.000003x1*x2+0.000002x1*x1+0.000016x2*x2 
 
s2cmax[x1_,x2_]=-0.0082+0.000068x1+0.000464x2-0.000003x1*x2-
0.00000011x1*x1+0.000003x2*x2 
 
varauc[x1_,x2_]=0.0426-0.000392x1-
0.00116x2+0.000002x1*x2+0.000001x1*x1+0.000039x2*x2 
 
varauc1[x1_,x2_]=0.0312-0.000261x1-
0.00125x2+0.000002x1*x2+0.000001x1*x1+0.000038x2*x2 
 
vartmax[x1_,x2_]=-0.71+0.0142x1-0.0917x2+0.000556x1*x2-0.000056x1*x1-0.00062x2*x2 
 
vartmax1[x1_,x2_]=0.137-0.0013x1-0.00249x2+0.000028x1*x2+0.000003x1*x1-0.00012x2*x2 
 
varcmax[x1_,x2_]=0.0129-0.000177x1+0.000776x2-
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0.000005x1*x2+0.000001x1*x1+0.000003x2*x2 
 
varcmax1[x1_,x2_]=0.0114-0.000125x1+0.0000773x2-
0.00000058x1*x2+0.00000036x1*x1+0.00000013x2*x2 
 
2.3 Optimization Models for Class 4 Drugs with Level 3 Changes 
obj1[x1_,x2_]=(tcmax[x1,x2]-rcmax[x1,x2])^2+varcmax[x1,x2]+(ttmax[x1,x2]-
rtmax[x1,x2])^2+vartmax[x1,x2]+(tauc[x1,x2]-rauc[x1,x2])^2+varauc[x1,x2] 
 
Minimize[{obj1[x1,x2],Abs[(x1-150)/278]>0.1,Abs[(x2-10.5)/278]<=0.06,Abs[(x1-
190)/278]+Abs[(x2-10.5)/278]<=0.1,lauc[x1,x2]>=-
0.2*rauc[x1,x2],uauc[x1,x2]<=0.25*rauc[x1,x2],lcmax[x1,x2]>=-
0.20*rcmax[x1,x2],ucmax[x1,x2]<=0.25*rcmax[x1,x2],0<=s2auc[x1,x2]<=0.1,0<=s2cm
ax[x1,x2]<=0.1,165.858<=x1<=194.142,6.5574<=x2<=15.0426,s[x1,x2,20,15,2.5]/xbar[
x1,x2,20,15,2.5]<=0.02,f1[x1,x2,20,15,2.5]/w[x1,x2,20,15,2.5]<=0.01,ci[x1,x2,20,15,2.5
r[x1,x2,20,15,2.5]<=1.105,0<=av1[x1,x2,20,15,2.5]<=0.15,s[x1,x2,20,15,2.5]>=0,f1[x1,
x2,20,15,2.5]>=0,ci[x1,x2,20,15,2.5]>=0,9.5<=n[x1,x2,20,15,2.5]<=10.5,tcmax[x1,x2]>
=0,rcmax[x1,x2]>=0,varcmax[x1,x2]>=0,ttmax[x1,x2]>=0,rtmax[x1,x2]>=0,vartmax[x1,
x2]>=0,tauc[x1,x2]>=0,rauc[x1,x2]>=0,varauc[x1,x2]>=0},{x1,x2}] 
 
obj2[x1_,x2_]=(tcmax1[x1,x2]-rcmax1[x1,x2])^2+varcmax1[x1,x2]+(ttmax1[x1,x2]-
rtmax1[x1,x2])^2+vartmax1[x1,x2]+(tauc1[x1,x2]-rauc1[x1,x2])^2+varauc1[x1,x2] 
 
Minimize[{obj2[x1,x2],Abs[(x1-150)/278]>0.1,Abs[(x2-10.5)/278]<=0.06,Abs[(x1-
190)/278]+Abs[(x2-10.5)/278]<=0.1,lauc1[x1,x2]>=-
0.2*rauc1[x1,x2],uauc1[x1,x2]<=0.25*rauc1[x1,x2],lcmax1[x1,x2]>=-
0.20*rcmax1[x1,x2],ucmax1[x1,x2]<=0.25*rcmax1[x1,x2],0<=s2auc[x1,x2]<=0.1,0<=s
2cmax[x1,x2]<=0.1,165.858<=x1<=194.142,6.5574<=x2<=15.0426,s[x1,x2,20,15,2.5]/x
bar[x1,x2,20,15,2.5]<=0.02,f1[x1,x2,20,15,2.5]/w[x1,x2,20,15,2.5]<=0.01,ci[x1,x2,20,15
,2.5]<=25,sd[x1,x2,20,15,2.5]>=0,d[x1,x2,20,15,2.5]>=0,w[x1,x2,20,15,2.5]>=0,0.985<
=xbar[x1,x2,20,15,2.5]<=1.105,0<=av1[x1,x2,20,15,2.5]<=0.15,s[x1,x2,20,15,2.5]>=0,f
1[x1,x2,20,15,2.5]>=0,ci[x1,x2,20,15,2.5]>=0,9.5<=n[x1,x2,20,15,2.5]<=10.5,tcmax1[x
1,x2]>=0,rcmax1[x1,x2]>=0,varcmax1[x1,x2]>=0,ttmax1[x1,x2]>=0,rtmax1[x1,x2]>=0,
vartmax1[x1,x2]>=0,tauc1[x1,x2]>=0,rauc1[x1,x2]>=0,varauc1[x1,x2]>=0},{x1,x2}]
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APPENDIX 3 
Mathematica Codes for the Example in Chapter 5 
 
3.1 Estimated Response Functions 
y1[x1_,x2_]=25.33-4x1+x2+x1*x2-2.33x1*x1-
4.33x2*x2+0.5x1*x1*x2+0.5x1*x2*x2+8.33x1*x2*x2*x1 
 
y2[x1_,x2_]=46.33-6.5x1-x2-1.25x1*x2-4.833x1*x1-
3.33x2*x2+0.75x1*x1*x2+0.75x1*x2*x2+9.083x1*x1*x2*x2 
 
y3[x1_,x2_]=68-8x1-2x2-3.75x1*x2-5x1*x1-
4x2*x2+2.25x1*x1*x2+1.75x1*x2*x2+9.75x1*x1*x2*x2 
 
y4[x1_,x2_]=87-7.5x1-2.5x2-5.25x1*x2-5.5x1*x1-
2.5x2*x2+1.75x1*x1*x2+3.75x1*x2*x2+7.75x1*x1*x2*x2 
 
y5[x1_,x2_]=101-3.5x1-2.5x2-3.5x1*x2-6.83x1*x1-2.83x2*x2+2x1*x2*x2+7.83x1*x1*x2*x2 
 
s1[x1_,x2_]=2.8-1.83x1+7.5x2+2x1*x2+5.7x2*x2-9.5x1*x1*x2-5.5x1*x1*x2*x2 
 
s2[x1_,x2_]=12.667-8.667x1*x1-8.667x2*x2+8.147x1*x1*x2*x2 
 
s3[x1_,x2_]=16-9.167x2*x2 
 
s4[x1_,x2_]=17.4-8.667x2-4.067x2*x2 
 
s5[x1_,x2_]=19.667+3.333x1+8.25x1*x2-13.167x1*x1-15.667x2*x2-
3.75x1*x1*x2+25.917x1*x1*x2*x2 
 
s13[x1_,x2_]=0.9083+2.1596x2-2.1464x1*x2-1.1335x1*x1+1.6509x2*x2-
1.7137x1*x1*x2+1.4781x1*x2*x2-2.724x1*x1*x2*x2 
 
s14[x1_,x2_]=0.2912+2.6292x2-1.5448x1*x1*x2-0.9812x1*x1*x2*x2 
 
s15[x1_,x2_]=0.5241+1.5428x2-1.6603x1*x2+1.4837x1*x2*x2-2.3758x1*x1*x2*x2 
 
s23[x1_,x2_]=1.1798-2.3364x1-1.4173x1*x1-2.6574x2*x2-
0.4314x1*x1*x2+1.1681x1*x2*x2+2.5304x1*x1*x2*x2 
 
s24[x1_,x2_]=0.5331-2.462x1+1.951x1*x2+2.744x1*x2*x2 
 
s25[x1_,x2_]=-1.4572+1.2974x1*x2+2.17x2*x2+1.793x1*x1*x2 
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s34[x1_,x2_]=2.3125+2.104x1+0.9361x2-2.608x1*x2*x2-4.233x1*x1*x2*x2 
 
s35[x1_,x2_]=-0.064-2.672x1*x1*x2-1.056x1*x2*x2+2.29x1*x1*x2*x2 
 
s45[x1_,x2_]=3.0493+1.8775x1-1.5451x2-2.0523x1*x2-1.5968x1*x1-
2.6055x2*x2+2.281x1*x1*x2 
 
3.2 Estimated Empirical DFs 
d1[x1_,x2_]=0.04123+0.23612x1-0.05889x2-0.07924x1*x2+0.20266x1*x1+0.29988x2*x2-
0.02035x1*x1*x2-0.15536x1*x2*x2-0.463x1*x1*x2*x2 
 
d2[x1_,x2_]=0.45476-0.08741x1-0.25742x1*x1+0.29891x2*x2+0.4471x1*x2*x2-
0.1366x1*x1*x2*x2 
 
d3[x1_,x2_]=0.27038+0.16835x2-0.1465x1*x1+0.357x2*x2-
0.1917x1*x1*x2+0.21794x1*x2*x2-0.21x1*x1*x2*x2 
 
d4[x1_,x2_]=0.31675+0.17898x2+0.1168x1*x2-0.1625x1*x1+0.2956x2*x2-0.2923x1*x1*x2-
0.206x1*x1*x2*x2 
 
d5[x1_,x2_]=0.50795-0.17436x1-0.28947x2-0.22744x1*x2-
0.30795x1*x1+0.26476x1*x1*x2+0.3101x1*x1*x2*x2 
 
ds1[x1_,x2_]=0.888+0.0733x1-0.3x2-0.08x1*x2-
0.228x2*x2+0.38x1*x1*x2+0.22*x1*x2*x1*x2 
 
ds2[x1_,x2_]=0.4933+0.3467x1*x1+0.3467x2*x2-0.3367x1*x1*x2*x2 
 
ds3[x1_,x2_]=0.6735+0.1871x2*x2 
 
ds4[x1_,x2_]=0.81257+0.107x2 
 
ds5[x1_,x2_]=0.83747-0.02755x1-
0.06818x1*x2+0.10882x1*x1+0.12948x2*x2+0.03099x1*x1*x2-0.21419x1*x1*x2*x2 
 
d12[x1_,x2_]=0.78905-0.23362x2+0.17063x1*x1+0.2248x1*x1*x2 
 
d13[x1_,x2_]=0.80472+0.07446x1-0.43191x2-0.22277x1*x2+0.08768x1*x1-
0.31997x2*x2+0.6907x1*x1*x2 
 
d14[x1_,x2_]=0.82298-0.17008x2-0.3488x2*x2+0.3058x1*x1*x2-
0.07486x1*x2*x2+0.3067x1*x1*x2*x2 
 
d15[x1_,x2_]=0.79688-0.20242x2-
0.22856x1*x2+0.127x1*x1+0.4605x1*x1*x2+0.21986x1*x2*x2-0.2174x1*x1*x2*x2 
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d23[x1_,x2_]=0.74022-0.06442x1+0.08802x2-0.08628x1*x2-0.20751x1*x1-
0.14719x1*x1*x2+0.23363x1*x1*x2*x2 
 
d24[x1_,x2_]=0.5617-0.24458x1-0.1614x1*x2 
 
d25[x1_,x2_]=0.68037-0.2417x1-0.1879x1*x2-0.1543x1*x1*x2 
 
d34[x1_,x2_]=0.3923-0.4162x1+0.2722x2*x2+0.2186x1*x1*x2+0.3154x1*x2*x2 
 
 d35[x1_,x2_]=0.436-0.12602x1*x2+0.3085x1*x1+0.4549x2*x2+0.35997x1*x1*x2-
0.6766x1*x1*x2*x2 
 
d45[x1_,x2_]=0.5682-0.3064x1-0.1675x1*x2+0.3044x1*x1*x2+0.4389x1*x2*x2 
 
3.3 Estimated Mechanistic DFs 
dd1[x1_,x2_]=Piecewise[{{0,y1[x1,x2]<0|| y1[x1,x2]>25},{(y1[x1,x2]-0)/(12.5-
0),0<=y1[x1,x2]<=12.5},{(25-y1[x1,x2])/(25-12.5),12.5<y1[x1,x2]<=25}}] 
 
dd2[x1_,x2_]=Piecewise[{{0,y2[x1,x2]<35|| y2[x1,x2]>50},{(y2[x1,x2]-35)/(42.5-
35),35=y2[x1,x2]<=42.5},{(50-y2[x1,x2])/(50-42.5),42.5<=y2[x1,x2]<=50}}] 
 
dd3[x1_,x2_]=Piecewise[{{0,y3[x1,x2]<55|| y3[x1,x2]>70},{(y3[x1,x2]-55)/(62.5-
55),55<=y3[x1,x2]<=62.5},{(70-y3[x1,x2])/(70-62.5),62.5<=y3[x1,x2]<=70}}] 
 
dd4[x1_,x2_]=Piecewise[{{0,y4[x1,x2]<75|| y4[x1,x2]>90},{(y4[x1,x2]-75)/(82.5-
75),75<=y4[x1,x2]<=82.5},{(90-y4[x1,x2])/(90-82.5),82.5<=y4[x1,x2]<=90}}] 
 
dd5[x1_,x2_]=Piecewise[{{0,y5[x1,x2]<95|| y5[x1,x2]>110},{(y5[x1,x2]-95)/(102.5-
95),95<=y5[x1,x2]<=102.5},{(110-y5[x1,x2])/(110-102.5),102.5<=y5[x1,x2] <=110}}] 
 
dds1[x1_,x2_]=Piecewise[{{1,s1[x1,x2]<=0},{(25-s1[x1,x2])/(25-
0),0<s1[x1,x2]<=25},{0,s1[x1,x2]>25}}] 
 
dds2[x1_,x2_]=Piecewise[{{1,s2[x1,x2] <=0},{(25-s2[x1,x2])/(25-
0),0<s2[x1,x2]<=25},{0,s2[x1,x2]>25}}] 
 
dds3[x1_,x2_]=Piecewise[{{1,s3[x1,x2] <=0},{(49-s1[x1,x2])/(49-
0),0<s3[x1,x2]<=49},{0,s3[x1,x2]>49}}] 
 
dds4[x1_,x2_]=Piecewise[{{1,s4[x1,x2] <=0},{(81-s4[x1,x2])/(81-
0),0<s4[x1,x2]<=81},{0,s4[x1,x2]>81}}] 
 
dds5[x1_,x2_]=Piecewise[{{1,s5[x1,x2] <=0},{(121-s5[x1,x2])/(121-
0),0<s5[x1,x2]<=121},{0,s5[x1,x2]>121}}] 
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dd12[x1_,x2_]=Piecewise[{{0,s12[x1,x2]<-5|| s12[x1,x2]>5},{(s12[x1,x2]+5)/5,-
5<=s12[x1,x2]<=0},{(5-s12[x1,x2])/5,0<=s12[x1,x2] <=5}}] 
 
dd13[x1_,x2_]=Piecewise[{{0,s13[x1,x2]<-5|| s13[x1,x2]>5},{(s13[x1,x2]+5)/5,-
5<=s13[x1,x2]<=0},{(5-s13[x1,x2])/5,0<=s13[x1,x2] <=5}}] 
 
dd14[x1_,x2_]=Piecewise[{{0,s14[x1,x2]<-5|| s14[x1,x2]>5},{(s14[x1,x2]+5)/5,-
5<=s14[x1,x2]<=0},{(5-s14[x1,x2])/5,0<=s14[x1,x2] <=5}}] 
 
dd15[x1_,x2_]=Piecewise[{{0,s15[x1,x2]<-5|| s15[x1,x2]>5},{(s15[x1,x2]+5)/5,-
5<=s15[x1,x2]<=0},{(5-s15[x1,x2])/5,0<=s15[x1,x2] <=5}}] 
 
dd23[x1_,x2_]=Piecewise[{{0,s23[x1,x2]<-5|| s23[x1,x2]>5},{(s23[x1,x2]+5)/5,-
5<=s23[x1,x2]<=0},{(5-s23[x1,x2])/5,0<=s23[x1,x2] <=5}}] 
 
dd24[x1_,x2_]=Piecewise[{{0,s24[x1,x2]<-5|| s24[x1,x2]>5},{(s24[x1,x2]+5)/5,-
5<=s24[x1,x2]<=0},{(5-s24[x1,x2])/5,0<=s24[x1,x2] <=5}}] 
 
dd25[x1_,x2_]=Piecewise[{{0,s25[x1,x2]<-5|| s25[x1,x2]>5},{(s25[x1,x2]+5)/5,-
5<=s25[x1,x2]<=0},{(5-s25[x1,x2])/5,0<=s25[x1,x2] <=5}}] 
 
dd34[x1_,x2_]=Piecewise[{{0,s34[x1,x2]<-5|| s34[x1,x2]>5},{(s34[x1,x2]+5)/5,-
5<=s34[x1,x2]<=0},{(5-s34[x1,x2])/5,0<=s34[x1,x2] <=5}}] 
 
dd35[x1_,x2_]=Piecewise[{{0,s35[x1,x2]<-5|| s35[x1,x2]>5},{(s35[x1,x2]+5)/5,-
5<=s35[x1,x2]<=0},{(5-s35[x1,x2])/5,0<=s35[x1,x2] <=5}}] 
 
dd45[x1_,x2_]=Piecewise[{{0,s45[x1,x2]<-5|| s45[x1,x2]>5},{(s45[x1,x2]+5)/5,-
5<=s45[x1,x2]<=0},{(5-s45[x1,x2])/5,0<=s45[x1,x2] <=5}}] 
 
3.4 Optimization Models  
 Model using proposed empirical DFs  
FindMinimum[{k21+k31+ks21+ks31,d2[x1,x2]+k21==1,d3[x1,x2]+k31==1,ds2[x1,x2]+ks21==
1,ds3[x1,x2]+ks31==1,0<=y1[x1,x2]<=25,35<=y2[x1,x2]<=50,55<=y3[x1,x2]<=70,75<
=y4[x1,x2]<=90,95<=y5[x1,x2]<=110,0<=s1[x1,x2]<=25,0<=s2[x1,x2]<=25,0<=s3[x1,
x2]<=49,0<=s4[x1,x2]<=81,0<=s5[x1,x2]<=121,-5<=s12[x1,x2]<=5,-
5<=s13[x1,x2]<=5,-5<=s14[x1,x2]<=5,-5<=s15[x1,x2]<=5,-5<=s23[x1,x2]<=5,-
5<=s24[x1,x2]<=5,-5<=s25[x1,x2]<=5,-5<=s34[x1,x2]<=5,-5<=s35[x1,x2]<=5,-
5<=s45[x1,x2]<=5,k21>=0,k31>=0,ks21>0,ks31>=0,-1<=x1<=1,-
1<=x2<=1,0<=d1[x1,x2]<=1,0<=d2[x1,x2]<=1,0<=d3[x1,x2]<=1,0<=d4[x1,x2]<=1,0<=
d5[x1,x2]<=1,0<=ds1[x1,x2]<=1,0<=ds2[x1,x2]<=1,0<=ds3[x1,x2]<=1,0<=ds4[x1,x2]<
=1,0<=ds5[x1,x2]<=1,0<=d12[x1,x2]<=1,0<=d12[x1,x2]<=1,0<=d13[x1,x2]<=1,0<=d1
4[x1,x2]<=1,0<=d15[x1,x2]<=1,0<=d23[x1,x2]<=1,0<=d24[x1,x2]<=1,0<=d25[x1,x2]<
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=1,0<=d34[x1,x2]<=1,0<=d35[x1,x2]<=1,0<=d45[x1,x2]<=1},{x1,x2,k21,k31,ks21,ks3
1},MaxIterations->1000] 
 
 Model using proposed mechanistic DFs  
Minimize[{k21+k31+ks21+ks31,dd2[x1,x2]+k21==1,dd3[x1,x2]+k31==1,dds2[x1,x2]+ks21==1
,dds3[x1,x2]+ks31==1,0<=y1[x1,x2]<=25,35<=y2[x1,x2]<=50,55<=y3[x1,x2]<=70,75<
=y4[x1,x2]<=90,95<=y5[x1,x2]<=110,0<=s1[x1,x2]<=25,0<=s2[x1,x2]<=25,0<=s3[x1,
x2]<=49,0<=s4[x1,x2]<=81,0<=s5[x1,x2]<=121,-5<=s12[x1,x2]<=5,-
5<=s13[x1,x2]<=5,-5<=s14[x1,x2]<=5,-5<=s15[x1,x2]<=5,-5<=s23[x1,x2]<=5,-
5<=s24[x1,x2]<=5,-5<=s25[x1,x2]<=5,-5<=s34[x1,x2]<=5,-5<=s35[x1,x2]<=5,-
5<=s45[x1,x2]<=5,k21>=0,k31>=0,ks21>0,ks31>=0,-1<=x1<=1,-
1<=x2<=1,0<=dd1[x1,x2]<=1,0<=dd2[x1,x2]<=1,0<=dd3[x1,x2]<=1,0<=dd4[x1,x2]<=1
,0<=dd5[x1,x2]<=1,0<=dds1[x1,x2]<=1,0<=dds2[x1,x2]<=1,0<=dds3[x1,x2]<=1,0<=dd
s4[x1,x2]<=1,0<=dds5[x1,x2]<=1,0<=dd12[x1,x2]<=1,0<=dd13[x1,x2]<=1,0<=dd14[x1
,x2]<=1,0<=dd15[x1,x2]<=1,0<=dd23[x1,x2]<=1,0<=dd24[x1,x2]<=1,0<=dd25[x1,x2]<
=1,0<=dd34[x1,x2]<=1,0<=dd35[x1,x2]<=1,0<=dd45[x1,x2]<=1},{x1,x2,k21,k31,ks21,
ks31}] 
 
 Model using the weighted overall DF  
objd[x1_,x2_]=(dd1[x1,x2]^10*dd2[x1,x2]^100*dd3[x1,x2]^100*dd4[x1,x2]^10*dd5[x1,x2]^10
*dds1[x1,x2]^10*dds2[x1,x2]^100*dds3[x1,x2]^100*dds4[x1,x2]^10*dds5[x1,x2]^10*d
d12[x1,x2]*dd13[x1,x2]*dd14[x1,x2]*dd15[x1,x2]*dd23[x1,x2]*dd24[x1,x2]*dd25[x1,
x2]*dd34[x1,x2]*dd35[x1,x2]*dd45[x1,x2])^(1/470) 
 
Maximize[{objd[x1,x2],0<=y1[x1,x2]<=25,35<=y2[x1,x2]<=50,55<=y3[x1,x2]<=70,75<=y4[x1
,x2]<=90,95<=y5[x1,x2]<=110,0<=s1[x1,x2]<=25,0<=s2[x1,x2]<=25,0<=s3[x1,x2]<=4
9,0<=s4[x1,x2]<=81,0<=s5[x1,x2]<=121,-5<=s12[x1,x2]<=5,-5<=s13[x1,x2]<=5,-
5<=s14[x1,x2]<=5,-5<=s15[x1,x2]<=5,-5<=s23[x1,x2]<=5,-5<=s24[x1,x2]<=5,-
5<=s25[x1,x2]<=5,-5<=s34[x1,x2]<=5,-5<=s35[x1,x2]<=5,-5<=s45[x1,x2]<=5,-
1<=x1<=1,-
1<=x2<=1,0<=d1[x1,x2]<=1,0<=d2[x1,x2]<=1,0<=dd3[x1,x2]<=1,0<=dd4[x1,x2]<=1,0
<=dd5[x1,x2]<=1,0<=dds1[x1,x2]<=1,0<=dds2[x1,x2]<=1,0<=dds3[x1,x2]<=1,0<=dds4
[x1,x2]<=1,0<=dds5[x1,x2]<=1,0<=dd12[x1,x2]<=1,0<=dd13[x1,x2]<=1,0<=dd14[x1,x
2]<=1,0<=dd15[x1,x2]<=1,0<=dd23[x1,x2]<=1,0<=dd24[x1,x2]<=1,0<=dd25[x1,x2]<=
1,0<=dd34[x1,x2]<=1,0<=dd35[x1,x2]<=1,0<=dd45[x1,x2]<=1,0<=objd[x1,x2]<=1},{x
1,x2}] 
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